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Abstract 
 Atrial fibrillation (AF) is the most common cardiac arrhythmia. It is 
distinguished by fibrillating or trembling of the atrial muscle instead of normal 
contraction. Patients in AF have a much higher risk of stroke. AF is often driven 
by the left atrium (LA) and the diagnosis of AF is normally made from lead V1 in 
a 12-lead electrocardiogram (ECG). However, lead V1 is dominated by right 
atrial activity due to its proximal location to the right atrium (RA). Consequently 
it is not well understood how electrical activity from the LA contributes to the 
ECG. Studies of the AF mechanisms from the LA are typically based on 
invasive recording techniques. From a clinical point of view it is highly desirable 
to have an alternative, non-invasive characterisation of AF.  
 The aim of this study was to investigate how the LA electrical activity was 
expressed on the body surface, and if it could be observed preferentially in 
different sites on the body surface. For this purpose, electrical activity of the 
heart from 20 patients in AF were recorded simultaneously using 64-lead body 
surface potential mapping (BSPM) and bipolar 10-electrode catheters located in 
the LA and coronary sinus (CS). Established AF characteristics such as 
amplitude, dominant frequency (DF) and spectral concentration (SC) were 
estimated and analysed. Furthermore, two novel AF characteristics (intracardiac 
DF power distribution, and body surface spectral peak type) were proposed to 
investigate the relationship between the BSPM and electrogram (EGM) 
recordings.  
 The results showed that although in individual patients there were body 
surface sites that preferentially represented the AF characteristics estimated 
from the LA, those sites were not consistent across all patients. It was found 
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that the left atrial activity could be detected in all body surface sites such that all 
sites had a dominant or non-dominant spectral peak corresponding to EGM DF. 
However, overall the results suggested that body surface site 22 (close to lead 
V1) was more closely representative of the CS activity, and site 49 (close to the 
posterior lower central right) was more closely representative of the left atrial 
activity. There was evidence of more accurate estimation of AF characteristics 
using additional electrodes to lead V1.    
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Structure of the Thesis 
 This doctoral thesis focuses on comparing the body surface potential 
maps (BSPM) and atrial electrograms (EGM) in patients with atrial fibrillation 
(AF). The presentation of this work is structured as shown below.        
 
Figure i. A schematic representation of the thesis outline. The chapter (ch) 
number are identified for each analysis. The pink box represents introduction 
(Chapter 1), the blue box represents methods (Chapter 2), and the red box 
represents results and discussion (Chapter 3 to Chapter 8). 
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 This thesis is comprised of four main parts of introduction, methods, 
results and discussion, and conclusion which are presented in nine chapters:  
Introduction (Chapter 1):  This chapter provides a clinical background of the 
heart and atrial fibrillation, as well as a review of the current signal processing 
'state of the art' from which the methods used in this work are advanced. 
Methods (Chapter 2): This chapter describes the body surface and intracardiac 
recording equipment, patient recruitment, data collection, signal processing and 
statistical methods. In the signal processing section, characterisation of the 
atrial activity from the body surface and intracardiac recordings are performed in 
two domains: time and frequency. AF amplitude from the body surface 
recordings and atrial activation time points from the intracardiac recordings are 
estimated in the time domain. Spectral analysis, and estimation of dominant 
frequency (DF) and spectral concentration (SC) are performed in the frequency 
domain. Moreover, in this chapter two novel AF characteristics for examining 
the body surface and intracardiac recordings are described.  
Results and Discussion (Chapter 3 to Chapter 8): In these chapters the AF 
characteristics estimated from the body surface and intracardiac recordings are 
analysed and compared, and the results are discussed. In chapters 3, 4, 5, and 
6, the data analysis is performed with limited aims to provide overview of the 
data. The intention at the end of each chapter is to find the linear relationship 
between the body surface and intracardiac recordings between subjects using 
selected body surface sites and/or using the median across the body surface 
sites for the characteristics of interest. In chapters 7 and 8, the body surface 
and intracardiac recordings are compared in more detail at individual body 
surface site with different approaches.   
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 Chapter 3 focuses on between subject differences in the AF 
characteristics estimated from the body surface (AF amplitude, DF and SC) and 
inside the heart (DF and SC). Moreover, the linear relationships between 
subjects are investigated linking body surface and intracardiac DF and SC.       
 Chapter 4 focuses on the influence of subject BMI on the AF 
characteristics estimated from the body surface recordings. It also investigates 
whether there is a relationship between subject BMI and the differences in the 
AF characteristics estimated from the body surface and inside the heart. 
 Chapter 5 focuses on the temporal variability of the AF characteristics 
during the two minute recordings to assess repeatability over this duration of 
recording. Moreover, the linear relationship between temporal variability 
estimated from the body surface and intracardiac recordings are studied for AF 
characteristics. 
 Chapter 6 focuses on the spatial variability of the AF characteristics 
across the 64 body surface sites, and at different groups of electrode sites. It 
also explores the spatial variability of the AF characteristics along the CS and 
PVAC catheters sites. Moreover, the linear relationship between all body 
surface sites and selected intracardiac sites are investigated across all subjects.              
 Chapter 7 then provides a more detailed comparison of individual body 
surface and intracardiac spectra using five approaches: visual interpretation; 
spectral morphology correlation; comparison using Bland-Altman plot; paired 
comparison of DF at individual sites; paired comparison of DF at the body 
surface site with the largest SC.  
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 Chapter 8 focuses on the comparison of the body surface and 
intracardiac recordings using novel methods previously not presented in the 
literature. Firstly, quantifying the intracardiac DF power distribution on the body 
surface spectra. Secondly, specifying the body surface spectral peak 
corresponding to the intracardiac DF. Thirdly, identifying any distinct F-wave on 
the AF segment corresponding to intracardiac atrial activity. 
Conclusion (Chapter 9): In this chapter the main scientific contributions of this 
work are summarised.   
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Results Summary 
Differences in Atrial Fibrillation Characteristics Between Subjects 
(Chapter 3): 
1. Atrial Fibrillation (AF) characteristics estimated from the body surface 
and inside the heart were significantly different between subjects 
(p<0.001).  
From the body surface:  
 Median amplitude ranged from 19.2 µV (subject 18) to 90.0 µV 
(subject 3) with median and inter-quartile range (IQR) of 35.9 (21.0 
– 57.3) µV across subjects. 
 Median dominant frequency (DF) ranged from 4.1 Hz (subject 12) 
to 7.5 Hz (subject 11) with median and IQR of 5.9 (5.1– 6.2) Hz 
across subjects. 
 Median spectral concentration (SC) ranged from 19.0 % (subject 
13) to 60.5 % (subject 3) with median and IQR of 31.0 (27.8  – 
43.8) % across subjects.  
 
           From inside the heart:  
 Median DF estimated from the coronary sinus (CS) ranged from 
4.3 Hz (subject 9) to 7.1 Hz (subjects 5 and 7) with median and 
IQR of 5.9 (5.1– 6.4) Hz across subjects.    
 Median DF estimated from the pulmonary vein ablation catheter 
(PVAC) ranged from 4.3 Hz (subject 18) to 7.1 Hz (subjects 7) with 
median and IQR of 5.6 (5.1– 6.0) Hz across subjects. 
 Median SC estimated from CS ranged from 21.1 % (subject 9) to 
86.0 % (subjects 3) with median and IQR of 47.5 (39.5 – 56.8) % 
across subjects.  
 Median SC estimated from PVAC ranged from 36.3% (subject 18) 
to 90.0% (subject 3) with median and IQR of 63.0 (53.3 – 70.0) % 
across subjects.  
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2. There was a strong positive linear relationship between DF of the body 
surface and CS (p<0.001,    = 54.3%), and between DF of the body 
surface and PVAC (p<0.001,   = 70.1%).      
3. There was a positive but weak linear relationship between SC of the 
body surface and CS (p=0.004,   = 38.4%), and between SC of the body 
surface and PVAC (p=0.006,   = 35.0%).   
Effect of Body Mass Index on Atrial Fibrillation Characteristics (Chapter 
4): 
1. Body surface amplitude was negatively correlated to BMI (p=0.043,   = 
20.2%). 
2. Body surface DF was positively correlated to BMI (p=0.046,   = 20.0%).    
3. The DF difference (BSPM site 22 - EGM) was negatively correlated to 
BMI (p=0.022 BSPM vs. CS, and p=0.019 BSPM vs. PVAC), with 
   30.0 %. 
4. There was no correlation between SC estimated from either the body 
surface or inside the heart and BMI (p>0.05,   = 9.0%). 
Temporal Variability of Atrial Fibrillation Characteristics (Chapter 5): 
1. AF characteristics estimated from the body surface and from inside the 
heart did not change significantly over the two minute recordings 
(p>0.05).   
2. There was no evidence that subjects with the large AF amplitude and 
high SC had more stable amplitude over the two minute recordings.  
3. There was no evidence that subjects with the small DF had more stable 
DF over the two minute recordings.   
4. There was no correlation between DF temporal changes estimated from 
the body surface or from inside the heart (p>0.05,   = 3.0%). 
5. There was no correlation between SC temporal changes estimated from 
the body surface or from inside the heart (p>0.05,   = 16.2%). 
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Spatial Variability of Atrial Fibrillation Characteristics (Chapter 6): 
1. AF characteristics exhibited significant differences between body surface 
sites (p<0.001).  
 Median amplitude ranged from 21.8 µV (site 60) to 77.4 µV (site 
22), with median and IQR of 34.4 (29.2– 44.9) µV across the sites.  
 Median DF ranged from 5.5 Hz (site 45) to 6.1 Hz (site 22), with 
median and IQR of 5.6 (5.3 – 6.0) Hz across the sites. 
 Median SC ranged from 22.0 % (site 5) to 44.5 % (site 23) with 
median and IQR of 31.0 (28.5 – 36.0) % across the sites. 
 AF amplitude estimated from the body surface changed 
significantly (least significant p=0.001) between the anterior and 
posterior (22.1 µV), left and right (8.0 µV), vertical electrode lines 
(35.4 µV), and horizontal electrode lines (78.0 µV).   
 DF estimated from the body surface did not change significantly 
(p>0.05) between the anterior and posterior, left and right, or 
vertical electrode lines.  
 DF estimated from the body surface changed significantly between 
the horizontal electrode lines 4 and 8 which were the anterior 
central and anterior upper sites (p=0.035, 0.2 Hz), and also 
between lines 8 and 13 which were the anterior upper and 
posterior central sites (p=0.032, 0.3 Hz).   
 SC estimated from the body surface did not change significantly 
between the anterior and posterior, or between the horizontal 
electrode lines (p>0.05).    
 SC estimated from the body surface changed significantly 
between the left and right (p=0.008, 5.0 %), and between the 
vertical electrode lines (p=0.008, 14.8 %).  
2. The anterior upper central right body surface sites had the largest 
amplitude, DF and SC.   
3. DF estimated from inside the heart did not change significantly from any 
of the electrodes of the same catheter, either CS or PVAC (p>0.05). 
However, there was a significant difference in DF between the CS and 
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PVAC catheters (p<0.001, the median DF was 0.5 Hz greater in PVAC 
than CS).   
4. SC estimated from inside the heart did not change significantly from any 
of the electrodes of the same catheter, either CS or PVAC (p>0.05). 
However, there was a significant difference in SC between the CS and 
PVAC catheters (p<0.001, the median SC was 21.5 % greater in PVAC 
than CS).    
Relationship Between Frequencies Derived from Individual and Groups of 
Body Surface Sites and Those Derived from Intracardiac Sites (Chapter 7): 
1. Visual comparison of frequency spectra estimated from the body surface 
and inside the heart showed that there was agreement between the 
spectral peaks which may or may not necessarily be the dominant one. 
In other words, the body surface sites may reflect all or some of the 
frequency components presented on the intracardiac spectrum. 
2. Spectra from body surface sites close to the anterior upper central right 
and the posterior lower sites had highest morphology correlation (75.0 
%) with the CS recordings. 
3. Bland-Altman plot showed no significant differences between DF 
estimated from body surface and inside the heart (PTrend > 0.05, limits of 
agreement (LOA) < 1.2 Hz).  
4. There was no significant difference between paired comparisons of DF of 
each BSPM site with each EGM site. 
5. There was no evidence that the body surface sites with the largest SC 
had closer DF to the intracardiac recordings.  
Innovative Methods for Examining the Relationship Between Body 
Surface and Intracardiac Signals (Chapter 8):  
1. The anterior upper body surface sites expressed the largest power at CS 
DF. Moreover, the posterior lower body surface sites expressed the 
largest power at PVAC DF. 
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2. DF estimated from inside the heart was likely to be seen as a dominant 
or non-dominant frequency peak on any of the body surface sites.   
3. Visual comparison of the body surface average beat generated by the 
intracardiac activations showed morphology of the peak or trough on the 
majority of the sites. This may suggest that the EGM activations were 
consistent on each body surface site.
1 
 
Chapter 1. Introduction 
1.1. Clinical Background  
1.1.1. The Heart 
 The heart consists of four chambers; the upper chamber on each side of 
the heart is called the atrium, which receives the blood coming to the heart. The 
atrium then delivers the blood to the powerful lower chamber on the same side, 
called the ventricle. The ventricle pumps the blood away from the heart through 
rhythmic contractions, see Figure 1. The right atrium (RA) receives de-
oxygenated blood from the body and the right ventricle (RV) pumps it into the 
lungs to add oxygen and remove the carbon dioxide. The left atrium (LA) 
receives the oxygenated blood from the lungs. The left ventricle (LV) pumps 
fresh blood to the organs and tissues of the body and provides the oxygen and 
nutrients. 
 
Figure 1. Mechanical function of the heart (Cardiac Health, 2009, [Online 
image]. Available from: http://www.cardiachealth.org).  
 
 The heartbeat consists of two stages, named systole and diastole. 
Systole is the stage when the ventricles are contracting and pump the blood out 
to the lungs and the rest of the body. Diastole is the stage when the ventricles 
are relaxed. During this stage, the atria are filled with blood and pass it into the 
ventricles. Oxygen-rich blood (arterial blood) flows from the heart to the body to 
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provide oxygen and nutrients. Oxygen-poor blood (venous blood) returns from 
the body to the heart. The blood then exchanges carbon dioxide with new 
oxygen in the lungs. The coronary sinus (CS) is a collection of veins joined 
together, which form a large vessel and collects blood from the heart muscle. It 
delivers this oxygen-poor blood to the RA, as do the superior and inferior vena 
cava (SVC, IVC). The pulmonary veins (PVs) are large blood vessels that carry 
oxygen-rich blood from the lungs to the LA of the heart, see Figure 2. 
 
Figure 2. The coronary arteries and pulmonary veins. Red: oxygen-rich blood, 
and blue: oxygen-poor blood (Expressions in cardiology, 2011, [Online image]. 
Available from: http://www.dartmouth.edu).    
 
 The contraction of the heart as a whole is as a direct result of the 
systematic contraction of all of the microscopic cells of the heart muscle. The 
mechanical force (contraction) of the heart muscle cells is triggered by electrical 
impulses known as the action potentials (AP). A conduction system of 
specialized cells in the myocardium spreads an electrical impulse throughout 
the heart. The conduction system includes sinoatrial node (SA node), atrial 
internodal areas, atrioventricular node (AV node) and the bundle of His, which 
divides into left and right bundle branches made up of specialized cells called 
Purkinje fibres. The SA node normally acts as the essential cardiac pacemaker 
that spontaneously generates the AP. The AP travels through atrial muscle 
fibres to the AV node, then to the bundle of His and then the right and left 
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bundles made up of large Purkinje fibres. These specialised fibres rapidly 
conduct the impulse to the ordinary muscle cells resulting in fast and rhythmic 
simultaneous excitation of all ventricular cells. The speed with which an 
electrical impulse can be transmitted through excitable tissue is called the 
conduction velocity. The period of time during which the cardiac cell is unable to 
initiate another AP is called refractory period (RP), which typically is 250 ms in 
duration (Fagan, 2002). The AV node receives two inputs from the atria through 
two different pathways: anteriorly, which has a slow conduction velocity but 
shorter RP, and posteriorly, which has a faster conduction velocity but longer 
RP.  Figure 3 shows the conduction pathway of the heart.     
  
Figure 3. Conduction pathway of the heart. The white arrows demonstrate major 
electrical signal pathways (The Nebraska Medical Centre, ND, [Online image]. 
Available from: http://www.nebraskamed.com).   
 
 The electrical activity of the heart comes from the electrophysiology of 
single cells. At rest, the myocardial cell has a trans-membrane potential of 
about -80 to -90 mV. The cell membrane controls permeability to a number of 
ions, including sodium, potassium, calcium and chlorine.  These ions pass 
across the membrane through specific channels that open and close in 
response to voltage changes. The variation of membrane conductance due to 
the opening and closing of ion channels generates changes in the AP over time 
(Wanger, 2008). An electrical impulse arriving at the cell allows positively 
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charged ions to cross the cell membrane causing depolarisation. The rapid 
depolarisation is caused by a transient fast increase in sodium channel 
conductance. The repolarisation occurs when potassium conductance 
increases. Calcium conductivity also contributes to the repolarisation of the cell 
and it is fundamental for the mechanism of muscle contraction. Therefore, both 
depolarisation and repolarisation of the myocardium are electrical phenomena 
caused by the movement of ions, see Figure 4.  
      
Figure 4. The action potential of a myocardial cell. In phase 0 a fast increase of 
sodium channel conductance causes the depolarisation. Then during plateau 
calcium ions enter and the contraction starts. Finally repolarisation is due to the 
exit of potassium ions. Cardiac action potential lasts 250 to 300 ms, which 
during this time the cell is unable to respond to new stimulations, known as 
refractory period.    
 
 As the body is conductive, the electrical activity of the heart can be 
detected, recorded, and interpreted from the skin surface. This can be 
performed through the use of sensitive monitoring equipment to obtain the 
Electrocardiogram (ECG). As shown in Figure 5, each heartbeat captured by 
the ECG signal during normal resting heart rate (known as sinus rhythm (SR)), 
consists of a P-wave (atrial activation), a QRS complex (contraction of the 
ventricles), and a T-wave (ventricular recovery). The conduction from the SA 
node in a wave travels downwards through both atria. This causes each cell to 
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depolarise in turn, and contracts the atria (the P-wave on the ECG). This 
conduction reaches the AV node and causes a delay in conducting the impulse 
from the atria to the ventricles. This delay allows the blood to fill the ventricles 
before they contract. The depolarisation travels down along the bundle of His. 
The left bundle branch is activated first, the depolarisation proceeds from left to 
right and gives rise to a small negative deflection on the ECG (the Q-wave). At 
the same time that the atria start to repolarise and relax, the wave of 
depolarisation continues down into the ventricular wall. The depolarisation takes 
place quickly and causes the ventricles to contract (the R-wave on the ECG).  
The RR interval is the distance between two following R-waves. The atria, AV 
nodal, and bundle of His are relaxed, and depolarisation ends with the S-
wave on the ECG.   
 
Figure 5. A presentation of an ECG. Typically the PR duration is 120-200 ms, 
the QRS duration is 120 ms, and  the QT interval (or QRST) is up to 420 ms in 
heart rate of 60 beat per minute (IVLine, 2010, [Online image]. Available from: 
http://www.ivline.info). 
 
 The ST segment represents completed ventricular depolarisation as a 
plateau on the ECG, followed by a deflection in the same direction as 
depolarisation (T-wave) and represents the recovery of the ventricles. When the 
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heart has repolarised, the chambers are relaxed until the SA node triggers the 
start of the next heartbeat.   
1.1.2. Atrial Fibrillation 
 Cardiac arrhythmia is a term for any condition in which there is abnormal 
electrical activity in the heart. The heartbeat may be too fast (tachycardia) or too 
slow (bradycardia), and may be regular or irregular. Atrial fibrillation (AF) is the 
most common cardiac arrhythmia, which is distinguished by fast and irregular 
electrical activity of the atria. Its name comes from the fibrillating or trembling of 
the atria muscle, instead of the normal contraction. In AF, control of the heart 
rhythm is taken away from the SA node by other electrical activities in different 
areas of the atria such as PVs (see Figure 6). Therefore, the ventricular rate 
during AF is no longer under physiological control of the SA node (Klabunde, 
2005). 
 
Figure 6. Simple illustration of electrical activities in the heart during AF 
(Harvard Medical School, 2013, [Online image]. Available from: 
http://www.patienteducationcenter.org).  
 
 Normally, the heart rate is adjusted to suit the body’s metabolic needs 
through physiological control of the SA node, which is typically ranged from 60-
80 beats per minute at rest. This can be increased to a typical maximum of 
180–200 beats per minute to cope with the increased oxygen demands of peak 
exercise. In AF, the atria contract rapidly and irregularly typically ranged from 
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400-600 beats per minute. If each atrial impulse were conducted to the 
ventricles, the rapid ventricular rate would lead to ineffective cardiac contraction 
and death. In AF, the AV node limits the impulses that reach the ventricles; 
typically between 110 and 180 beats per minute, thus the coordination between 
atria and ventricles is lost (Waktare, 1998), see Figure 7. In this case, the 
amount of blood pumped out of the ventricles to the body would change 
randomly. The volume of blood (cardiac output) which is pumped to the body by 
the normal heart is about 5 litres per minute in an average person. In the case 
of AF, the body may receive smaller and occasionally larger amounts of blood 
(Milnor, 1990).  
 
Figure 7. Simple illustration of action potentials from the atrium and ventricles 
during normal rhythm and atrial fibrillation. The red vertical line on each action 
potential recording corresponds to a common time reference (Nattel, 2002a).   
 
1.1.3. Theories on Concept of Atrial Fibrillation Mechanism  
 In 1874, the electrical stimulation of animal hearts led to the discovery of 
AF. By 1909 simultaneous recordings of the human heart and ECG activity had 
revealed the common origin of AF events. Subsequently, attention focused on 
whether AF was sustained by an abnormal focus or by a closed circuit. The 
debate has advanced as electrophysiological measurement techniques have 
become more sophisticated (Kenneth, 1995). 
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I. Circus Movement Theory  
 Garrey in 1914 discussed a hypothesis that concerned pathway 
conduction block. The assumption was that impulses can travel in any direction 
but they become limited by localised blocks in the tissue mass, which cause a 
series of ring-like circuits (Garrey, 1914). The hypothesis was called circus 
movement theory and came to prevail for the next 30 years. Figure 8 
demonstrates simple example of circus movement theory. 
 
Figure 8. Illustration of circus movement theory of AF (Wellsphere, Health 
knowledge, 2009, [Online image]. Available from: http://www.wellsphere.com).        
 
II. Multiple Wavelet Hypotheses  
 The circus movement theory was later tested by cutting or burning the 
route of the specific circus pathway, and it was found to have no effect on the 
propagation of the fibrillation wave (Mansour, 2006). Prinzmetal in 1950 used 
multiple site electrocardiography to investigate the AF mechanism. He showed 
that the electrically stimulated fibrillation wave proceeded uniformly in all 
directions from the point of stimulation. No circus movement could be shown, 
the waves moved into different paths, weaving, crossing and re-crossing old 
paths (Prinzmetal et al. 1950). The theory of circus movement as the 
mechanism of AF was no longer acceptable.  A new mechanism of AF was 
proposed in 1959 as a self-sustaining arrhythmia and called the multiple 
wavelet hypotheses (Moe and Abildskov, 1959). In this proposal it was thought 
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that although the fibrillation may have originated from one focus, it did not 
depend on it to persist and propagate, but rather depended on a random 
fractionation of the wave front around tissue. In 1962 this theory was explained 
in more detail: ''during AF, many independent wavelets propagate in an ever-
changing pattern around continuously shifting areas of conduction block'' (Moe 
et al. 1962). Figure 9 shows simple illustration of multiple wavelet theory.  
 
Figure 9. Simple illustration of the multiple wavelet hypothesis. Wavelets 
indicated by arrows randomly enter tissue that was previously activated by the 
same or another wavelet (Health from Trusted Sources, 2008, [Online image]. 
Available from: http://health-fts.blogspot.co.uk).         
 
III. Re-entry Theory 
 Modern electrophysiological evidence for block with re-entry began in 
1977. Of particular interest in the explanation of AF is the type called "leading 
circle". In this type, the initiation of re-entry takes place because of non-uniform 
RP in atrial fibres in close proximity to one another. The initiating impulse 
propagates along fibres with short RP and is blocked in those with longer ones, 
allowing re-entry into them before the impulse has died out. The size of the 
circle is determined by the recovery time of the tissue forming the circuit, as 
tissue on both sides is kept depolarised by the leading circle, ''It is said that 
what goes around, comes around'’ (Allessie et al. 1977).  
 By mapping the heart electrical activity during AF, in 1985, Allessie 
provided the first experimental evidence supporting Moe’s multiple wavelets 
hypothesis. According to this evidence, AF is associated with multiple indirect 
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activation waves, which propagate randomly within the atria. The fractionation 
of the wavefronts as they propagate, results in self-continuing independent 
wavelets, called re-entries (Allessie et al. 1985). Re-entry arises from abnormal 
impulse propagation between different zones of tissue. Figure 10 shows re-
entry occurring between two tissue zones (I and II) which are connected. An 
ectopic activation (2) arising in zone II during the RP of AP in zone I, which fails 
to initiate firing in zone I. However, it may propagate (red dashed line) through 
an alternative pathway to zone I (3). The impulse then leaves zone I and move 
towards zone II (4) and the process can continue indefinitely (Nattel, 2002a). 
 
Figure 10. Re-entry occurring between two tissue zones, I and II, which are 
connected as shown on the right. A premature activation (2) in zone II fails to 
initiate firing in zone I because zone I is still refractory. It may conduct back (red 
dashed line) to zone I at a time when it can respond with an action potential (3). 
This action potential may propagate to initiate (4) in zone II, and the process 
can continue indefinitely (Nattel, 2002a). 
 
 A more detailed model of re-entry is shown in Figure 11. In normal tissue 
(A), if a single fibre forms two branches (1 and 2) the AP will travel down each 
branch. An electrode (indicated by a green star) in a side branch would record 
single, normal APs as they are conducted down branch 1 and into the side 
branch. If branches 1 and 2 are connected together by a common pathway 
(branch 3), the APs that travel into branch 3 will cancel each other out. Re-entry 
(B) can occur in a branch that has an unidirectional block. In such a block, 
impulses can travel retrograde (from branch 3 into branch 2) but not 
orthograde. With this condition, an AP will travel down branch 1, into the 
common distal path (branch 3), and then travel retrograde through the 
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unidirectional block in branch 2 (blue line). Within the block (grey area), the 
conduction velocity is reduced because of depolarisation. When the AP exits 
the block, if it finds the tissue excitable, then the AP will continue by travelling 
down (re-enter) the branch 1.  
 
Figure 11. Illustration of re-entry model of AF. Normal tissue (A), tissue with re-
entry (B), green star indicates an electrode and gray area indicates a block. 
(Cardiovascular Physiology Concepts, 2007, [Online image]. Available from: 
http://www.cvphysiology.com).        
 
 If the AP exits the block in branch 2 and finds the tissue unexcitable 
(within its RP) then the AP will cease. If it can re-excite the tissue, a circular 
(counter-clockwise in this case) pathway of high frequency impulses will 
become the source of APs. They may spread throughout a region of the atria 
(e.g. lone AF, see section 1.1.8) which is called local re-entry, or occur between 
the atria and ventricles (e.g. Wolf Parkinson White) which called global re-entry, 
see Figure 12.   
 
Figure 12. Simple illustration of re-entry of AF (Cardiovascular Physiology 
Concepts, 2007, [Online image]. Available from: http://www.cvphysiology.com).       
  
 While supporting re-entry as the major mechanism of AF, an idea was 
put forward arguing that AF could be produced by several factors including a 
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single rapidly discharging ectopic focus, multiple rapidly discharging foci, or 
rapidly circulating circus movement (Ziad et al. 2008).  
IV. Electrophysiological Remodelling  
 A further development in understanding AF came through consideration 
of the electrophysiological mechanisms, which confirmed AF alters the atrial 
electrophysiological properties in a way that promotes its own maintenance. 
Wijffels demonstrated that, when AF is induced in goats by electrical-burst 
stimulation, the interval of spontaneous reversions increases progressively from 
several seconds to hours or days. He described this phenomenon “AF begets 
AF” (Wijffels et al. 1995). It was also demonstrated by Biffi that atrial 
remodelling is a time-dependent process that develops as an adaptive 
regulation of cardiac myocytes to maintain cell homeostasis against external 
tachycardia. This ‘structural remodelling’ adds the abnormalities of 
refractoriness and may explain the reduced efficiency of the AF therapy in 
patients with enlargement of the atria (Biffi and Boriani, 2003).  
V. Complexity 
 AF posses different degrees of complexity and may be organised or 
disorganised. Organised AF may have one re-entrant circulating round the atria, 
with regular fibrillatory rate and localised frequency spectrum. Disorganised AF 
may have several re-entrant pathways circulating round the atria, taking 
different paths, with possible variations in frequency, or directional switches in 
time. In addition they have irregular fibrillatory rate and wider frequency 
spectrum compared to organised AF. A simplified model (ideal sphere) of the 
atrial wall will be adopted to demonstrate AF rhythms organisation. Based on 
the assumption that a well organised AF is characterised by a single dominant 
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re-entrant circuit of electrical propagation (Moe et al. 1962), the spectral 
distribution of intracardiac signals is synchronously recorded at multiple sites 
(S1,S2,…, SN). This will exhibit a dominant peak. On the other hand, 
disorganised AF will exhibit multiple re-entrant pathways, generating different 
spectral distributions for different points of observation, see Figure 13.    
  
Figure 13. Illustration of organised (top) and disorganised AF (bottom). (Left 
figures: Atrial Fibrillation Press Office, 2012, [Online image]. Available from: 
http://www.dronedarone-atrial-fibrillation-pressoffice.com) 
 
VI. Atrial Fibrillation Propagation  
 In order to characterize the rotation path of the AF non-invasively, 
wavefront propagation maps have been introduced (Kim 2012; Guillem 2009; 
Sanchez 2008). The wavefront propagation maps show irregular pattern, with 
multiple simultaneous wavefronts on the anterior sites of the torso. These 
activation patterns reflect different degrees of AF complexity (Sanchez, 2008). 
Two opposite rotation directions are observed in typical organised AF: (1) 
compatible with counter-clockwise activation (see Figure 14, A), downward 
14 
 
propagation on the anterior sites of the torso, moving towards the posterior 
torso and then continuing with an upward propagation on the posterior torso, 
and final downward propagation that ends at the same point at which the 
wavefront propagation map started. (2) Compatible with clockwise activation 
(see Figure 14, B), upward propagation on the anterior torso that spreads 
towards the superior part of the posterior torso and ends with a downward 
propagation on the back. Patients with less organised AF present varying 
propagation directions (Guillem et al. 2009).  
 
Figure 14. Wavefront propagation maps of two different patients in organised 
AF (Guillem et al. 2009).   
 
 1.1.4. Epidemiology  
 AF is age-dependent, affecting 4% of persons older than 60 years and 
8% older than 80 years. Approximately 25% aged 40 years and older will 
develop AF during their lifetime. The prevalence of AF is 0.1% in persons 
younger than 55 years. The incidence of AF is significantly higher in men than 
in women in all age groups (Cotter et al. 2013).    
1.1.5. Causes  
 AF may happen with or without evidence of heart disease. Some of the 
causes of AF not involving disease of the heart are: hyperthyroidism (overactive 
thyroid), acute infection, excess alcohol intake, intra-thoracic pathology (e.g. 
lung cancer), postoperative problems, and pulmonary embolism (a blood clot in 
15 
 
the lungs).  Most commonly, AF occurs as a result of some other cardiac 
condition such as, sick sinus syndrome, ischaemic heart disease, pre-excitation 
syndromes, heart valve disease, rheumatic heart disease, enlargement of the 
left ventricle walls, coronary heart disease, and high blood pressure.  Less 
common causes of AF are cardiomyopathy (disease of the heart muscle), atrial 
septal defect, atrial myxoma, and pericardial disease (Lip and Beevers, 1996).  
1.1.6. Symptoms  
  AF may be asymptomatic (Wattigney et al. 2002). Usually the 
associated symptoms of AF are related to a rapid heart rate. The common 
symptoms are: chest discomfort, palpitation, exercise intolerance, light-
headedness, dyspnea, fatigue, syncope, pulmonary oedema, pedal oedema, 
cerebral under-perfusion, dizziness, shortness of breath, and irregular fluttering 
in the chest (Alpert, 2005). 
1.1.7. Screening and Diagnosis  
 Screening of AF could be performed through a simple check of the 
arterial pulse (e.g. radial pulse) to assess the pulse rate and rhythm. The AF 
rhythm is usually described as “irregularly irregular” (Walsh and King, 2007). 
The diagnosis of AF typically is confirmed through a 12-lead ECG, Holter 
monitoring, or implantable loop recorder.  
I.      12-lead ECG 
 When an irregular heartbeat is suspected, a 12-lead ECG test is 
performed. The 12-lead ECG system consists of twelve leads (I, II, III, aVR, 
aVL, aVF, V1, V2, V3, V4, V5, and V6). The first three leads are the Einthoven 
limb leads, and then three Goldberger augmented leads and, finally six 
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precordial leads. The first three leads are defined as bipolar leads, and the 
others are defined as unipolar leads. The precordial leads are measured with 
respect to a reference. The Wilson Central Terminal (WCT) is chosen as 
reference, and it approximates the potential at infinity. It is formed by averaging 
the voltage from each limb lead. The WCT represents the average of the limb 
potentials. The 12-lead ECG is the most common non-invasive technique in 
cardiology, due to its capability to assess the cardiac disorders in a simple low-
cost manner. Figure 15 demonstrates the placement of the 12-lead ECG 
electrodes on the torso. 
    
Figure 15. Left: Position of the 12-lead ECG on the torso (ECG exercise 
positioning). RAr: right arm, LAr: left arm, and LL: left leg. Right: The Wilson 
Central Terminal, I: electrical current (Geeky Medics, 2013, [Online image]. 
Available from: http://www.geekymedics.com and http://www.bem.fi).   
 
 The characteristic ECG findings of AF are as follows: (1) the absence of 
P-wave, (2) irregular electrical activity instead of P-wave known as fibrillatory 
wave or F-wave, (3) irregular RR interval due to the irregular conduction of the 
impulses to the ventricles. The F-wave is displayed as small rapid activity on the 
baseline of the ECG leads (Fuster et al. 2006).  Figure 16 demonstrates ECG of 
a normal heart rhythm and AF with irregular rhythm. 
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Figure 16. A: ECG of a normal heart rhythm, the arrows display P-waves. B: 
ECG showing AF, in contrast F-waves (irregular electrical activity) are present 
instead of P-waves (Nattel, 2002b).    
 
II.      Holter Monitoring 
 When irregular heartbeats are intermittent, it is likely that they will not be 
recorded on the ECG. In this case a small portable ECG, called a Holter 
Monitor, is worn for 24-48 hours in order to capture the episodes, see Figure 17. 
The heart electrical activity are continuously recorded and stored in the monitor. 
After the monitor is removed, a technician uses a computer to analyse the 
recorded signal to evaluate the heart’s rhythm.   
 
Figure 17. Illustration of a 12-lead Holter monitor (DM Systems, 2013, [Online 
image]. Available from: http://www.dmsmed.en.alibaba.com).  
 
III.      Implantable Loop Recorder 
 The implanted recorder continuously monitors the heartbeat, 24 hours a 
day, 7 days a week.  The recorder is implanted under the skin, below the 
collarbone. This device is used for patients who occasionally feel palpitations, 
light-headedness or fainting, to assess whether the heart is causing these 
symptoms.  
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1.1.8. Classification  
 Guidelines of the American College of Cardiology (ACC), American Heart 
Association (AHA), and the European Society of Cardiology (ESC) recommend 
the following classification of AF based on simplicity and clinical application;  
 Acute AF with new-onset of AF and lasting less than two days. 
 Lone AF: with absence of clinical findings of any cardiovascular disease. 
The frequency of attacks in lone AF may vary from less than one a year 
to three per year or more. 
 Paroxysmal (intermittent): if there are recurrent episodes of AF that come 
and go spontaneously. Each episode stops just as suddenly as it starts 
without treatment within seven days. The period of time between each 
episode (each paroxysm) can vary greatly from case to case.   
 Chronic Persistent: if lasting longer than seven days, and is unlikely to 
revert back to normal without treatment, such as cardioversion. 
Persistent AF is likely to be recurrent so it may come back again even 
after successful cardioversion treatment.  
 Permanent (established): if there is an ongoing long-term episode. This 
means that the AF is presenting long-term. This may be because 
cardioversion treatment was not successful, or because cardioversion 
has not been tried. In permanent AF, it should be tried to bring the heart 
rate back to normal although the rhythm may remain irregular. Figure 18 
shows a schematic representation of AF classification. 
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Figure 18. Patterns of atrial fibrillation types. 1: episodes that last ≤ 7 days. 2: 
episodes that last > 7 days. 3: cardioversion failed. 4: either paroxysmal or 
persistent AF may be recurrent (ACC/AHA Practice Guidelines, Available from: 
http://www.circ.ahajournals.org). 
 
1.1.9. Complications  
 The main complication of AF is an increased risk of systemic thrombo-
embolism. This is because in AF, blood is pumped into the ventricles randomly, 
and the amount of blood pumped out of the ventricles is based on the 
randomness of the atrial beats, subsequently a blood clot forms. The clot can 
block blood supply in the heart and cause a heart attack, or travel to the brain 
and cause a stroke. Other complications of AF include the following (Cohn, 
2008): 
 Heart failure 
 Cardiomyopathy; atrial fibrillation can decrease the heart’s pumping 
ability and efficiently. In addition, atrial fibrillation occurs over a long 
period of time and can lead to weakening of the heart muscle 
 Other organ damage due to systemic emboli. 
1.1.10. Management and Therapy 
 The management of AF can be broken down into management of new-
onset and long-standing AF. The new-onset AF management is rhythm control, 
with pharmacological or/and electrical cardioversion. Rhythm control is 
restoration and maintenance of the normal rhythm of the heart. The long-
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standing AF management is rhythm control or rate control strategy. Rate control 
is used to minimise symptoms associated with excessive heart rates. This 
involves the use of drugs or electrophysiological/surgical approach to reduce 
the rapid ventricular rate. Choosing each strategy requires integration of several 
factors, including degree of symptoms, and likelihood of restoration of SR. In 
respect to management and treatment of AF there are pharmacological and 
non-pharmacological therapies (Zimetbaum and Josephson, 2003). 
I.     Pharmacological  
 Antiarrhythmic therapy is used for the following purposes: to convert AF 
into SR, to prevent recurrence after electrical cardioversion, or to achieve rate 
control in patients with permanent AF. Anticoagulation (antithrombotic) therapy 
is used to prevent thromboembolic complications. Antithrombotics therapy is 
used to reduce the risk of stroke. They include anti-platelet agents (e.g. Aspirin, 
Clopidogrel) and anti-coagulant agents (e.g Warfarin) (Anfinsen, 2002).    
Some of the pharmacological agents used for management of AF are:  
 Rate control agents: control the ventricular rate in response to AF. These 
include Digoxin, Calcium channel blockers (e.g. Verapamil, Diltiazem), 
and Beta-blockers (e.g. Atenolol, Metoprolol, Esmolol, Propranolol).  
 Rhythm control agents: maintain the SR and prevent the recurrence of 
AF. They include Quinidine, Disopyramide, Flecainide, Propafenone, 
Dofetilide, Ibutilide, Procainamide, and Amiodarone. 
II.     Non-Pharmacological  
     Some choices of non-pharmacological treatments are: surgical therapies, 
electrical cardioversion, and catheter ablation, which are explained in the 
following sections:  
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Surgical Therapies 
 The corridor procedure: in this procedure a strip of myocardium tissue 
connects the SA node to the AV node. This results in the isolation of the 
remainder of both left and right atrium, see Figure 19. The SR is restored in 
69% of patients. However, the left atrioventricular synchrony could not be re-
established in the majority of the patients, so the heart remained still a source of 
thromoboembolism (Liem, 2001). 
 
Figure 19. Illustration of the corridor procedure (Medscape education, 2009, 
[Online image]. Available from: http://www.med-scape.org).  
 
 The maze procedure:  a series of specific lesions are made in the left 
and right atrium to confine the electrical impulses and define pathways to reach 
the AV node, see Figure 20. These lesions block the abnormal electrical 
impulses from being conducted through the heart. Early results of the maze 
procedure were 89% SR restoration. However follow-up showed that up to 40% 
of patients required a pacemaker (Cox 1995 and 1993; McCarthy 1993).  
  
Figure 20. Illustration of the maze procedure. (Medscape education, 2009, 
[Online image]. Available from: http://www.med-scape.org).  
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Electrical Cardioversion 
 Electrical cardioversion (atrial defibrillator) is a procedure where an 
electrical shock (low-voltage electric current) is delivered to the heart through 
metal patches to convert an abnormal heart rhythm back to a normal rhythm, 
see Figure 21. It is used to stop AF that has not stopped after catheter ablation 
or a trial of pharmacological cardioversion has failed.  
 
Figure 21. Illustration of electrical cardioversion (Walker Heart Institute/ 
Cardioversion, 2012, [Online image]. Available from: http://www.wregional.com).   
 
Catheter Ablation 
 The catheter ablation is used to either heat up (Radiofrequency (RF) 
ablation) or freeze (cryoablation) the tissue causing the arrhythmia. The 
catheter ablation is performed through an electrophysiology (EP) study. Ablation 
means making small scar(s) in the heart tissue, so that it is unable to conduct 
electrical impulses. This is done using a long wire (catheter) into the heart 
through the femoral vein (groin) then moving the catheter tip towards the heart 
under the guidance of X-ray, see Figure 22.  
 
Figure 22. Left: example of an electrophysiology laboratory. Middle: the catheter 
is inserted into the femoral vein and advanced through the inferior vena cava, 
right atrium, then left atrium. Right: example of the catheter tip inside the left 
upper pulmonary vein.   
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 With the catheters in place, recordings of the heart’s electrical activity 
can be made from inside the heart known as Electrogram (EGM), see Figure 
23. Signals from inside the heart are collected, and show changes in electrical 
potential, usually displayed over a period of time. In an EGM, the baseline 
corresponds to a value of zero. Each change of electrical potential represents 
atrial activation, and the distance between two neighbouring activations is 
defined as the cycle length (CL).    
 
Figure 23. Left: example of signals between the distal and proximal bipoles from 
a catheter. Right: example of a catheter that is used for RF ablation (Takahashi, 
2008).    
 
 There are two main recording modes used to generate the EGM, 
unipolar and bipolar. All EGMs are recorded using two electrodes. One is 
positive and one is negative, which are computed by subtracting the information 
at the negative from the positive electrode. In fact, a bipolar EGM is a derivative 
of two unipoles.  A unipolar EGM uses the same process, but the negative 
electrode has a zero reference potential. This means that there is no electrical 
activities at the location of the negative pole, so unipolar EGM represents the 
view from one pole, see Figure 24. Once the physicians have identified the 
abnormal heart tissue, the catheter tip is positioned against the inner surface of 
the heart muscle close to the site of the origin of abnormal rhythm. At this point 
RF current (energy) is then passed into that area in order to burn the cells 
responsible for conducting abnormal rhythm, see Figure 25.   
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Figure 24. Examples of bipolar (top) and unipolar (bottom) signals, (The EP lab, 
2012, [Online image]. Available from: http://www.theeplab.com).  
 
   
Figure 25. Left: the catheter tip sent the RF energy that destroys the abnormal 
tissues. Right:  A, a focus (shown as star) is repeatedly firing and spreading to 
other cells. B, after ablation the tissue of the focus has been damaged and is no 
longer firing. Arrows show normal electrical propagation.  
 
Cardiac ablation can be performed for rate control (destroy the AV node) 
or rhythm control (isolate the PVs). The ablation of the AV node destroys the AV 
node and block AV conduction. This has been an effective treatment for rate 
control but requires permanent pacemaker implantation (Ganz and Saperia, 
2012). The ablation of the PVs ostium focuses on the elimination of triggers for 
AF via electrical isolation of the PVs. Sometimes it also includes additional 
lesions to be made in the body of the LA (e.g. roof and floor, see Figure 26) to 
modify arrhythmic substrate (Cox et al. 1991).  
 
Figure 26. Illustration of PV isolation (orange lines) (Virtual medical centre, 
2012, [Online image]. Available from: http://www.virtualmedicalcentre.com).   
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There is no recommend standard ablation procedure. More information 
on mapping, ablation lesions, and origins of AF is needed to improve AF 
treatment. Using catheters for mapping or ablation has some risks such as: 
bleeding, infection, damage to left atrial esophageal, damage to blood vessels 
and pain at the site where the ablation catheter was inserted.  
The outcome of AF ablation differs depending on the AF type, and 
related heart disease. Practical difficulties in determining the outcome of AF 
therapy success rate depend on: the regularity and intensity of arrhythmia 
monitoring, whether patients on antiarrhythmic drugs during follow-up are 
categorised as successes or failure. Focusing on the RF ablation at 12 months 
of follow-up, it has been observed that the single procedure success of patients 
with persistent AF ranged from 22% to 45% (Calkins 2007; Fuster 2006). 
Another research study shows more than 80% of patients who undergo 
cardioversion for persistent AF after ablation, have recurrence (Chilukuri et al. 
2010).                             
1.2. Engineering Background  
 The complexity of AF signals has been identified as targets for AF 
ablation. As a result, an understanding of the complexity of AF signals has been 
shown to be helpful in the detection and treatment of AF (Ng et al. 2010). Such 
signals contain information about the AF mechanism, which is hidden in its 
structure and may not be readily observed. This information has to be extracted 
so that the signal can be given meaningful interpretation. Therefore, signal 
processing techniques have become an essential tool for extracting clinically 
significant information from AF signals. These signal processing techniques are 
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used to understand the mechanism and possible sources of AF, resulting in 
guiding ablation or drug therapy in the treatment of AF.   
 This section reviews the signal processing techniques which have been 
used to analyse AF. The aim of this review was to introduce different methods 
concerning the understanding of AF, and to define the current ‘state of the art’ 
from which this project will advance. This section has been grouped in terms of 
body surface signal analysis (see section 1.2.1), intracardiac signal analysis 
(see section 1.2.2), and joint body surface and intracardiac signals analysis 
(see section 1.2.3). Finally, the methods that will be used in this PhD project to 
investigate AF characteristics are introduced (see section 1.2.4).  
1.2.1. Review of Body Surface Signal Processing  
 The 12-lead ECG is the most common and readily available method to 
characterise cardiac activity non-invasively (Donnelly 2006; Trobec 2003). In 
body surface potential mapping, increased spatial sampling is used to allow 
more accurate detection of a cardiac abnormality (Finlay et al. 2005), and more 
accurate diagnosis of the cardiac pathologies (Bond et al. 2010). This has 
become a strong motivation for extracting cardiac activity from the body surface 
using more than 12 leads. In order to achieve this, the 12-lead ECG has been 
extended through the use of additional electrodes, a technique known as body 
surface potential mapping (BSPM). The BSPM uses 32 to 219 electrodes 
(leads) to record electrical activity over a large portion of the torso and back 
(Huebner 2010; Donnelly 2008; Finlay 2006; Hanninen 2001; Hoekema 1999a; 
Kornreich 1997). Unlike the 12-lead ECG technique, there is no standard 
representation or acquisition of the BSPM, however a lead system incorporating 
64 leads is suffice for most applications (Hoekema et al. 1999b). AF could be 
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episodic, so it is possible to study AF when patients are in SR or when they are 
in AF. In the literature, the BSPM has been widely used to investigate the P-
wave propagation across the body surface (Kozlikova 2011, 2007; Macfarlane 
2010; Krandycheva 2006; Lian 2002; Medvegy 2002; Yamada 1999; Watanabe 
1988). However, as patients studied in this PhD project were in AF, this section 
describes techniques for analysis when the patients are in AF.  
 Ihara suggested that the adaptation of the 12-lead ECG by putting one 
lead on the back produces a better view of AF (Ihara, 2007).  Kornreich also 
explored using additional leads to the 12-lead ECG, and found that adding four 
leads to the 12-lead ECG (see Figure 27) improves diagnostic performance 
regardless of the subject or the disease group (Kornreich et al. 2008).    
 
Figure 27. A schematic of the four additional leads to the 12-lead ECG 
(Kornreich et al. 2008). 3 limb leads have not been shown in the figure.  
 
 Figure 28 represents the steps involved in analysing the surface ECG 
signal when the patient is in AF, regardless of the number of electrodes that 
have been used.  
                 
Figure 28. A schematic representation of the steps involved in analysing the 
surface ECG when patient is in AF.  
 
 Pre-processing includes filtering of baseline wander, muscle artifact, and 
mains interference 
 Atrial activity (AA) estimation is achieved using QRST cancellation 
 Parameter estimation includes estimating AF characteristics such as 
amplitude and frequency (rate). 
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Pre-processing  
 The methods of noise reduction have an important influence on the 
performance of the ECG signal processing. Baseline wander is a common 
artifact in the body surface signal caused by varying electrode contact during 
the recording. This could be due to patient movement, poor electrode contact 
with skin and breathing. The frequency range of baseline wander is usually less 
than 1 Hz (Karthikeyan et al. 2012). Good skin preparation can help to eliminate 
this type of artifact. However, removal of baseline wander is required in order to 
minimise changes in beat morphology which do not have cardiac origin. 
Different methods for removing the baseline wander have been presented such 
as; nonlinear filter (Jackek and Norbert 2005), time-varying digital filtering 
(Sörnmo, 1993), nonlinear filter bank (Leski and Henzel 2005), linear low-pass 
filter (Hargittai, 2008), cascade adaptive filtering (Laguna, 1992), selective 
filtering (Shusterman et al. 2000), and wavelet-based cascaded adaptive filter 
(Xu et al. 2007). An important concern in all of these methods is to remove the 
low-frequency components that are not related to the cardiac electrical activity. 
Figure 29 shows an ECG before and after filtering baseline wander.  
 
Figure 29. Illustration of an ECG with a baseline wander (A), and a clean ECG 
(B) (Computers in Biology and Medicine, 2012, [Online image]. Available from:  
http://www.computersinbiologyandmedicine.com).  
 
 Electromagnetic fields caused by a power line represent a noise source 
in the ECG. This artifact is characterised by 50 Hz sinusoidal interference, 
possibly accompanied by a number of harmonics (Husser et al. 2005). Removal 
of this interference is done using a 50 Hz Notch filter, since the spectral content 
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of atrial activity typically is below 25 Hz (Sandberg, 2007). Figure 30 shows an 
ECG with 50 Hz power line noise, before and after filtering.   
 
Figure 30. Illustration of an ECG with 50 Hz power line interference (A), and a 
clean ECG (B) (Levkon et al, 2005). 
 
 Muscle artifact with small amplitude and high frequency is another 
problem in ECG, since the spectral content of this artifact overlaps with QRS 
complex. Different filter systems have been provided to remove the muscle 
artifact (Mak 2010; Rahman 2009; Do-Un 2008; Kim 2006). 
Atrial Activity Estimation 
 As AA has much smaller magnitude than ventricular activity (VA) in the 
surface ECG, the VA needs to be cancelled before the AA can be studied 
(Lemay et al. 2007). One of the most essential steps for this purpose is QRS (or 
beat) detection. Moreover, QRS detection could be used to identify AF as it 
distinguishes the ventricular rate and rhythm (Abacherli et al. 2009). QRS, 
followed by T-wave detection (QRST) is used in order to extract AA. Algorithms 
for the detection of QRST can significantly affect the signal analysis process, as 
they must be able to detect a variety of different morphologies and also ectopic 
beats. Many algorithms have been introduced such as:  mathematical 
morphology (Trahanias 1993; Portet 2005), filter banks  (Hamilton, 2002), 
adaptive filtering and wavelet transform (Kozakevicius, 2004), adaptive 
threshold QRS detector (Chiarugi et al. 2007a), first-derivative-based methods 
(often used in real-time analysis or for large datasets since they do not require 
manual segmentation of data, training of the algorithms) (Kohler et al. 2002),  
30 
 
zero-crossing (Arzeno et al. 2008), adaptive quantised threshold (Chouhan 
2008; Elgendi 2009), and wavelet and artificial neural network (Abibullaev and 
Don Seo 2011). Figure 31 shows detected QRSTs of an ECG signal.      
     
Figure 31. Illustration of a detected QRST of an ECG signal (Rooijakkers, 
2012).   
  
 AA extraction or QRST cancellation is performed using various methods 
and algorithms such as; QRST morphology clustering cancellation (Di Marco 
2011; Karimifard 2011), average beat subtraction (ABS) (Sörnmo 2009; Petrutiu 
2006; Bollmann 2006a; Lemay 2007 and 2005; Xi 2003), spatiotemporal QRST 
cancellation (Klamor  2011; Stridh 2001), adaptive singular value (Alcaraz and 
Rieta 2008), independent components analysis (ICA) (Lemay et al. 2007), 
principal component analysis (PCA) (Langley  2006, 2000; Castells  2005a), 
maximum likelihood source separation (Castells et al. 2005b), blind source 
separation (BSS) (Rieta, 2004), and packet wavelet decomposition (Sanchez et 
al. 2002). Evaluations of QRST cancellation methods have confirmed that the 
cancellation methods are reliable for studying atrial fibrillatory wave 
characteristics (Vaya 2007; Lemay 2007; Langley 2006, 2002, 2000; Xi 2003). 
An evaluation by Langley showed that the extracted atrial signals from ICA, 
PCA and ABS algorithms exhibit very similar amplitude and frequency 
characteristics (Langley, 2002). Figure 32 shows the recording of lead V1 from 
a patient with AF and an appearance of the signal after subtraction of the QRST 
using ABS algorithm.  
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Figure 32. (A) Recording of lead V1 from a patient in AF and a rapid ventricular 
response. (B) Appearance of the signal after subtraction of the QRST using a 
template matching algorithm (Bollmann et al. 1998).   
 
Parameter Estimation 
 Various parameters have been introduced to characterise AF in the time 
and frequency domains. The most common parameters based on surface ECG 
are amplitude, dominant frequency (DF), spectral concentration (SC) and 
organisation index. Methods to estimate these parameters are the focus of this 
section. 
 Amplitude 
 It is believed that lead V1 has high amplitude F-waves due to the 
proximity of the lead to the RA (Petrutiu et al. 2006). Mostly regular AF cases 
known to have high-amplitude F-waves, while less regular  AF cases have 
lower amplitude (Petrutiu et al. 2006). Measured AF amplitudes are used to 
make the distinction between coarse and fine AF (Langley et al. 2000). The AF 
amplitude is often described as fine (< 50 μV) or coarse (> 50 μV), which has 
been linked to specific heart conditions (Thurmann, 1965). Different studies of 
coarse versus fine AF, consider that either left atrial size or heart disease are 
responsible for the AF amplitude. These studies associate rheumatic heart 
disease with coarse F-waves and arteriosclerotic heart disease with fine F-
waves (Morganroth et al. 1979). Xi showed that median peak to peak AF 
amplitude has intra-patient repeatability over 24 hours, whereas the inter-patient 
variability is high (Xi et al. 2004a). The relationships of AF amplitude were also 
investigated for different types of AF. It was found that there is no statistical 
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significance between AF amplitude and different types of AF, which include 
paroxysmal, persistent, and permanent. AF amplitude is also not different for 
patients taking anti-fibrillatory drugs when compared with those not taking anti-
fibrillatory drugs, and AF amplitude is not age dependent (Petrutiu et al. 2006).  
 Xi described two methods to quantify F-wave amplitude. In the first 
method, the region of QRST complexes is excluded from analysis to avoid 
contribution of QRS residuals. Subsequently, the four individual F-waves with 
the largest peak-to-peak amplitude are selected. The average of these four 
amplitudes is selected as the representative peak-to-peak amplitude. The 
second method is by observation of the average value of the peak-to-peak F-
wave amplitude for the entire duration of the recording (Xi et al. 2004b). The F-
wave amplitude proved to be a successful predictor of AF recurrence after 
electrical cardioversion, with a diagnostic accuracy approximately 80% (Alcaraz 
and Rieta 2009a). 
 Spectral Analysis  
 A periodic signal can be expressed as a sum of sine waves in the 
frequency domain. As a result, spectral analysis can be used to study AF with 
the goals of determining the location of dominant (fundamental) peak, and 
investigating the spectral shape (Corino et al. 2007).  
 i.    Dominant Frequency 
 An AA signal typically exhibits a narrowband spectrum with a main 
frequency between 3–9 Hz (Castells 2005a; Bollmann 2000a; Holm 1998). The 
main peak in the frequency band determines the fibrillatory rate and is termed 
DF (Bollmann and Lombardi, 2006b). Previous studies have shown that DF is 
widely used as an indicator of atrial refractoriness (Chiarugi 2007b; Hayn 2007; 
33 
 
Nilsson 2006; Capucci 1995). AF DF has proved to be successful in monitoring 
AF treatment (Husser 2007; Raine 2004; Langley 2003) as well as in predicting 
spontaneous AF termination (Nilsson et al. 2006). Several studies support the 
idea that AF with a low DF is more likely to terminate spontaneously and 
responds better to treatment. When the fibrillation frequency is below 6 Hz the 
likelihood of successful pharmaceutical cardioversion is higher. These are 
important considerations when selecting candidates for cardioversion. 
Conversely, high AF DF is more often persistent and harder to manage (Nilsson 
2006; Bollmann 2006a, 2000; Lazar 2004; Meurling 2001). Fibrillatory rate 
changes have been observed and showed that freedom from recurrent AF has 
been associated with the degree of fibrillatory rate reduction in lead V1 (Husser 
et al. 2006). Furthermore, several studies have shown that DF obtained from 
lead V1 is highly correlated with the fibrillatory rate of the RA (Petrutiu 2009; 
Hsu 2008; Husser 2007; Holm 1998). According to Langley, DF measurement 
reveals information regarding the atrial rhythm and AF stability non-invasively 
(Langley et al. 2000). Bollmann showed that the AF frequency decreases at 
night and increases in the morning. The above results should be taken into 
consideration in the management of AF.  Also Sandberg showed that there is 
0.15 ± 0.09 Hz circadian variation in the AF frequency. In previous studies 
(Meurling 2001; Langley 2000; Bollmann 2000b) the AF frequency was sparsely 
measured and consequently, the short-term variation could not be observed 
(Sandberg et al. 2010). A study of the fibrillatory rate in single paroxysmal AF 
episodes showed that the rate of long AF episodes increase over the first four 
minutes, while short episodes also showed an increase from the first to the 
second minute (Petrutiu et al. 2007).  
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 From an electrophysiological point of view, the F-waves have time 
dependent properties. Therefore, time-frequency analysis can be used in order 
to investigate the variations in frequency over time to determine the atrial rate 
and AF characterisation (Petrutiu 2006; Stridh 2004). This method allows non-
invasive monitoring of the fibrillatory rate and waveform of lead V1 on the ECG. 
The F-waves of surface ECG on lead V1 closely reflect right atrium activity 
(RAA) and, to a smaller degree, left atrium activity LAA (Husser et al. 2007). 
Vaya undertook a study to distinguish between the AF episodes that terminate 
immediately and those that sustain. He concluded that the combined analysis of 
time and frequency can be used to predict spontaneous termination of 
paroxysmal AF (Vaya and Rieta 2009). However, time-frequency analysis is 
more suitable when the outcome of AF treatment is under investigation as this 
method detects the changes in AF frequency (Corino et al. 2007).  
ii.    Spectral Concentration 
 SC is the atrial signal concentration of power around a main peak. This 
parameter can be used for different purposes, such as estimation of the quality 
of the AA extraction and the AF degree of organisation. Phlypo stated that 
higher SC is associated with more accurate AA estimation. SC decreases as 
the VA are not being cancelled properly (Phlypo et al. 2010). Moreover, lower 
SC is related with more spectral peaks in the AF frequency band, which may 
suggest disorganised AF. Higher SC is associated with a prominent spectral 
peak in the AF frequency band, which may suggest organised AF (Di Marco et 
al. 2012). However as all non-related AA components have spectral contents 
outside the AF frequency band (3–9 Hz), SC is suitable to estimate the AF 
degree of organisation (Castells et al. 2003). 
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iii.    Organisation Index                  
 AF organisation is defined as the degree of repetition in the AA (Everett 
2001; Sih 1999). Investigation of AF organisation can potentially be used to 
provide information about the AF mechanism, as it has been demonstrated that 
the number of re-entries is related to AF organisation (Everett, 2001). AF 
organisation can be used to provide information about time variation in the 
onset and termination of AF.  AF organisation is quantified by different methods 
such as studying TQ segments, non-linear metrics (e.g. sample entropy 
(SampEn), approximate entropy), and as previously mentioned, studying the SC 
(Alcaraz and Rieta 2010, 2009d; Nollo 2008; Nilsson 2006; Mainardi 2001; 
Hoekstra 1995). SampEn examines a time series and associates a positive 
number to the sequence, with low values corresponding to higher levels of 
regularity (Richman and Moorman 2002). However, a study has shown that the 
existence of QRST residual in the AA signal affects AF organisation estimation 
using non-linear methods. To improve upon on this, the fundamental waveform 
associated with the AA is obtained, and called main atrial wave (MAW). The 
MAW is obtained through selective filtering of the AA by tracking its DF. Alcaraz 
has demonstrated that AF organisation variation can be estimated from surface 
ECG through the application of SampEn to the MAW (Alcaraz and Rieta 2009c). 
His study has shown that the use of SampEn on the MAW predicts 
spontaneous termination of paroxysmal AF in 92% of the analysed episodes 
(Alcaraz and Rieta 2009b). The results of studying TQ segments suggest that a 
higher degree of spatial organisation is associated with a reduced variability of 
spatial organisation over time, and lower spectral variability associated with a 
more prominent spectral peak in the AF frequency band (Di Marco et al. 2012). 
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1.2.2. Review of Intracardiac Signal Processing  
 EP study is the cornerstone of AF ablation therapy (Baykaner et al. 
2012). Processing and interpretation of the EGM recorded from inside the atria 
have played an important role in understanding the mechanisms of AF. 
However, as yet the extent to which the analysis of EGM can improve the 
efficacy of AF ablation therapy is still unknown.  This section describes the 
steps involved in analysis of AF based on EGM (see Figure 33).  
 
Figure 33. A schematic representation of the steps involved in analysing EGM.  
 
 Pre-processing includes filtering of baseline wander, and mains 
interference 
 Far-field VA cancellation, which is achieved by subtracting far-field QRS 
from EGM  
 Parameter estimation, e.g. frequency (rate).   
 
Pre-processing  
 Electrical activity recorded from inside the heart is passed through a 
series of electronic devices. This may cause artifacts from the circuits within the 
electronic sources during recording. Filters are used to remove artifacts while 
allowing frequencies of interest to pass. Choosing the filter is important and has 
a significant impact on the outcome of any analysis, and hence the conclusions 
which are drawn. The low-pass filter allows lower frequencies to pass and helps 
to remove high frequency environmental noise. Most common EGM pre-
processing  uses a band-pass filter with cut-offs at 40 to 250 Hz, followed by 
rectifying (using the absolute value of the output of the band-pass filter), and 
low pass filtering with a cut-off of 20 Hz (see Figure 34). This pre-processing 
extracts high-frequency components, and transforms a complex waveform of 
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the EGM into a series of atrial activations. This reduces the effect of varying 
EGM morphology and emphasizes the possible periodicity of the signal (Ng 
2012, 2011, 2007; Richter 2011; Ravi 2009; Petrutiu 2009; Takahashi 2008; Lin 
2006; Lazar 2004; Botteron 1996, 1995).  
 
Figure 34. Illustrations of an EGM signal processing steps during atrial 
fibrillation. A: Unprocessed EGM, B: Band-pass filtering of 40 and 250 Hz, C: 
Rectifying, D: Low-pass filtering at 20 Hz (Ng et al. 2007).  
 
Far-field Ventricular Activity Cancellation 
 Cancelling far-field VA on EGM allows detection of true atrial signals. 
Far-field VA was originally noted in recordings from CS, though it may be 
recorded from any part of the atrium. On bipolar atrial recordings far-field VA 
are significantly lower in amplitudes compare to unipolar atrial recordings 
(Griffin, 2012). However, Elvan’s study of EGM before and after far-field VA 
subtraction shows there is no difference in DF derived from the bipolar and 
unipolar EGM (Elvan et al. 2009). The most common procedure for far-field VA 
subtraction is as follows: the surface ECG is used as a guide to identify the 
QRS, atrial signal windows synchronised with the detected QRS are averaged, 
and the templates are subtracted from the atrial signal at each ventricular 
activation time (Yoshida 2012; Faes 2002, 2001; Kandori 2002; Hoekstra 2000, 
1997; Shkurovich 1998; Slocum 1985). In Salinet’s study, QRST subtraction is 
based on the application of a band-pass filter between 8 and 20 Hz and low-
pass filtering the rectified signal. The cut-off of frequency of the low-pass filter is 
38 
 
determined by the lowest RR interval of the ECG signals (354 beats per minute) 
and was chosen as 6 Hz. The peaks of the resulting signals were determined 
and areas corresponding to VA were replaced by flat interpolation, which is 
similar to the baseline (Salinet Jr et al. 2010). Jarman proposed an algorithm for 
far-field VA removal based on morphology. In this algorithm far-field QRS 
components of the unipolar non-contact EGM were subtracted using three 
steps: first, timing of far-field QRS was identified automatically from a reference 
site in the LA. The EGM from the LA site with clearest ventricular depolarisation 
were defined as a reference. Second, all of the identified ventricular 
components were overlaid to obtain a mean. Third, the mean ventricular 
complex was used to subtract the ventricular component of the EGM (Jarman et 
al. 2012). It should be noted that there are studies in which far-field VA 
subtraction has not been performed as it was not observed on the EGM 
(Petrutiu 2009; Sanders 2006; Biffi 2003).  
Parameter Estimation 
 The evaluation of EGM parameters, such as fundamental frequency, 
provides a basis for selecting the appropriate AF treatment (Houben and 
Allessie 2006). Frequency analysis provides some explanation of the EGM by 
estimating both the fundamental frequency and the AF rhythm (Barquero-Perez 
et al. 2009). Frequency analysis was performed on the EGM recorded from PV, 
LA, CS, RA, and SVC. The highest DFs are mostly located at the 
arrhythmogenic PV ostium (Lin, 2006).  
 In a study presented by Sheldon, sites of complex fractionated atrial 
electrogram (CFAE) with a short mean CL (MCL) and sites with a high DF have 
been targeted for ablation in patients with persistent AF (Sheldon et al. 2009). A 
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characteristic frequency of CFAEs offers details of complexity of an EGM during 
AF; so it is capable for real-time application and can be a guide during catheter 
ablation (Nguyen et al. 2009).  To investigate the atrial substrate characteristics 
near the SA node during SR, ongoing AF and before AF termination showed 
that the SA node activity during ongoing AF was similar to the rest of the RA 
and also DF around SA node area during AF termination was similar to during 
SR.  This suggests that the sinus automaticity is preserved with local entrance 
block from the rest of the atrium (Tso et al. 2005). Advanced mapping 
techniques in AF showed that sufficient success rates can be achieved with left 
atrial ablation, in addition to complete PV isolation. Important techniques in this 
regard are the mapping of CFAE as well as identification of sites serving as 
sources of AF (Lickfett et al. 2008). Habel explained that DF and CFAE are 
temporally variable; consequently, sequential mapping can be misleading 
because of temporal variability (Habel et al. 2010). Since Haïssaguerre showed 
that ectopy from the PVs trigger AF, PV isolation has become central to most 
ablation approaches (Baykaner et al. 2012).  
 EGM AF organisation was defined by Faes as atrial activation 
morphology uniformity in time (Faes et al. 2002). Several methods for 
quantifying AF organisation estimated from inside the heart have been 
introduced including linear and non-linear analysis (Mainardi 2001; Sih 1999; 
Hoekstra 1995). Faes presented a method of evaluation AF organisation using 
regularity index. In his study the regularity index is defined by calculating the 
similar pairs of local activation waves in a window length of 90 ms. This enables 
the temporal AF organisation to be followed as well as identifying regions with 
different degrees of organisation. Assessment of the EGM regularity during AF 
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plays an important role in the treatment of AF, such as catheter ablation (Faes 
et al. 2002).  
1.2.3. Review of Joint Body Surface and Intracardiac Signal Processing     
 There have been a few studies considering the joint body surface and 
intracardiac signals in AF.  This helps to investigate whether intracardiac sites 
can be identified non-invasively, as well as allowing a non-invasive 
characterisation of AF. These should help AF intervention planning and therapy.  
It has been thought that the ablation of high frequency sources is an 
effective therapy to restore SR. However, with this approach DF gradient need 
to be understood, which requires a study of the propagation of cardiac potential 
across the torso and back. Guillem studied 67-lead ECG recordings and EGM 
from both atria. She showed that spectral analysis of body surface recordings 
during AF allows a non-invasive identification of the atrium with the high 
frequency (Guillem et al. 2013). She used cardiac potential mapping method, 
which is not an approach followed in this study. Holm assessed the AF CL using 
the surface ECG and compared it with the intracardiac signal. They showed that 
AF CL correlates with the degree of atrial organisation. In general, shorter CL 
during AF was associated with a more organised AF. He also showed that the 
atrial CL in lead V1, ranging from 130 to 185 ms, represents the right atrium CL 
(Holm et al. 1998). A recent study showed that in AF, the correlation between 
the frequency of surface AA and atrial refractoriness, although significant, is not 
strong (Raitt et al. 2012). Several studies have quantified the frequency range 
of AF using the surface ECG. In these studies, ECG recordings obtained in 
patients during AF are compared to direct measurements from the RA and CS. 
AF DF on lead V1 and frequency measured in the RA and CS are significantly 
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correlated (Hsu 2008; Husser 2004; Shimizu 2003; Bollmann 1998). Ravi 
compared AF CL between the LA, RA, CS and 12-lead ECG. He estimated AF 
CL from the surface ECG in patients with persistent and paroxysmal AF prior to 
ablation. His study suggests that the mean of AF CL in leads V5, I and aVL can 
be used to estimate LA CL, leads aVF, II and III can be used to estimate CS CL, 
and V1, V2 and aVR can be used to estimate RA CL (Ravi et al. 2009). Sörnmo 
showed that the fibrillatory rate obtained from the surface ECG could be 
considered as an index to determine atrial fibrillatory cycle. He also suggested 
that the rate differences and variability between ECG and EGM increased with 
growing anatomical distances of the LA, RA, and PVs to lead V1 (Sörnmo et al. 
2009).  
1.3. Methods and Parameters Used in This PhD Study 
 In this study signal processing methods chosen to extract and study AF 
characteristics are based on the reviewed literature and are as follows:    
I. The 12-lead ECG is the most common and readily available method to 
characterise cardiac activity non-invasively. In this study, AF was 
investigated in a more comprehensive way by using a 64-lead ECG. This 
could potentially discover body surface sites which might be particularly 
sensitive to atrial electrical activity, and it may spur the development of a 
greater understanding of the AF mechanism from the body surface. 
II. AA estimation from the body surface and inside the heart was performed 
using the ABS method. The motivation for choosing this method was 
three-fold. Firstly, it allows a consistent method for signal processing of 
the body surface and intracardiac signals; Secondly, in this method all 
body surface sites can be studied individually whereas in other methods 
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(e.g. PCA) the body surface sites are combined; Thirdly, it has been 
shown that AA estimation using existing QRST cancellation methods 
exhibit similar results of the frequency characteristics.   
III. AF amplitude (estimated from the body surface), DF and SC (estimated 
from the body surface and inside the heart) were chosen to be 
investigated.  Amplitude was chosen to study how AF complexity is 
expressed on the body surface. SC was chosen to compare the body 
surface with intracardiac recordings. DF was chosen as it is the most 
common parameter used to study AF.  
IV. New approaches were introduced for time synchronisation of the BSPM 
and EGM recordings, and to estimate amplitude of the AF signal from the 
BSPM recordings. 
V. Although DF provides information about the main AF rate, other 
frequency components may be omitted or neglected. In this study a novel 
parameter was proposed and called Peak Type. This investigates any 
distinct frequency components on the body surface spectra and relates 
them to intracardiac DF to help determine if intracardiac DF agrees with 
body surface DF. If it does not, are there any other frequency 
components on the body surface sites that correspond to intracardiac 
DF. 
VI. There is no evidence of AF investigation from the body surface and 
inside the heart in the time domain. In this study a novel method was 
proposed to relate AA from the body surface and inside the heart in time 
series with the following goals: firstly, to avoid QRST cancellation 
limitations such as VA residuals after cancellation, and secondly to study 
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AF in less processed signals which may present the true AF 
characteristics.   
VII. A novel parameter was introduced and called intracardiac power. This 
investigates intracardiac DF power distribution on the body surface 
spectra. This is an important extension to the literature which helps to 
clarify where on the body surface intracardiac DF contributes as a 
dominant or non-dominant spectral peak.  
1.4. Aim of Result Chapters in This PhD Study  
 The aim of this project was to investigate if the LA electrical activity could 
be observed preferentially in different sites on the body surface. This would be 
an asset to investigate and improve diagnosis of AF from the body surface. This 
aim was investigated exclusively in chapters 7 and 8, and to some extent in the 
end of chapters 3, 4, 5, and 6. However, prior to comparing the body surface 
and intracardiac recordings across subjects, following were essential to explore; 
each subject's data to justify outliers if there were any (chapter 3), if BMI had 
influence on the body surface recordings (chapter 4), if the body surface 
recordings were consistent over time (chapter 5), and over space (chapter 6).    
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Chapter 2. Methods 
 This chapter describes the recording equipment, patient recruitment, and 
recording protocols used in the study. The methods of data analysis, including 
signal processing and statistics are also discussed in this chapter. The body 
surface and intracardiac recording systems are explained in section 2.1 which 
introduces the components of these recording systems. Section 2.2 explains the 
data collection procedure and also provides background to the patients whose 
data is the focus of this work. The signal processing is explained in section 2.3, 
which includes body surface and intracardiac processing and estimation of 
different features. In section 2.4 different grouping of the body surface electrode 
sites are illustrated. Finally, statistical tests performed to interpret and 
understand the features are described in section 2.5.    
2.1. Recording Equipment 
  Body surface potential mapping and electrophysiology recording systems 
were used to collect the data during this project. Familiarisation and a good 
understanding of the recording systems were essential prior to the start of data 
collection. 
2.1.1. Body Surface Potential Mapping Recording System 
 BioSemi® (BioSemi, Amsterdam, Netherlands) ActiveTwo™ was used to 
record the cardiac electrical activity from the body surface. This equipment 
consists of sets of electrodes, an analogue to digital converter (A/D box), a USB 
receiver and a display device. A simple block diagram of the BSPM recording 
system is depicted in Figure 35, and each component is explained in the 
sections to follow. 
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Figure 35. A schematic representation of the BSPM recording system 
components.     
 
Electrodes: There are 3 bipolar electrodes that are used as limb leads, and 64 
monopolar integrated pre-amplifier carbon electrodes (active electrodes) that 
are used as 64-lead BSPM. The active electrodes make the signal less 
sensitive to environmental noise and movement of the electrode cables. Carbon 
electrode discs and wires are invisible under X-ray machine. The 64-lead BSPM 
are arranged in 8 flexible rubber strips (length of 43 cm) with 8 electrodes on 
each strip (each 45 mm apart, centre distance). They are fixed in two sets of 4 
strips, the electrodes in one set are numbered 1 to 32 (Set A), and the other set 
33 to 64 (Set B).    
A/D box: The electrode cables are fed into an analogue to digital convertor 
which digitises the signals with 24 bit resolution, 31nV digital resolution (least 
significant bit (LSB)) and sample rate of 2048 Hz. The digitised data is 
transmitted via an optical fibre data link to a USB receiver. A fibre optic link 
enhances the interference rejection and subject safety.    
USB Receiver: The USB receiver converts the optical data coming from 
the A/D box to a USB output.  
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Data Acquisition Programe: LabVIEW  software is used to display the signal 
on a digital screen. The collected signals are stored in BioSemi Data 
Format (BDF) on a standard personal laptop.  
2.1.2. Intracardiac Recording System  
 LabSystem™ PRO EP recording system (Bard Electrophysiology, 
Lowell, MA, USA) was used to record the cardiac electrical activity from inside 
the heart. This contained a catheter, connection box, amplifier and a display 
device. A simple block diagram of instrumentation and component connections 
of the intracardiac recording system is depicted in Figure 36. An explanation of 
each component follows.  Appendix A contains information about more 
sophisticated instrumentation and component connections.  
   
Figure 36. A schematic representation of the EGM recording system 
components.    
 
Catheter: A range of catheters are used in the EP labs. Catheters differ based 
on the electrode spacing and the shape. Some types of catheters are used for 
mapping the electrical activity of the heart, and others are used for delivering 
ablation therapy. There are also some catheters that perform both mapping and 
ablation. Depending on the anatomical location within the heart that is being 
studied, the cardiologist will chose the appropriate type of catheter.  
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 The types of mapping catheters that were used in this study are as 
follows:   
 PVAC:  A pulmonary vein ablation catheter (PVAC) (Ablation Frontiers, 
Carlsbad, CA, USA) was used to record EGM from the PVs. The PVAC®  
is a bipolar 10-electrode catheter with 3 mm long electrodes and 3 mm 
spacing between each electrode, see Figure 37 below.   
 
Figure 37. The PVAC catheter. Device view (Left), x-ray view (middle), and 
location in the heart (right). 
 
 CS:  A CS catheter (Bard Electrophysiology, Lowell, MA, USA) was used 
to record EGM from the CS. The CS® is a bipolar 10-electrode catheter 
with 2-5-2 mm spacing, see Figure 38 below. 
                         
Figure 38. The CS catheter. Device view (Left), x-ray view (middle), and 
location in the heart (right). 
 
Amplifier: A CLEARSIGN Bard amplifier was used to amplify signals with 16-bit 
A/D converter and noise rejection filters. In order to find the frequency 
characteristic of the amplifier, which was not specified by the manufacturer, a 
test signal was performed in the EP lab. A 7 mV sine wave signal was 
generated by a signal generator (LEVELL R.C. Oscillator Type TG200DMP).  
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 The generated signal was applied to the distal electrode pairs of a CS 
catheter. The catheter was connected to the amplifier via the connector box. 
The signal was displayed on the screen with sample rate of 1000 Hz. Figure 39 
shows a block diagram of the component connections for this purpose.   
              
Figure 39. A schematic representation of the connection route from the signal 
generator to display.   
 
 From the available software filter settings (band-pass filter cut-off 
frequencies 0.01- 400 Hz) two filter settings were selected for the experiment. 
(1) 30 - 200 Hz which was the standard setting used in the EP study, and (2) 
0.01 - 400 Hz, which the frequency range of interest was well within this band. 
For characterising the frequency response of the amplifier, data was stored in 
American Standard Code for Information Interchange (ASCII) format, and 
loaded into Matlab. The gain was calculated and the frequency response curves 
were plotted, as shown in Figure 40. The results showed a flat frequency 
response curve when the 0.01 to 400 Hz filter setting was applied. This 
confirmed that the amplifier was sensitive to all frequencies in this range. It also 
suggested that the band-pass agreed with the filter cut-off frequency, as the 
amplifier passed the signals within the filter range. Moreover, the results 
showed a curved frequency response when the 30 to 200 Hz filter setting was 
used. This curved frequency response suggested that the band-pass agreed 
with the filter cut-off frequency as the amplifier passed the signals within the 
filter range and attenuated what was outside the defined range.   
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Figure 40. Amplifier frequency response plot. Top: 0.01 - 400 Hz filter setting. 
Bottom: 30 - 200 Hz filter setting. The red vertical dashed lines indicate the 
band-pass of the frequency response curve.     
 
Data Acquisition Programe: LabSystem™ PRO V2-4a software was used to 
display the collected signals, as shown in Figure 41. 
 
Figure 41. Illustration of the EGM recordings from 3 leads of the 12-lead ECG 
(blue), five CS sites (green), and five PVAC sites (yellow).  
 
2.2. Patient Recruitment and Recording Protocols 
 To compare body surface and intracardiac recordings in AF patients, 
electrical activity from the heart was recorded simultaneously from the body 
surface and inside the heart. To obtain permission for recruiting patients and 
recording signals, letters of access and ethical approval were obtained.  
50 
 
2.2.1. Letter of Access for Research 
 This letter confirmed the right of access to conduct research through the 
Newcastle upon Tyne Hospitals NHS Foundation Trust. To obtain this access, a 
good understanding and strict adherence to the requirements of the NHS 
confidentiality code of practice and the Data Protection Act 1998 was 
demonstrated. This was done by undertaking good clinical practice (GCP) and 
Caldicott /data protection trainings. 
2.2.2. Ethical Approval 
 The ethical approval form was completed and submitted to the Research 
Ethics Committee (REC), through the Integrated Research Application System 
(IRAS). For this purpose the project protocol, participant information sheet and 
participant consent form were prepared. The ethical approval form contained 
seventy six questions (e.g. summary of the study, methodology, identifying the 
potential risks and burdens for the participants, physical security arrangements 
for storage of personal data during the study). After submitting the completed 
form, an interview took place with the Sunderland Research Ethics Committee. 
The interview panel consisted of hospital consultants, nurses, healthcare 
professionals, statisticians, and lay people. The PhD student was interviewed 
by the panel, and the panel gave a favourable ethical opinion for three years 
(Ref: 10/H0904/55).  
2.2.3. Patient Recruitment 
 Patients in AF coming to the Freeman Hospital for cardiac catheter 
ablation as part of their treatment were candidates for this research. To 
approach this group, initially a participant information sheet (see Appendix B) 
was sent to these patients. This information sheet was sent with their pre-
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assessment appointment letter at least one week prior to their procedure being 
scheduled. The following were clearly explained on the information sheet: the 
purpose of the study, who is a suitable candidate, what will happen to patients 
who take part, any risk that personal information of the patients will be kept 
confidential, and who is organising the research. With the co-operation of the 
out-patient department nurses, these patients were seen by the PhD student 
after their pre-assessment appointment. If they were interested in the study and 
had questions, appropriate information was given and discussed. If they were 
willing to participate, they were seen on the day of their ablation procedure and 
informed consent was obtained. 
2.2.4. Electrode Positioning 
 Prior to the ablation procedure, while patients were on the couch in the 
EP lab, the 67 electrodes (3 limb leads, and 64-lead BSPM) were attached to 
enable signals to be recorded from the body surface. This was done after skin 
preparation, such as shaving hair from electrode sites and wiping the skin 
surface to remove skin oil. Pre-defined anatomical references were identified for 
attaching the electrodes on the body surface. The anatomical references were 
important to keep the location of the electrodes consistent across all patients. 
However, it was essential to work around the cardiologist and technicians. As 
the data was being collected from patients during surgery, if necessary, the 
quality of signals for the cardiologist was prioritised over electrode placement. 
The electrode placement used in this study is shown in Figure 42. The Set A 
was used to record signals from anterior sites, and the Set B was used to 
record signals from posterior sites. The electrodes on Set A were placed 
approximately parallel with one another on the torso from the level of the top of 
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the sternum, down to the waist (anterior sites). The electrodes on Set B were 
placed on the back (posterior sites), in the corresponding locations as the 
anterior sites.  
 
Figure 42. Electrode positioning on the body surface. One set with four flexible 
rubber strips numbered from 1 to 32 was used to record signals from anterior 
sites, and the other set numbered from 33 to 64 was used to record signals 
from posterior sites.   
 
Distances between each vertical strip on the anterior and posterior were 
identified according to the other recording or mapping devices that were needed 
to be placed on the patients for the ablation procedure, e.g. electrode pads, see 
Figure 43. 
 
Figure 43. Spacing between vertical strips. Left: position of the anterior strips. 
Right: position of the electrode pads (blue) between the anterior and posterior 
strips.    
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For the BSPM recordings, site 22 was chosen for illustration and to 
compare between subjects. This site was chosen because: (1) it is closest to 
lead V1 on the 12-lead ECG which is often used for AF analysis (Petrutiu et al. 
2006); (2) It usually has the largest AF signal amplitude between the 64 body 
surface sites (see chapter 6). Figure 44 shows the location of site 22 and lead 
V1 on the body surface.  
 
Figure 44. Illustration of location of site 22 (blue) and lead V1 (red).  
 
 For the intracardiac recordings, the signal recorded between electrode 
pairs 1 and 2 on the PVAC catheter was named PVAC1, between 3 and 4 was 
named PVAC2, between 5 and 6 was named PVAC3, between 7 and 8 was 
named PVAC4, and finally the signal between electrode pairs 9 and 10 was 
named PVAC5. In the same manner, signals recorded from the CS catheter 
were named CS1 to CS5. For the EGM recordings, sites CS4 and PVAC4 were 
chosen for illustration, in addition to comparing between subjects. These sites 
were chosen as they had good signal quality (kurtosis < 3) across all 20 
subjects. Figure 45 shows the location of CS4 and PVAC4 on the catheters 
located inside the heart.   
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Figure 45. Illustration of locations of CS4 and PVAC4 inside the heart.  
 
 However, it is important to note that: (1) the location of the CS4 was not 
consistent across subjects, with small perturbations to the horizontal position in 
different patients.  (2) The location of the PVAC4 was not consistent across 
subjects as it was in different PVs.  
2.2.5. Description of Patients 
 Forty two patients were approached. Thirty five patients agreed to take 
part and were consented. Data was recorded from November 2010 to 
December 2011. In four patients, recorded data were not usable due to high 
levels of noise caused by excessive movement, breathing and x-ray machine 
noise. In six patients, recordings were not completed because they were in 
sinus rhythm as AF could not be induced. In five patients, recordings were not 
completed because they had some complication during the cardiac ablation and 
the electrodes had to be removed.  
 Data from twenty patients was analysed and the results are presented in 
this study. Table 1 summarises the patients recruited to this study for whom 
complete data was acquired.   
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Table 1. Description of subjects. Subject=patient’s number. Gender: M=male, 
F=female. BMI=body mass index (kg/m2). Type of AF: Par=paroxysmal, Per 
=persistent. Ending the procedure: at the end of the ablation procedure patient 
was in SR, or AF. If AF, patient finished in AF, or electrical cardioversion (EC) 
was performed, or Flecainide injected (F). 
 
2.2.6. Recording Data 
 Two minute recordings were obtained simultaneously from the 64-lead 
body surface, five CS and five PVAC sites during catheter ablation procedure. 
The recordings were obtained before starting the procedure (baseline), before 
and after ablation of each PV, and after ending the procedure. In this study the 
baseline was analysed and the rest of the data is to be made available for future 
studies such as AF characteristics changes between ablation, which was 
beyond the aim of this work. 
2.3. Signal Processing  
 The recorded signals contain information hidden in their structure, which 
was not readily observed when recording. This information had to be extracted 
in some way so that the signals could be given meaningful interpretation. 
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Therefore, signal processing was used for extracting clinically significant 
information hidden in the signals. The signal processing was performed using a 
laptop operated by Windows 7 Home Premium, 2.50 GHz processor 64-bit and 
i5-3210M CPU. All algorithms were developed in Matlab® (The MathWorks Inc., 
Natick, MA, USA) version 7.10.0. The following signal processing section is 
presented in four main groups:  
 Time synchronisation between the body surface and intracardiac (section 
2.3.1).  
 Body surface processing (section 2.3.2): This includes format 
conversion, down sampling, WCT computation, and filtering, followed by 
AA estimation which was achieved via two methods: QRST cancellation, 
and isolating AF segments. Subsequently parameters of interest were 
estimated in two domains: Time (to estimate AF amplitude) and 
Frequency (to estimate DF and SC).  
 Intracardiac processing (section 2.3.3): This includes format conversion, 
filtering, far-field ventricular activity cancellation, further filtering and 
rectification. The parameters of interest (DF and SC) were estimated in 
the same manner as used for the BSPM recordings.  
 Body surface and intracardiac comparison (sections 2.3.4 to 2.3.8). This 
includes BSPM and EGM spectra morphology correlation, BSPM and 
EGM comparison in time domain, and estimation of two novel 
parameters, which are the intracardiac power distribution and the body 
surface peak type.  
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 Figure 46 and Figure 47 show schematic representations of the BSPM 
and EGM processing, respectively. 
 
Figure 46. A schematic representation of BSPM processing. The 67 sites 
includes 3 limb leads and 64-lead BSPM. The red box denotes pre-processing 
and the blue box represents atrial activity estimation.      is the BSPM 
sampling frequency.  
 
 
Figure 47. A schematic representation of EGM processing. The 13 sites 
includes 3 limb leads, 5 CS and 5 PVAC sites.       is the EGM sampling 
frequency. 
  
2.3.1. Surface and Intracardiac Recording Time Alignment 
Differences in the sample rate of the BSPM and EGM recordings were 
taken into account and the first beat of these recordings was synchronised 
manually. However, there was a time shift between the BSPM and EGM 
recordings over time, see Figure 48. To solve this problem, the EGM recordings 
were synchronised in time with BSPM recordings. For this purpose, lead I from 
the 12-lead ECG of the EP recording system (EP lead I), and lead I from the 
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BSPM recording system (ECG lead I) were used. Lead I was chosen as this 
signal was recorded independently on both the intracardiac and the body 
surface recording systems. 
 
Figure 48. Illustration of the time shift between the EP lead I (red) and ECG lead 
I (blue) from subject 3. Top: the grey dashed circle show the first beat which is 
well synchronised, and the green dashed circle highlights a visible time shift in 
the 4th beat. Bottom: the last three seconds of the signals which are clearly 
desynchronised.   
 
 The time of the EGM signal (  ) was modified using the following linear 
scaling:    
          
Where    is the BSPM time,    is the time difference between the two 
recordings, and   is some scaling parameter which adjusts for the differing clock 
speeds. Initially     was fixed at a pre-computed, empirically determined, value. 
Then optimal temporal shift in the EGM signal was searched for by looping over 
a wide range of values in   . Within this loop the sum of squared differences 
between the normalised EGM and BSPM signals was computed, setting   
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Where   and   are the signals from the EGM and BSPM respectively, and   is 
the size of both time-series. The value of       , which minimises the sum of 
squares,   (for the fixed value of  ) was taken. The next step was to use the 
calculated value of      to minimise   as a function of    and  . A reduced range 
in    such that                      and                 was taken. 
Over these parameter values the following quantity was calculated     
          
 
   
        
Again, the values of    and    which minimised   were searched through. Once 
these values were found, the time axis of the EGM signal was scaled with the 
chosen values of    and   and further analysis proceeded with this modified 
signal. Figure 49 shows the synchronised BSPM and EGM signals.  
 
Figure 49. Illustration of the synchronised EP lead I (red) and ECG lead I (blue) 
for three seconds from the beginning and end of the two minute recordings 
(subject 3). 
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 The BSPM and EGM time alignment was checked visually, and also 
through plotting the time points of the detected R-waves from both systems (see 
Figure 50). The results were satisfactory for all subjects. 
 
Figure 50. Illustration of time alignment accuracy between the BSPM and EGM 
recordings (subject 3).   
2.3.2. Surface Recording Processing 
Pre-Processing  
 The BSPM recordings in BDF format were loaded into Matlab and stored 
as .mat format. Sampling frequency (    ) of the data was down sampled from 
2048 Hz to 512 Hz, using the 'resample' function in Matlab. This reduced both 
the computational effort and more importantly, the memory requirements. AF 
exhibits DF 3 - 9 Hz components, which are far below        (Nyquist 
Frequency), therefore the spectral content of AF was not altered by down 
sampling. The BSPM recordings were referenced to WCT by computing the 
average of the 3 limb leads and subtracting this from the 64 sites. The BSPM 
was filtered to clear the artifacts such as baseline wander, power line noise, 
patient movement noise, and any other possible noise. A second order, infinite 
impulse response (IIR), elliptical filter of low cut-off at 0.5 Hz and high cut-off at 
100 Hz, for baseline wander removal and high frequency noise suppression 
was chosen. An elliptic filter was chosen as it provides the sharpest transition 
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between the pass-band and the stop-band. In addition, a Notch filter at 50 Hz 
was added to reduce electromagnetic (mains) interferences. Figure 51 shows 
the BSPM before and after filtering.  
 
Figure 51. Illustration of the BSPM signal before (black) and after (red) filtering. 
 
Atrial Activity Estimation 
 Atrial activity estimation was performed in two methods. QRST 
cancellation and isolation of the AF segments. Atrial activity estimated by QRST 
cancellation was used to investigate dominant frequency and spectral 
concentration variability between subjects, over time and over space. Atrial 
activity estimated by isolation of the AF segments was used to investigate AF 
amplitude variability between subjects, over time, over space, and comparing 
BSPM and EGM in time domain.  
Method 1: QRST Cancellation 
QRST Detection: This section explains the process by which the R-waves and 
the QRST windows (beats) were detected on the BSPM recordings. R-wave 
detection was performed on a single body surface site with a prominent upright 
T-wave. Subsequently these time points were used to detect the R-waves on all 
the BSPM sites. The entire procedure is outlined in Figure 52 and each step is 
explained later. The R-waves were clearly visible on the filtered BSPM, see 
Figure 53. A simple procedure to detect the temporal locations of these R-
waves was to take the time derivative of the signal,  , which was defined as 
     . This gave a measure of the gradient of the signal,  , at a particular 
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instance of time,  . A threshold based on the 99.5 percentile of the positive 
gradient of the signal was defined.  
  
Figure 52. A schematic representation of R-wave detection algorithm.   
 
 
Figure 53. Illustration of five R-waves (the red crosses) on the filtered BSPM. 
 
 Since the R-waves in the signal were located where there was a rapid 
change in the sign of the signal (hence large gradients), location of the R-waves 
were readily identified, see Figure 54. From this, values of the positive gradients 
which mark the 99.5 percentile were computed, and the temporal locations of all 
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gradients were stored. When performing this analysis, the R-waves were 
checked manually and the threshold was modified if there were any missed R-
waves or duplicate in detection. Importantly the separation between different R-
waves was forced to be larger than 0.2 s.   
 
Figure 54. Illustration of five R-wave derivatives. The red dots are detected 
peaks and the green line is the threshold.    
 
 The detection of R-waves within milliseconds of each other arose due to 
fluctuations in the gradient of the signal at the location of the R-wave. If this 
check had not been performed then it could have incorrectly identified R-waves 
very close to each other. The second aspect of the algorithm was designed to 
account for the fact that the identified temporal locations were not true peaks of 
the R-waves. Indeed, maximal changes in the gradient were only located in the 
neighbourhood of the true peaks. To find the exact location of these peaks, the 
maximum value of the peaks within symmetric windows of 0.05 s on both sides 
of the identified temporal locations were searched through (see Figure 55). After 
identifying them, the temporal locations were moved to the maximum. The 
length of this window was chosen empirically to capture the whole QRS-wave.  
 
Figure 55. A schematic representation of floating detected peaks to local 
maximum. 
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 After identifying the R-waves, a specific window associated with each R-
wave was defined to capture the whole QRST-wave, and this was subsequently 
removed from the signal in a procedure defined later. In order to identify the 
QRST window, the start of the Q-wave and end of the T-wave were manually 
defined as      and     , respectively. The window was delimited as    to    
containing the QRST and optimised individually for each patient, see Figure 56. 
The window was sufficiently long to ensure it contained the full VA, from the 
start of the Q-wave to the end of the T-wave in all leads.  
 
Figure 56. Illustration of a QRST-window. A window was specified associated 
with each R-wave (green dots) as      and     .   
 
QRST Morphology Clustering: Using the previous algorithm, the QRST-
waves (beats) were identified, with the goal of removing them from the signal to 
‘extract’ the AA for further analysis. However, removing these beats from the 
signal caused the loss of the entire AA within these time periods. It could also 
have potentially led to erroneous artifacts associated with repetitive periods of 
zero signals. A more robust approach was to subtract the beats from the signal 
using the ABS method. A limitation of this method was the residuals after 
subtraction. The ABS method relied on the assumption that the average beat 
represents each individual beat. However, beat morphology changes in time 
due to variations in the electrical axis of the heart and respiratory activity. The 
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approach taken in this study was to subtract the morphology of a ‘typical’ beat 
from the signal within each beat, known as beat morphology clustering. Figure 
57 shows a schematic representation of this procedure.  
 
Figure 57. A schematic representation of beat morphology clustering procedure.  
 
 If there were   beats within the signal, then    QRST windows were 
identified. If the     of these windows to be denoted   , then the average window 
was computed as  
  
 
 
     
 
   
 
However this was not a particularly satisfactory approach due to morphology 
changes and ectopic beats (see Figure 58). In this example, which was typical 
of the data, the majority of the beats had a similar morphology (coloured in 
black), and a small number of them had a very different morphology (coloured 
in blue). If the average of all the beats is computed, then the    was expected to 
have a very similar shape to the majority of the beats. Subtracting this average 
from the beats with similar morphology would give very satisfactory results.  
Nevertheless it was clear that subtraction of this average from the beats with 
different morphology is not appropriate.  Mathematically the majority of the 
beats were identifiable by the sum of square differences, defined as       
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where       represents the  
th member of the vector     So    is the sum of the  
 th vector after subtracting the average and squaring.   
        
Figure 58.The beats within two minutes recordings from one BSPM site. The 
ectopic beats were coloured in blue to illustrate different morphologies.    
 
 Large values of    indicated that the morphology of that particular beat 
was very different to the average morphology, whereas low values indicated 
that the morphology of the beats were very similar to the average. The    was 
used as a guide and morphology clustering was performed manually (see 
Figure 59). Panel A shows the identified beats from one BSPM site. The red line 
shows the average according to all beats. Panel B shows the selected beats in 
a group on the right side of the vertical dashed line, and the beats to be 
selected into another group(s) on the left side of the vertical dashed line. Each 
bar corresponds to one beat. The arrow bar, underneath panel B, was moved to 
select the beats with the same morphology, with the aim of grouping them. By 
moving the arrow bar to the left, the vertical dashed line moved to the left and 
selected the bars on its right (green circle) in one group.  The associated beat to 
each selected bar was coloured in blue on panel A.  This was continued until all 
beats were grouped.  
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 Using this technique the beats were grouped and their average 
morphology defined based on all the beats which fall within that group.  
 
Figure 59. Morphology clustering of the beat inspection. 1 to 6 show different 
stages of the group selection.   
   
 
QRST Subtraction: Having computed the average for each beat group, the 
average was subtracted from the associated group. Figure 60 shows the 
estimated AA after QRST cancellation.   
           
Figure 60. Illustration of the estimated atrial activity after QRST cancellation.  
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Method 2: Isolate AF Segments  
 AF can be observed without presence of VA, during the TQ segment of 
the ECG. This is the interval between the end of the T-wave and the start of the 
Q-wave of the next beat. These segments were extracted (explained later) and 
used to analyse the spatial and temporal variability of amplitude of AF signal. 
Figure 61 shows the TQ segment for one BSPM site, and Figure 62 shows the 
TQ segment for all BSPM sites, in one subject.  
 
Figure 61. The     TQ segment within a two minute BSPM recording. TQ 
segments are the interval between the end of the T-wave and the start of the Q-
wave of neighbouring beats, and contain F-waves.   
 
             
Figure 62. Spatial illustration of the     AF segment for each site (identified 1 to 
64), subject 6.  
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 Having identified the VA (previous section), TQ segments were 
automatically identified relative to the interval between the QRST windows 
containing only the AA and were referred to as ‘AF segments’. 
Parameter Estimation 
I.       In the Time Domain  
Amplitude: To estimate amplitude of the AF signal, the longest AF segment 
within the two minute BSPM recordings was selected (see section 2.3.2, isolate 
AF segments). Given the inherent noise in the AF segment, estimation of the 
amplitude was not a trivial process. AF signal amplitude was estimated by fitting 
a sinusoidal model to the AF segment. It was necessary to tune the model 
according to amplitude and frequency of the AF segment. An automatic 
algorithm was developed for this purpose. Figure 63 shows a schematic 
representation of the algorithm. Figure 64 shows an example of fitting the model 
to the AF segment in different stages for a noisy segment.  Figure 65 shows 
some examples of the final step of fitting the sinusoidal model for the cases of 
both clean and noisy AF segments.   
 Peak to peak amplitude of the AF signal was estimated by fitting a 
sinusoidal model to each AF segment. Firstly, the AF segment was rescaled by 
subtracting the mean to stabilise the baseline, as shown below  
                           
where t is time of the     signal. Secondly, a sine wave with amplitude of     
was defined as   
                         ,          
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in discrete intervals with    steps. The    is the frequency resolution equal to 
0.125 Hz (parameter estimation in frequency domain).    was added to be able 
to translate the sine wave and match it with the shape of the signal.    is a 
period sufficient to capture a full waveform with a length proportional to the 
inverse of the sampling frequency        .   
 
Figure 63. A schematic representation of AF amplitude estimation algorithm, by 
fitting a sinusoidal model.   
 
 The frequency range of    is 3 - 9 Hz. This range was chosen as it agrees 
with estimation of the typical AF DF in literature, and it fits with the estimation of 
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AF DF between subjects that were studied in this project (see chapter 3). Within 
each    , the amplitude was estimated as   
                                
then       was overlapped with        from the first sample to the last sample 
moving one sample forward each time. So;     
  
                    
where   
  is the model response, and   is number of samples within the       
     intervals. The sinusoidal fit was estimated by subtracting    from        for 
each sample, with the squared residuals then averaged.  To measure the 
discrepancy between this estimate and its true shape, the normalised root mean 
square error (RMSE) was computed and defined as    
     
     
           
 
   
 
    
The normalised sum takes into account amplitude variation and the number of 
points that were used to calculate the figure of merit, so it is an unbiased 
estimator of the quality of fit. The values of    were determined by seeking the 
combination of    and    which minimised RMSE. The pair (       which does this 
was taken as the estimation of amplitude of the given AF segment, in a given 
body surface site. Mathematically it can be shown as 
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Figure 64. Illustration of AF signal amplitude estimations by the sinusoidal fit for 
a noisy AF segment. Eight panels show different steps of the fitting model to the 
segment from body surface site 45, subject 9. The blue signal is the AF 
segment. The red signal is the model. The model is overlapped with the AF 
segment from the first sample to the last sample moving one sample forward 
each time. The entire procedures for matching each sample are not shown. 
Eight steps that were more indicative were chosen to be shown.     
 
       
Figure 65. Illustration of AF signals amplitude estimation by the sinusoidal fit for 
the cases with clean (a) and noisy (b to h) AF segments. The blue signal shows 
the longest AF segment from different subjects at different body surface sites. 
The red signal shows the best sinusoidal fit. Peak to peak amplitude with the 
best sinusoidal fit was measured as AF amplitude.   
 
 Limitations of the estimation of the AF signal amplitude using AF 
segments are: (1) The     AF segment may not be the same length between 
subjects, thus observations may not be consistent; (2) the longest AF segments 
are collected from different times within the two minute recordings. Since AF is 
irregular, the AA within the two minutes may change, therefore observations for 
the same study group may be different if other segments were to be studied; (3) 
the model measures only one F-wave, which may not be representative of all.    
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II.       In the Frequency Domain  
 To describe the periodicity of the AA, the frequency spectrum of the AA 
was computed, and DF and SC were estimated. The frequency spectrum 
describes how the power of the AA is distributed over different frequencies. This 
is known as power spectral density (PSD) and defined as the Fourier transform 
of the autocorrelation function of a continuous time process. Due to the inherent 
noise in the AA, the ‘raw’ PSD was not suitable. To reduce the spectrum 
variance, whilst keeping the estimation efficient, the Welch periodogram 
technique was used. This method sacrifices frequency resolution in exchange 
for noise reduction, and hence produces a smoother estimate of the PSD. 
Figure 66 shows a schematic representation of the steps that were taken to 
apply Welch’s method to the data in this study. 
                                                                                         
Figure 66. A schematic representation of Welch’s method. 
 
 The DC and first order trend were removed from the      , to meet the 
assumption that signals were stationary. The       was divided into   
overlapping segments. The Hamming window function was applied to each 
segment and then they were overlapped. The window function is normally small 
or zero near its boundaries. As a result a significant portion of the signal is 
ignored in the analysis, which could be detrimental to the analysis. Overlapping 
the segments maximised the information that can be extracted from the signal 
and avoided this potential problem. Periodograms of the segments were 
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computed and averaged. In order to find the appropriate segmentation, different 
window and overlap durations were tested, and the trade-off between time and 
frequency resolution was experienced.  A phenomenon encountered with using 
long window length was the large variance in the computed spectra. In this 
case, detection of the frequency components in the spectrum was highly 
sensitive to noise and the risk of false detection was high. In contrast, using a 
short window length led to inaccurate frequencies. In this case, detection of the 
frequency components in the spectrum was not exact as the frequencies were 
mainly obtained at one wide peak, see Figure 67.     
 
Figure 67. PSD estimation with different window duration and overlap to find 
appropriate segmentation (Subject 1, body surface site 22). The y-axis is 
normalised power. With long window length, variance of spectra was increased 
(e.g. f), and with short window length, frequencies were inexact (e.g. a). Panel d 
was used for analysis in this study as a compromise between extremes.   
 
 Finally, the       was divided into    overlapping segments, with each 
segment being 8 seconds long, with a 1 second overlap (sliding factor of 7 
seconds). Each segment was windowed with a Hamming window, PSDs were 
computed for each segment, and then averaged. Given the ratio of sampling 
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frequency (      512 Hz) to length of the segments, frequency resolution (  ) 
was 0.125 Hz. Figure 68 shows the PSD for all body surface sites in one 
subject.  
 
Figure 68. Spatial illustration of the PSD for each site (identified 1 to 64), 
subject 1.The y-axis is normalised power density to the maximum of each site.  
 
Dominant Frequency: Given the         , DF was defined as the frequency    
where:       
                                  
Here    and    define the frequency range of interest 3 to 9 Hz. 
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Spectral Concentration: Given the         , SC was defined with similar 
approach to Castells, as    
    
          
    
    
          
  
  
  
where                                  , and        ,    is sampling 
frequency (Castells et al.  2003). However, several changes were applied to the 
parameters defined by Castells: (1) It is likely that SC is affected by the 
effectiveness of the QRST suppression. To avoid this,    was defined as the 
lowest value between 3 Hz and      Hz. (2) If          , it is likely that SC is 
affected by harmonics. To avoid this,    was defined as the highest value 
between 9 Hz and      Hz. (3) If              and                then 
the area under the curve between the      and      would be larger with higher 
DF.  To define consistent window around DF,      and      were described as 
       and      , respectively, where        Hz. This was chosen 
empirically to capture the whole frequency peak.  
2.3.3. Intracardiac Recording Processing 
 The EGM recordings with sampling frequency (    ) of 1000 Hz, stored 
in American Standard Code for Information Interchange (ASCII) format, were 
loaded into Matlab and stored in .mat format. A second order, IIR, Butterworth 
filter at low cut-off 40 Hz and high cut-off 250 Hz was used to remove baseline 
shift and high-frequency noise (see Figure 69). In order to identify and cancel 
far-field VA, the R-waves were detected on lead I from the 12-lead ECG of the 
EP recording system by means of a proprietary threshold-based automated 
detector (see section 2.3.2, QRST detection). The detected points (far-field VA) 
from all recordings were inspected visually to remove any missed or false 
77 
 
detections. A window with duration of 0.12 s (±0.06 s either side of the R-
waves) was defined and called the VA-window, and marked on the EGM sites 
(see Figure 70). A template was constructed from averaging the VA-windows 
and subtracted from each VA-window for each EGM site. 
 
Figure 69. Illustration of the EGM signal before (black) and after (red) band-
pass filtering. 
 
 
Figure 70. Illustration of identifying far-field VA on the EGM signal. 
 
 Afterwards, the EGM was rectified using the 'abs' function in Matlab. The 
signal was further low-pass filtered at low cut-off 20 Hz, see Figure 71. The 
EGM parameters (DF and SC) were estimated in the same manner as BSPM 
recordings. 
 
Figure 71. Illustration of the EGM signal after processing.  
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 Figure 72 and Figure 73 show EGM signals, for one subject at all sites in 
the time and frequency domains, respectively.  
 
Figure 72. The EGM signals from subject 11. The y-axis is amplitude which was 
normalised to the maximum of each site.   
 
 
Figure 73. The EGM spectra from subject 11. The y-axis is the normalised 
power density to the maximum power of each site.  
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2.3.4. Morphology Correlation  
 In order to study correlation between the BSPM and EGM spectra the 
PSDs were normalised to the maximum power of each site and then the 
Pearson correlation coefficient was computed. Figure 74 and Figure 75 show 
three representative cases.  
 
Figure 74. The PSDs with different correlations between BSPM site 22 (black) 
and CS4 (red). Left to right the PSDs are from subjects 1, 8 and 13. 
 
 
Figure 75. The PSDs with different correlations between BSPM site 22 (black) 
and PVAC4 (green). Left to right the PSDs are from subjects 1, 8 and 13.  
 
The result of this study will be shown in chapter 7.2. 
2.3.5. Innovative Method: Estimation of Intracardiac Dominant Frequency 
Power Distribution on the Body Surface Spectra   
 The dominant peak of the BSPM and EGM spectrum may not be the 
same. Of interest was if the BSPM spectra had large power associated with 
EGM DF. A method was developed to determine in which BSPM sites EGM DF 
power associated with BSPM spectrum is highest.  DF estimated from the EGM 
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was marked on the BSPM PSD to measure EGM DF power distribution on the 
BSPM spectrum. Figure 76 shows a schematic representation of this procedure.  
 
Figure 76. A schematic representation of determining EGM DF power 
distribution associated with BSPM DF.   
 
 If      is DF of a given EGM site and the power spectral density of a 
BSPM site is given by        , then the power of       on         denoted,  
P, computed as  
                            
Note that each         (computed at each BSPM site) was normalised to the 
maximum power of all the sites. Hence the unit of P is a percentage, and 
defines the percentage of the         power associated with     .  
 Figure 77 gives a visual definition of this quantity for four representative 
cases of the     .  The result of this study will be shown in section 8.1.  
 
Figure 77. Illustration of a BSPM PSD from subject 1, site 22 and      power for 
four representative cases. In these examples the red dots indicate locations of 
CS DF on a given BSPM spectrum, and the PCS  indicates CS DF power 
distribution.    
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2.3.6. Innovative Method: Classifying Body Surface Frequency 
Components According to Intracardiac Dominant Frequency  
 Typically there are several peaks in the BSPM spectrum (        . The 
frequency and power density of these peaks may differ across the BSPM sites. 
Therefore, analysing only DF omits some information in the spectrum. To avoid 
this, a method was developed to determine which BSPM sites exhibit a peak 
(not necessarily the dominant one) at the AF frequency estimated from EGM 
recordings.  In this approach, DF estimated from the EGM (      was 
contrasted with the         to identify if      corresponds to any peak of the 
       . Figure 78 shows a schematic representation of this procedure.  
 The      was estimated for each EGM site and the         for each 
BSPM site was computed and normalised to the site with maximum power. 
Frequency components that appeared as distinct peaks were then detected in 
the        . This was done in the following manner: a distinct peak was said to 
occur if amplitude of the         was larger than the preceding or following 
value, along the frequency axis, i.e. 
                                                 
where    is the value of the i
th discrete frequency. The frequencies at which this 
occurs were denoted        , and had an associated spectral power       . This 
procedure was repeated for all BSPM sites and the method could be used 
efficiently by pre-computing all the PSDs. By performing this identification of 
peaks in the        , some small peaks were identified which may just be due 
to noise in the signal. Hence a threshold was set; any        less than 20% of 
the maximum of         were discarded. 
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Figure 78. A schematic representation of determining EGM DF to corresponding 
peaks on the BSPM PSD. 
 
 The      may not perfectly align with a value of         and a small 
amount of  deviation from the values was allowed. A window of width 0.25 Hz 
(one sample either side of the     ) was defined (i.e. for the i
th DF the window is 
              ), then any peaks of        within this  window were identified. A 
further classification of the peaks was then made as follows; the maximal peak 
of the         was identified as BSPM DF. If there was a dominant-peak within 
0.25 Hz of      then the peak was classified as a Type I (see Figure 79, A). If 
there was a non-dominant peak within 0.25 Hz of      then that the peak was 
classified as Type II (see Figure 79, B). Afterwards the number of each peak 
type was counted at each BSPM site across all subjects. This was then used to 
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investigate if there are any BSPM sites where the peaks are classified as Type I 
in the majority of  subjects. The result of this study will be shown in section 8.2.  
 
Figure 79. Illustration of a BSPM PSD and its corresponding peaks to EGM DF 
(subject 18, site 22). The distinct frequency peaks were identified as red circles. 
The horizontal black line indicates the threshold.    
 
2.3.7. Innovative Method: Time Domain Analysis to Identify Intracardiac 
Activations on the Body Surface       
 This section explains the method used to investigate if there is any 
relationship in the time series between the body surface and intracardiac 
recordings. In other words, are intracardiac activations preferentially detectable 
at different body surface sites? In this analysis, the longest AF segment was 
selected from the BSPM recordings (Figure 80, step 1). The corresponding 
segments, in the same time interval, on the CS and PVAC recordings were 
selected (Figure 80, step 2). CS and PVAC activations were detected on the 
segments (Figure 80, step 3). The time points of the CS and PVAC activations 
were marked on the AF segment on the BSPM recordings (Figure 80, step 4). 
After that, a window around the EGM activations on the BSPM AA was defined, 
sufficiently wide to cover the activation phase shifts, shown in Figure 81. The 
windows were averaged and the EGM activations were marked on the average, 
see Figure 82. Figure 83 shows all these steps together. The aim of the 
averaging was to check consistency of the CS and PVAC activations on the 
BSPM. In other words, if the AA waveforms are triggered by EGM activations 
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then the average will possess a large amplitude, with similar shape to that of 
each AA waveform. To quantify the relationship between AA and EGM 
activations, it was attempted to detect the atrial activations from the BSPM and 
EGM separately, calculate the MCL for each measurment source, then 
correlation the BSPM and EGM MCL. The result of this study will be shown in 
section 8.3.  
 
Figure 80. Illustration of detecting EGM activations on the BSPM signal. Step 1: 
the AF segment was selected on BSPM site 22. Step 2: the corresponding 
segment (in time) was selected on CS4 and PVAC4 (interval between red 
dashed lines). Step 3: CS (red crosses) and PVAC (green crosses) activations 
were detected. Step 4: the CS and PVAC activations were marked on the 
BSPM data (red and green lines).     
 
 
Figure 81. Illustration of windowing (orange dashed squares) the EGM 
activations (red and green lines) on the BSPM signal. The activations whose 
window includes the part of the T-wave or Q-wave have been discarded from 
averaging. An example of this case is shown by the black arrow.   
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Figure 82. Illustration of a normalised generated beat from the BSPM by the 
EGM activations. The red and green lines indicate CS and PVAC activations, 
respectively (for illustration purpose only, it is not constructed from Figure 81).  
 
 
Figure 83. Example of detected EGM activations and the averaged window from 
the second longest AF segment at site 1 (subject 1). 
 
2.4. Data Analysis Design      
 In this section, the different statistical arrangements (each chosen to 
extract different information from the data) are outlined. The majority of the 
analysis was performed on three distinct arrangements: the AF characteristic 
differences between subjects (see chapter 3), the AF characteristic changes 
over time (see chapter 5), and the AF characteristic changes over space (see 
chapter 6). Depending on the aim of each study, a table for statistical analysis 
was constructed and denoted ‘Design’. The Design indicates size of the 
statistical table, and has different numbers of rows and columns as necessary.  
If 'A' is to be denoted for a parameter of interest then; 
 Two dimensional statistical Design:  
Design = number of sites × number of subjects, or Design = number of 
subjects × number of sites, was mainly used for constructing plots (e.g. 
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Box and Whisker plot), testing distribution for normality, and non-
parametric tests (e.g. the Friedman test) to study the AF characteristics 
between subjects and spatial variability, see Figure 84.   
 
 Three dimensional statistical Design:  
Design = (number of subjects × number of sites) × 3, was mainly used for 
parametric tests (e.g. factorial analysis of variance (ANOVA)) when there 
were two fixed factors (e.g. subjects and sites), see Figure 85.  
 
 Four dimensional statistical Design:  
Design = (number of subjects × number of repetitions × number of sites) 
× 4, was mainly used for ANOVA when there were three fixed factors 
(e.g. subjects and sites over time), see Figure 86.    
 
 
Figure 84. Example of Design = 64 × 20 or Design = 5 × 20, were used for the 
BSPM and EGM non-parametric test, respectively.      
 
 
Figure 85. Example of Design = (20 × 64) × 3 or Design = (20×5) × 3, were 
used for the BSPM and EGM parametric test, respectively.         
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Figure 86. Example of Design = (20 × 4 × 64) × 4 or Design = (20 × 4 × 5) × 4, 
were used for the BSPM and EGM parametric test of temporal variability, 
respectively.        
 
2.4.1. Between Subject Analysis 
 To investigate differences in the AF characteristics between subjects, the 
parameter of interest was analysed across the sites for each subject (Design = 
number of sites × number of subjects). A Box and Whisker plot was 
constructed, and normality of data distribution in each subject was tested. To 
test for a significant difference in the data a non-parametric test (Design= 
number of sites × number of subjects) or a parametric test (Design= (number of 
subjects × number of sites) × 3) was used according to the normality test result.   
2.4.2. Temporal Variability Method Description 
Signal Processing: Temporal variability of AF amplitude, DF and SC were 
investigated for all subjects. For AF amplitude, the five longest AF segments 
were selected and amplitude of the AF signal was estimated for each segment. 
For AF DF and SC, the temporal variability was investigated with two related 
approaches. Firstly, the two minute BSPM and EGM recordings were divided 
into four consecutive, non-overlapping segments (T1 to T4), each 30 seconds 
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long. Secondly, the two minute BSPM and EGM recordings were divided into 
two consecutive, non-overlapping segments (T1 and T2), each 60 seconds 
long. In both approaches, PSD and then DF and SC were estimated for each 
segment.   
Statistical Tests: Using the median value across the sites in each subject, a 
Box and Whisker plot was constructed for each segment (Design= number of 
subjects × number of segments). The data distribution was tested across the 
sites in each segment (Design= (number of subjects × number of sites) × 
number of segments). A parametric test (Design= (number of subjects × 
number of segments × number of sites) × 4), or a non-parametric test (Design= 
(number of subjects × number of sites) × number of segments) was used 
according to the normality test result, to test for a significant difference in the 
parameter of interest between the segments.  
2.4.3. Definition of Electrode Groups Used to Describe Spatial Variability 
 To investigate spatial variability, the parameter of interest was analysed 
from two minute recordings between the sites. A Box and Whisker plot was 
constructed (Design= number of subjects × number of sites), and data 
distribution was checked across subjects in each site. A parametric test 
(Design= (number of subjects × number of sites) × 3), or a non-parametric test 
(Design= number of subjects × number of sites) was used according to the 
result of the data distribution test.  
For additional investigation of the spatial variability estimated from the 
body surface recordings, the 64 sites were grouped into anterior and posterior, 
left and right, vertical electrode lines, and horizontal electrode lines. The aim of 
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grouping the body surface sites was to facilitate a reduction in the number of 
sites to be studied each time. These classifications are explained as follows:  
Anterior and Posterior Sites: the 64 body surface sites were grouped into 
anterior (sites 1 to 32) and posterior (sites 33 to 64), see Figure 87.  The 
median values of the parameter of interest across the anterior and the posterior 
sites were calculated (Design= number of subjects × 2).     
 
Figure 87. Illustration of the anterior (sites 1 to 32) and posterior (sites 33 to 64) 
electrode arrangements.  
 
Left and Right Sites: the 64 body surface sites were grouped into left and right 
with two approaches. Initially, sites on the left anterior and posterior (sites 1 to 
16 and sites 33 to 48) were denoted Left, and sites on the right anterior and 
posterior (sites 17 to 32 and sites 49 to 64) were denoted Right, see Figure 88. 
The median values of parameter of interest across Left and Right were 
calculated (Design = number of subjects × 2). The 64 body surface sites were 
then grouped into four further classes, anterior left (sites 1 to 16), anterior right 
(sites 17 to 32), posterior left (sites 33 to 48), and posterior right (sites 49 to 64), 
see Figure 89. The median values of the parameter of interest across each 
class were calculated (Design = number of subjects × 4).     
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Figure 88. Illustration of the left and right electrode arrangements, first 
approach. The left body surface is shown in red. The right body surface is 
shown in blue. 
 
 
Figure 89. Illustration of the left and right electrode arrangements, second 
approach. The anterior left, anterior right, posterior left, and posterior right are 
shown in different colours.  
 
Vertical Electrode Lines: the 64 body surface sites were also grouped into 
eight vertical lines (8 electrode strips, 8 electrodes on each strip, e.g. sites 1 to 
8 vertical line one, 9 to 16 vertical line two, etc), see Figure 90. The median 
values of the parameter of interest across each vertical line were calculated 
(Design = number of subjects × 8). The vertical lines were named according to 
their anatomical location on the body surface as follows: on the anterior side, 
four vertical lines from left to right were named anterior lateral left (ALL), 
anterior central left (ACL), anterior central right (ACR), and anterior lateral right 
(ALR).  On the  posterior side, four vertical lines from left to right were named 
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posterior lateral left (PLL), posterior central left (PCL), posterior central right 
(PCR), and posterior lateral right (PLR).  
 
Figure 90. Illustration of the vertical electrode lines arrangement.  
 
Horizontal Electrode Lines: the 64 body surface sites were also grouped into 
sixteen horizontal lines, (sites 1, 9, 17, 25 called line one, sites 2, 10, 18, 26 
called line two, etc), see Figure 91. The median values of the parameter of 
interest across each line was calculated (Design = number of subjects×16).    
 
Figure 91. Illustration of the horizontal electrode lines arrangement. 
 
2.5. Statistical Analysis 
 To describe and interpret the AF characteristics obtained through the 
measurements, statistical analysis was performed. To choose an appropriate 
statistical test, the question posed was "is the data independent?”. As a rule of 
thumb, results on the same individual are not independent. The data in this 
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study was collected from one source (the heart) at different locations (body 
surface and inside the heart) at the same time in each subject, so the data is 
not independent.  Consequently, the statistical tests for related samples were 
used.  
 As appropriate, different plots were used to summarise the data. In this 
study Box and Whisker, Bland-Altman, and scatter plots were most commonly 
used for the analysis. These are described later in this section.  
 To describe the shape and spread of the data, statistical distribution was 
analysed. Knowing the distribution of the data was important as it determined 
whether parametric or non-parametric statistical tests were appropriate. Since 
the sample sizes of the data used for the analysis in some designs were small 
(e.g. between intracardiac sites was 10), the distribution was checked in two 
ways: numerically using the Kolmogorov–Smirnov test, and graphically using 
visual inspection of a histogram. The null hypothesis (  ) was that the data 
follow a specified distribution.   
 Paired t-test (for paired comparison of two groups) or ANOVA for 
repeated measures (for the comparison of more than two groups) was used 
when data was normally distributed. Wilcoxon signed-rank (for paired 
comparison of two groups) or Friedman test for related samples (for the 
comparison of more than two groups) was used when data was not normally 
distributed.    was set as there is no difference between the  variable being 
compared. In the entire statistical tests that have been used in this study, the 
hypothesis was rejected if p-value was less than the fixed significance level (α) 
of 0.05.   
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 In multiple comparisons, the type I error (or false positive, when the null 
hypothesis is rejected although it is true) was controlled using Bonferroni 
correction.  
Box and Whisker Plot 
 Here the data was described through a five-number summary: the 
smallest observation (min), lower quartile or      percentile (Q1), median or 
     percentile (Q2), upper quartile or      percentile (Q3), and largest 
observation (max). The Box and Whisker plot was used to visualise the centre, 
spread, and overall range of the data distribution. The whiskers extended from 
Q1 to the smallest non-outlier, and from Q3 to the largest non-outlier in the data 
set (see Figure 92). Outliers were considered as values larger than Q3 by at 
least 1.5 times the inter-quartile range (IQR), or smaller than Q1 by at least 1.5 
times the IQR. The range is the spread of all data, the distance between the 
smallest and largest values, including any outliers.   
 
Figure 92. Illustration of a Box and Whisker plot.   
 
Bland-Altman Plot 
 To compare AF characteristic estimated from the body surface and 
inside the heart, a Bland-Altman plot was used.  The aim was to verify whether 
AF characteristic estimated from these measurement methods were similar or 
not. AF characteristic estimated from inside the heart were used as reference 
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value. Limits of agreement (LOA) and bias were used to describe whether there 
is an agreement between these two measurement methods (see Figure 93):   
 Limits of agreement (LOA) are limits that 95 % of the points fall either 
side of the bias. There are upper and lower LOA which show the 
minimum and maximum error between the two measurements. LOAs are 
calculated as bias ± 1.96 of standard deviation (SD). LOA describes the 
range for 95% of comparison points. 
 Bias is the mean difference between the two methods of measurement 
(ideal bias is zero).  
 
Figure 93. Illustration of a Bland-Altman plot.  
 
Scatter Plot for Regression Analysis 
 Linear regression analysis was used to investigate how independent 
variables related to dependent variables. This shows the effect of the 
independent variable on the dependent variable. Mathematically if there is a 
single independent variable the following model fits,  
                
   quantifies the relationship between the independent variable X and the 
dependent variable Y (see Figure 94).    and    represent the Y-intercept and 
the slope of the relationship, respectively. The   represents normally distributed 
noise. The null hypothesis is that there is no significant difference between the 
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slope of the fitted line and zero. This is quantified by p-value. Coefficient of 
determination (  ) is the square of the correlation between the dependent and 
independent variable, which shows how each independent variable correlates 
with dependent variable. The    can be used to assess the strength of the 
correlation. Effectively, it quantifies the spread of the points along the line.  
 
Figure 94. Illustration of a linear regression plot.   
 
 In this study plots were constructed using Minitab® 16.1.0 (Minitab, PA, 
USA), and IBM® SPSS® Statistics version 19 (SPSS Inc, IL, USA) was used for 
statistical tests.  
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Chapter 3. Differences in Atrial Fibrillation Characteristics 
Between Subjects  
 As described in chapter 1, AF history is known to affect AF 
characteristics. Since subjects who have been recruited for this study had 
different AF histories, this chapter quantifies the AF characteristics in each 
subject to have overview of each subject's data and justify outliers. For this 
purpose, differences in AF characteristics estimated from the body surface 
(amplitude, DF and SC) and inside the heart (DF and SC) were investigated 
between subjects. DF and SC were also compared between the body surface 
and intracardiac recordings. 
3.1. Amplitude   
I. AF Amplitude Estimated from the Body Surface 
Figure 95 shows the longest AF segment within the two minute 
recordings (see section 2.3.2 for the methodology of isolating AF segments) 
selected from body surface site 22 for each subject and Figure 96 shows the AF 
segments' durations. Peak to peak amplitude of this segment was measured for 
each site for each subject and shown in Figure 97 in the Box and Whisker plot. 
A colour map of amplitude on a global scale across all subjects is shown in 
Figure 98, and Figure 99 shows the individual scale for each subject. The 
Friedman test showed that subjects exhibited significant differences in 
amplitude (p<0.001), (Design=64×20, see section 2.4).   
The median amplitude measured across the 64 sites ranged from 19.2 
µV (subject 18) to 90.0 µV (subject 3) with median and IQR of 35.9 (21.0 – 
57.3) µV across all subjects.       
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Figure 95. Illustration of the longest AF segment for each subject (identified 1 to 
20) from body surface site 22.   
 
 
Figure 96. Duration of the longest AF segment for each subject.  
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Figure 97. AF amplitude across the body surface sites for each subject. Each 
bar is constructed from 64 values.  
 
 
Figure 98. Spatial colour map of AF amplitude for each subject (identified 1 to 
20) global scale.  
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Figure 99. Spatial colour map of AF amplitude for each subject (identified 1 to 
20) individual scale. 
 
 According to the literature, mostly organised AF cases are known to have 
high-amplitude F-waves, while less organised AF cases have lower amplitude 
(Petrutiu et al. 2006). However, in this study cases with well organised AF (e.g. 
subjects 7 and 8) had small amplitude, and cases with disorganised AF had 
larger amplitude (e.g. subjects 11 and 19).  
 In some subjects there were relatively small differences in amplitude 
across the sites, whereas in other subjects there were relatively large 
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differences. For example, the amplitude range (maximum – minimum) in subject 
2 was 39.0 µV and in subject 6 was 168.0 µV.  
 Interestingly there was a consistent pattern of high amplitude on the 
anterior upper right body surface sites, close to site 22, in all subjects. Although 
there were some posterior sites with high amplitude in each subject the sites 
were not consistent between subjects.  The amplitude difference between 
subjects could be related to certain factors such as: complexity of AF, subject's 
BMI and AF history which includes the type of AF and the number of previous 
ablations. To investigate these factors, the complexity of AF and the effect of 
BMI on AF amplitude were investigated, and these results are shown in section 
3.3 and chapter 4. 
A limitation of this analysis was that AF amplitude was estimated from a 
single AF segment within the two minute BSPM recordings. As the AF 
segments may fluctuate over time, it is possible that the AF amplitude could be 
different for the same study group if other AF segments were studied. This 
concern was investigated in chapter 5 by studying temporal variability of AF 
amplitude.   
II. AF Amplitude Estimated from Inside the Heart  
Several factors may influence measurements of the intracardiac signal 
amplitude, e.g. catheter contact with the heart tissue, thickness of the atrial 
muscle, pressure to the catheter applied by the cardiologist, and previous scars. 
As a result, amplitude of the local atrial electrogram may not be indicative of AF 
amplitude estimated from the body surface. For this reason, amplitude of the 
intracardiac recordings was not studied in the thesis. 
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3.2. Dominant Frequency 
I. Dominant Frequency Estimated from the Body Surface 
 PSD and then DF were estimated from the two minutes of the BSPM AA 
for each site in each subject. Figure 100 shows the PSD from body surface site 
22 for each subject. The Box and Whisker plot of DF across the body surface 
sites for each subject is shown in Figure 101. The colour map of DF across the 
body surface sites is shown later in Figure 106.  
   
Figure 100. Illustration of the PSD for each subject (identified 1 to 20) from body 
surface site 22. The y-axis denotes normalised power density to the maximum 
of each subject. 
 
  The Friedman test showed that subjects exhibited significant differences 
in DF (p<0.001). The median DF measured across the 64 sites ranged from 4.1 
Hz (subject 12) to 7.5 Hz (subject 11) with median and IQR of 5.9 (5.1– 6.2) Hz 
across all subjects. DF estimated from the body surface was significantly 
different between subjects. Moreover, in some subjects there were relatively 
small differences in DF across the sites, whilst in others there were relatively 
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large differences across the sites (e.g. DF range in subjects 3 and 8 were 0.0 
Hz, and in subject 10 was 3.3 Hz). 
 
Figure 101. DF across the body surface sites for each subject. Each bar is 
constructed from 64 values.  
 
The DF difference between subjects could be related to the same factors 
as mentioned in the previous section (complexity of AF, type of AF and the 
number of previous ablations). To investigate the DF difference further, 
complexity of AF and effect of BMI on DF were investigated and the results are 
shown in section 3.3 and chapter 4, respectively.  
II. Dominant Frequency Estimated from Inside the Heart  
 PSD and then DF were measured from the two minute EGM recordings 
for each site in each subject. Figure 102 and Figure 103 show the PSD from 
CS4 and PVAC4 for each subject, respectively. The Box and Whisker plots of 
DF across the five CS and five PVAC sites are shown in Figure 104.  DF was 
not normally distributed across all the EGM sites in most of subjects 
(Design=10×20). The Friedman test showed that subjects exhibited significant 
differences in DF (p<0.001) estimated from either CS sites or PVAC sites 
(Design=5×20). The median DF, measured across the five CS sites ranged 
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from 4.3 Hz (subject 9) to 7.1 Hz (subjects 5 and 7) with median and IQR of 5.9 
(5.1– 6.4) Hz across all subjects. The median DF, measured across the five 
PVAC sites, ranged from 4.3 Hz (subject 18) to 7.1 Hz (subject 7) with median 
and IQR of 5.6 (5.1– 6.0) Hz across all subjects.  
 
Figure 102. The PSD for each subject (identified 1 to 20) from CS site 4.  
 
 
Figure 103. The PSD for each subject (identified 1 to 20) from PVAC site 4.  
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Figure 104. DF across CS (light grey) and PVAC (dark grey) for each subject. 
Each bar is constructed from 5 values.  
 
The results showed that in some subjects there were relatively small 
differences in DF across both CS and PVAC sites (e.g. in subject 7, CS DF 
range = 0.7 Hz and PVAC DF range = 0.5 Hz), whereas in others there were 
relatively large differences in DF across both CS and PVAC sites (e.g. in 
subject 15, CS DF range = 1.7 Hz and PVAC DF range = 2.0 Hz). However in 
some subjects the differences in DF across the CS sites was relatively small, 
but across the PVAC sites was not, or vice versa (e.g. in subject 12, CS DF 
range = 1.5 Hz and PVAC DF range = 0.6 Hz).   
Consistency in DF between the CS and PVAC sites may suggest less 
complexity of the AF (see section 3.3). However, differences may suggest that 
the CS and the PVAC electrodes captured atrial activations from different AF 
sources as they were located in different AF re-entrant pathways.  
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III. Comparison of Dominant Frequency Estimated from the Body 
Surface and Inside the Heart in Individual Subjects  
It was evident from the previous section that some subjects had a single 
narrow dominant peak, and some subjects had broad multiple peaks in their 
frequency spectra computed from both body surface and intracardiac 
recordings. However, some subjects had a single dominant peak in the 
intracardiac frequency spectrum but multiple peaks in the body surface 
frequency spectrum (e.g. subject 1).  
To facilitate the comparison, the data from Figure 101 and Figure 104 
have been combined into Figure 105.  
  
Figure 105. DF across BSPM, CS and PVAC sites for each subject. This figure 
is constructed using the data from Figure 101 and Figure 104 plotted together. 
 
 This figure showed that DF between the BSPM, CS and PVAC across all 
sites in some subjects were in perfect agreement (e.g. subjects 3 and 8), in 
some subjects were in good agreement but not necessarily with the same range 
of values (e.g. subject 19), and other subjects had poor agreement in DF (e.g. 
subject 11). To further facilitate the comparison of body surface and intracardiac 
DF, Figure 106 shows DF of the BSPM, CS and PVAC plotted in colour for each 
subject.  
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Figure 106. Spatial colour maps of DF for each subject (identified as 1 to 20). 
The vertical panels indicate BSPM anterior (left) and posterior (right). The 
horizontal panels indicate EGM from five CS sites (top: CS1 to CS5 from left to 
right) and five PVAC sites (bottom: PVAC1 to PVAC 5 from left to right).   
 
Figure 106 did not reveal any consistent pattern in DF between subjects 
meaning there were no specific body surface sites that capture the same DF as 
the EGM sites in all subjects.   
Good agreement in DF between the body surface and intracardiac 
recordings may indicate well organised AF (see section 1.1.3, AF complexity) 
with a single pathway as all the sites from different measurements capture one 
frequency. However, poor agreement may indicate less organised AF with more 
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than one pathway as the sites from different measurements capture different 
frequencies. Each component may represent a re-entrant pathway within the 
atria. This illustrates the limitation of using only DF as a measure of AF, since it 
fails to capture the full information contained in the frequency spectrum.    
The linear regression analysis and scatter plots between the median DF 
estimated from the BSPM and both the CS and PVAC are shown in Table 2 and 
Figure 107.  
 Median DF [Hz]  
Source p-value    [%]       
BSPM  & CS  <0.001 54.3   1.2 0.8 
BSPM  & PVAC  <0.001 70.1   0.5 0.9 
Table 2. Linear relationship between the median BSPM and EGM DF for 20 
subjects.  
 
 
Figure 107. Linear relationship of the median DF estimated from the body 
surface and inside the heart.   
 
The strong positive linear relationship between body surface and 
intracardiac DF may suggest that AF DF could be consistently estimated from 
body surface sites. However, DF estimated from the body surface showed 
closer agreement with DF estimated from the PVAC recordings rather than from 
CS.  
Similarly, this analysis was repeated between DF estimated from BSPM 
site 22 with both CS4 and PVAC4 (see Table 3 and Figure 108).   
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 DF [Hz]  
Source p-value    [%]       
BSPM  site 22 & CS4  0.042 21.0   3.8 0.4 
BSPM  site 22 & PVAC4  0.026 24.6   3.2 0.5 
Table 3. Linear relationship between BSPM site 22 and EGM DF for 20 
subjects.  
 
 
Figure 108. Linear relationship of DF estimated from the body surface site 22 
and inside the heart.   
 
 The weak positive linear relationship between body surface site 22 and 
intracardiac DF may suggest that additional electrodes to the 12-lead ECG give 
more accurate estimation of DF from the body surface. 
3.3. Spectral Concentration  
I. Body Surface Spectral Concentration 
 SC was estimated from the PSD computed over the two minute BSPM 
AA for each site in each subject. The Box and Whisker plot of SC across the 
body surface sites for each subject is shown in Figure 109. The results of the 
Friedman test showed that subjects exhibited significant differences in SC 
(p<0.001).  
 The median SC, measured across the 64 sites, ranged from 19.0 % 
(subject 13) to 60.5 % (subject 3) with median and IQR of 27.8 (31.0 – 43.8) % 
across all subjects.     
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Figure 109. SC across the body surface sites for each subject. Each bar is 
constructed from 64 values.  
 
SC significant difference between subjects suggested that subjects had 
different degrees of AF complexity. This was expected as subjects had different 
AF histories. To investigate whether these results agreed with the AF degree of 
complexity estimated from the intracardiac recordings, SC was estimated from 
inside the heart as explained below and later compared to SC from the body 
surface.    
II. Inside the Heart Spectral Concentration 
 SC was measured from the two minute EGM recordings in the same 
manner as the BSPM for each site in each subject. The Box and Whisker plot of 
SC across the five CS and five PVAC sites is shown in Figure 110. The 
Friedman test showed that subjects exhibited significant differences in SC 
(p<0.05) estimated from either CS or PVAC sites.  
 The median SC, measured across the five CS sites, ranged from 21.1 % 
(subject 9) to 86.0 % (subjects 3) with median and IQR of 47.5 (39.5 – 56.8) % 
across all subjects. The median SC, measured across the five PVAC sites, 
ranged from 36.3% (subject 18) to 90.0% (subject 3) with median and IQR of 
63.0 (53.3 – 70.0) % across all subjects. 
110 
 
 
Figure 110. SC across CS (light grey) and PVAC (dark grey) for each subject. 
Each bar is constructed from 5 values. 
 
The results showed that SC estimated from inside the heart was 
significantly different between subjects. Eighty percent of subjects1 had larger 
median SC in PVAC than in CS. This may suggest that there was far-field atrial 
activity from the RA or other AF pathways on the CS. In other words, the PVAC 
sites may capture more localised frequencies from the LA, while the CS sites 
capture AF frequencies from different sources (e.g. the LA and RA). Further 
evidence of this is apparent in Figure 102 and Figure 103, as the PVAC 
frequency spectra had a single dominant peak in most subjects compared to the 
CS which had multiple peaks in those subjects (e.g. subjects 4, 5, 9, and 14). 
Differences in SC between the CS and PVAC sites were investigated 
statistically in chapter 6 by studying spatial variability. 
III. Comparison of the SC Estimated from Body Surface and Inside the 
Heart in Individual Subjects 
 To facilitate the comparison of body surface and intracardiac SC, Figure 
111 combines the data from Figure 109 and Figure 110.  
                                            
1
 Subjects 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 19. 
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Figure 111. SC across the BSPM, CS and PVAC sites for each subject. This 
figure is constructed by jointly plotting the data from Figure 109 and Figure 110. 
 
 Figure 111 showed that all subjects had larger SC in PVAC than BSPM, 
and ninety-five percent of subjects2 had larger SC in CS than BSPM. 
Figure 112 shows SC of the BSPM, CS and PVAC plotted in colour for 
each subject. This figure did not show any consistent pattern in SC between 
subjects. This may suggest that there was no specific body surface site that 
consistently represent AF organisation in all subjects. 
The linear regression analysis and scatter plots between the median SC 
estimated from the BSPM and both the CS and PVAC are shown in Table 4 and 
Figure 113.   
                                            
2
 Subjects 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20. 
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Figure 112. Spatial colour map of SC for each subject (identified 1 to 20). The 
vertical panels indicate BSPM anterior (left) and posterior (right). The horizontal 
panels indicate EGM SC from five CS sites (top: CS1 to CS5 from left to right) 
and five PVAC sites (bottom: PVAC1 to PVAC 5 from left to right).   
 
 Median SC [%]  
Source p-value    [%]       
BSPM   & CS  0.004 38.4   11.0 0.5 
BSPM   & PVAC  0.006 35.0   5.6 0.5 
Table 4. Linear relationship between the median BSPM and EGM SC for 20 
subjects. 
 
Figure 113. Linear relationship of the median SC estimated from body surface 
and inside the heart.   
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Figure 113 showed a positive linear relationship between BSPM and 
EGM SC. However, the strength of the relationship was weak and SC values 
were not normally distributed around the linear fit. To investigate whether the 
three subjects (3, 7 and 8) on the right side of the linear fit in Panel A, and the 
four subjects (3, 7, 8, and 14) on the right side of the linear fit in Panel B were 
influential to show the positive relationship or not, these subjects were 
discarded and analysis was repeated. The results showed no linear relationship 
between SC estimated from the body surface and inside the heart (p>0.05,   < 
0.2 %). Subjects 3 and 8 are in well organised AF and subjects 7 and 14 are 
more organised compared to the other subjects. This suggests that the body 
surface was unlikely to indicate AF complexity estimated from inside the heart in 
less organised AF cases.  
Similarly, this analysis was repeated between SC estimated from BSPM 
site 22 with both CS4 and PVAC4 (see Table 5 and Figure 114).    
 SC [%]  
Source p-value    [%]       
BSPM  site 22 & CS4  0.002 42.4   13.3 0.6 
BSPM  site 22 & PVAC4  0.003 39.8   8.6 0.6 
Table 5. Linear relationship between BSPM site 22 and EGM SC for 20 
subjects.  
 
 
Figure 114. Linear relationship of SC estimated from the body surface site 22 
and inside the heart.   
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 The positive linear relationship between body surface site 22 and 
intracardiac SC may suggest that the body surface site with large amplitude 
was more likely to represent a degree of AF organisation estimated from inside 
the heart. The median SC may have been affected by noise at the posterior 
body surface sites due to low amplitude at these sites.  
3.4. Relationship Between Atrial Fibrillation Characteristics  
The AF characteristics estimated from the body surface and inside the 
heart for each subject were shown earlier in this chapter. Investigation of 
relationship between these characteristics estimated either from the body 
surface or inside the heart may motivate the development of a better 
understanding of the AF mechanism.  For this purpose, the relationships 
between the AF characteristics estimated from body surface and from inside the 
heart form the focus of this section.  
To investigate further the relationship between the AF characteristics 
estimated from the body surface, the linear regression analysis was performed 
with median values computed across the 64 sites in each subject between 
amplitude with DF, amplitude with SC, and SC with DF, see Table 6. 
Source: Estimate from BSPM p-value    [%]       
Amplitude  &  DF 0.741 0.6 5.9 0.0 
Amplitude  &  SC 0.013 30.1 18.8 0.4 
SC                 &  DF 0.648 1.6 5.4 0.0 
Table 6. Linear relationship between the atrial fibrillation characteristics 
estimated from the body surface. 
 
 To investigate relationship between AF characteristics estimated from 
inside the heart, the linear regression analysis was performed with median 
values computed across the five CS and five PVAC sites in each subject 
between SC with DF (see Table 7). 
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Source: Estimate from EGM p-value    [%]       
     CS  SC          &  CS  DF 0.247 7.7 5.0 0.0 
PVAC  SC    &  PVAC  DF 0.131 12.0 4.5 0.0 
CS  SC          &  PVAC  SC <0.001 59.3 24.3 0.7 
CS  DF          &  PVAC  DF <0.001 57.6 1.5 0.7 
Table 7. Linear relationship between the atrial fibrillation characteristics 
estimated from inside the heart.  
 
According to the results, there was no linear relationship between signal 
amplitude and DF estimated from the body, nor between DF and SC estimated 
from the body surface and inside the heart. However, there was a weak positive 
linear relationship between amplitude and SC estimated from the body surface. 
This may suggest that SC computed from the AF signal with large amplitude 
was less affected by noise. As a result, components of the frequencies in the 
AF band were less undulated.   
Chapter Summary   
In this chapter AF characteristics (amplitude, DF and SC estimated from 
the BSPM recordings, and also DF and SC estimated from the EGM recordings) 
were analysed between subjects. AF amplitude estimated from the body 
surface ranged from 19.0 to 90.0 µV. AF DF estimated from the body surface 
ranged from 3.5 to 8 Hz which agreed with DF estimated from inside the heart. 
AF SC ranged from 19.0% to 60.5% estimated from the body surface, and from 
21.0% to 90.0% estimated from inside the heart.  
There was a significant difference in AF characteristics between 
subjects. These differences could be related to factors such as complexity of 
AF, BMI, and AF history.  
In some subjects there were relatively small differences in AF 
characteristics across the body surface and intracardiac sites and in others 
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relatively large differences.  Subjects in well organised AF exhibited good 
agreement of the AF characteristics between the BSPM, CS and PVAC 
recordings. However, subjects in less organised AF exhibited poor agreement 
of the AF characteristics between the BSPM, CS and PVAC or else between 
the CS and PVAC recordings. The AF characteristic differences in each subject 
may suggest that different sites captured atrial activations from different AF 
sources as they were located in different AF re-entrant pathways.  
There was a positive strong linear relationship between the median DF 
estimated from the body surface and intracardiac recordings across the sites. 
However, this relationship decreased between single body surface site (site 22, 
closest to lead V1) and intracardiac recordings. This suggested more accurate 
estimation of AF DF using additional electrodes to lead V1. Furthermore, there 
was a positive but weak linear relationship between the median SC estimated 
from the body surface and intracardiac recordings across the sites. However, 
this relationship increased between single body surface site (site 22, with the 
largest amplitude) and intracardiac recordings. This suggested that there were 
other factors that may affect estimation of SC from the body surface sites such 
as noise and BMI.    
It can be concluded that in subjects with organised AF, the AF 
characteristics estimated from the body surface sites can be used as a measure 
of AF. However, in subjects with complex AF, the AF characteristics estimated 
from the body surface sites may not be in good agreement with the 
measurements from inside the heart.  
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Chapter 4. Effect of Body Mass Index on Atrial Fibrillation 
Characteristics 
 There are no known studies of effect of BMI on the AF characteristics in 
the literature. As the aim of this PhD study was to investigate how AF 
characteristics were expressed on the body surface, it was important to know if 
any physiological factors affect AF characteristics estimated from the body 
surface. The effect of BMI on the AF characteristics were investigated in this 
chapter using linear regression analysis between BMI with the AF 
characteristics estimated from anterior site 22, posterior site 49, and the median 
across 64 sites.  
 Site 22 was chosen as it had the largest AF signal amplitude on the 
anterior site (see chapter 6). In addition, as discussed earlier, site 22 was 
closest to lead V1 on the 12-lead ECG, the commonly used lead for AF 
analysis. 
 Site 49 was chosen as it had the largest AF signal amplitude on the 
posterior site (see chapter 6). Moreover, it had strong morphology 
correlation with PVAC (see chapter 7). 
 The median across 64 body surface sites was also investigated as there 
was large variability of the AF characteristics between body surface sites 
(see chapter 6). It was thought that one body surface site might not be 
indicative of the actual value of the AF characteristics across the whole 
body surface.   
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This chapter also investigates whether there is a relationship between 
subject's BMI and the differences of the AF characteristics estimated from the 
body surface and inside the heart.  
4.1. Amplitude and BMI 
 The linear regression analysis between amplitude estimated from the 
longest AF segment (see chapter 2, parameter estimation, amplitude) showed a 
negative correlation (  = 20.2 %, p=0.043) between site 22 and BMI, see 
Figure 115. There was also no correlation between site 49 and BMI, or between 
the median across the sites and BMI (   10.0 %, p>0.05), see Table 8. 
Figures are shown in Appendix C. 
 
Figure 115. Linear relationship between BMI and AF amplitude from body 
surface site 22.     
 
The results suggested that BMI may explain 20.2 % of the variance in 
amplitude estimated from the anterior body surface sites. The negative 
relationship suggested that amplitude decreased with an increase in BMI. 
However, as the    value was small it may suggest that other factors affect 
amplitude as well, for example the type of AF. No relationship between 
amplitude estimated from site 49 and BMI may suggest that the effect of BMI 
may not be perceived on the posterior sites. This could be the reason for not 
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having any linear relationship between the median amplitude across the body 
surface sites as well. Calculating the median value possibly blurs the effect of 
BMI, as large BMI appears to have more effect on the anterior body surface 
sites.   
4.2. Dominant Frequency and BMI  
 The linear regression analysis showed no correlation (  < 12.2 %, 
p>0.05) between DF estimated from sites 22 and 49 with BMI (see Appendix 
C). However, it showed a positive correlation (  = 20.0 %, p=0.046) between 
BMI and the median DF across the sites as shown in Figure 116 and Table 8.  
 
Figure 116. Linear relationship between BMI and the median DF across the 
BSPM sites.   
 
The results may suggest that BMI explains 20.0 % of the variance in DF 
estimated from the body surface sites. In addition, the linear regression analysis 
was used between BMI and the estimated error in DF (see Figure 117 and 
Figure 118). The estimated error was introduced to study DF differences 
between the body surface and inside the heart. Using EGM DF as a reference, 
the estimated error was calculated by subtracting CS4 and PVAC4 DF from 
BSPM DF site 22. This would indicate if body surface DF had been under or 
overestimated in relation to BMI.  
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Figure 117. Linear relationship between BMI vs. estimated error DF (BSPM site 
22 vs. CS4) for 20 subjects. There are 19 points visible as subjects 1 and 10 
had overlapping values.    
      
Figure 118. Linear relationship between BMI vs. estimated error DF (BSPM site 
22 vs. PVAC4) for 20 subjects. There are 19 points visible as subjects 1 and 10 
had overlapping values.    
 
The results showed a negative correlation (p=0.022 BSPM site 22 vs. 
CS, and p=0.019 BSPM site 22 vs. PVAC), with    30.0 %. This suggested 
that the BMI may explain 30.0 % of the variance in DF estimated from the 
anterior body surface sites compared to DF estimated from inside the heart.  
To examine if the relationship between BMI and BSPM DF, as well as 
BMI and DF estimated error were not because of artifacts, CS and PVAC DF 
versus BMI were plotted (see Figure 120).  
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Figure 119. Linear relationship between BMI and the median DF across the CS 
sites (top) and PVAC sites (bottom).   
 
The results suggest that subjects with larger BMI had AF with larger DF. 
Similarly, this analysis was repeated for site 49 and the median across all the 
sites. These results showed no significant correlation between the BMI and the 
estimated error DF for both analysis (p>0.05,     2.0 %). A positive linear 
relationship between the median DF and BMI, as well as a negative linear 
relationship between the estimated error DF and BMI may suggest that with 
increasing BMI, the body surface recordings underestimate DF. However, the 
estimated error DF was 0.0 Hz in four subjects (3, 8, 14 and 16) from BSPM site 
22 vs. CS, and in three subjects (3, 8, and 12) from BSPM site 22 vs. PVAC. 
This suggested that there was no difference between BSPM and EGM DF in 
these subjects. Two of these subjects (3 and 8) had consistent DF across all 
BSPM, CS and PVAC sites and they were in well organised AF (see section 
1.1.3, description of AF complexity). The other subjects: 14 (Male, overweight, 
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paroxysmal AF), 12 (Male, overweight, paroxysmal AF), and 16 (Female, very 
obese, persistent AF) were overweight but DF from site 22 and EGM DF were 
the same. This suggested that BMI could not predict the DF difference between 
the body surface and inside the heart. 
4.3. Spectral Concentration and BMI 
The relationship between BMI and SC was also studied in the same 
manner as DF. The results showed no significant correlation between BMI with 
SC from site 22, site 49, and the median across the sites (p>0.05) with     4.0 
% (see Appendix C). In addition there was no significant correlation between 
BMI and the estimated error SC (p>0.05) with     7.0%, see Table 8. Hence, 
BMI was unlikely to have influenced estimation of SC from the body surface 
sites. 
Source p-value    [%]       
BMI  & Amplitude site 22 0.043 20.2 220.5 -4.4 
BMI  & Amplitude site 49 0.238 10.0 69.6 -1.1 
BMI  & Median Amplitude  0.175 7.3 99.5 -2.0 
BMI  & DF site 22 0.758 5.3 5.7 0.1 
BMI  & DF site 49 0.069 12.1 1.1 0.1 
BMI  & Median DF 0.046 20.0 3.1 0.1 
BMI  & ΔDF (site 22 vs. CS) 0.022 30.0 3.2 -0.1 
BMI  & ΔDF (site 22 vs. PVAC)  0.019 30.0 3.3 -0.1 
BMI  & ΔDF (site 49 vs. CS) 0.950 2.0 1.1 0.1 
BMI  & ΔDF (site 49 vs. PVAC)  0.751 1.0 1.1 0.1 
BMI  & ΔDF (median vs. CS) 0.850 1.0 1.1 0.1 
BMI  & ΔDF (median vs. PVAC)  0.765 1.1 1.1 0.1 
BMI  & SC site 22 0.650 1.2 33.5 0.4 
BMI  & SC site 49 0.613 1.0 51.9 -0.4 
BMI  & Median SC 0.835 2.0 19.5 -0.1 
BMI  & ΔSC (site 22 vs. CS) 0.950 2.0 1.1 0.1 
BMI  & ΔSC (site 22 vs. PVAC)  0.761 6.3 1.1 0.1 
BMI  & ΔSC (site 49 vs. CS) 0.850 2.0 1.3 0.1 
BMI  & ΔSC (site 49 vs. PVAC)  0.781 3.6 1.6 0.1 
BMI  & ΔSC (median vs. CS) 0.780 2.0 1.1 0.1 
BMI  & ΔSC (median vs. PVAC)  0.776 3.0 1.2 0.1 
Table 8. Linear relationship between the atrial fibrillation characteristics and 
BMI.    
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Chapter Summary 
 In this chapter the effect of BMI on the AF characteristics estimated from 
the body surface recordings was investigated. The weak linear relationship 
between the AF characteristics and BMI may suggest that BMI had a small 
effect (less than 30.0%) on AF characteristics estimated from the body surface. 
Moreover, other factors may affect the AF characteristics estimated from the 
body surface, for example type of AF and noise. This could not be further 
investigated as the number of subjects with each type of AF was not statistically 
powerful enough to indicate this. 
The limitation of this study was that the BMI was not normally distributed. 
Fourteen subjects had BMI less than 30       and six subjects had BMI 
greater than 30      , so this could have biased the results.   
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Chapter 5. Temporal Variability of Atrial Fibrillation 
Characteristics  
In this chapter the AF characteristics repeatability over the two minute 
recordings were investigated. The aim was to study the consistency of the AF 
characteristics over the duration of the recordings. This can indicate stability of 
the AF rhythm and determine whether these characteristics vary over time or 
are constant during stable clinical conditions. Moreover, the linear relationship 
between temporal variability estimated from the body surface and intracardiac 
recordings were studied for DF and SC. 
5.1. Amplitude Temporal Variability    
 To investigate how AF amplitude changes over time, amplitude of the 
five longest AF segments, TQ1 to TQ5, was measured within the two minute 
BSPM recordings at each site for each subject. The median amplitude across 
the body surface sites and duration for each segment are shown in Figure 120.    
 
Figure 120. The median amplitude (left) and its duration (right) for each AF 
segment. Each bar is constructed from 20 values.  
 
 An example of the signals from the five longest AF segments for one 
subject is shown in Figure 121.  
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Figure 121. AF signal from five longest AF segments, within two minutes, for 64 
body surface sites, subject 20. For each AF segment: the x-axis is time [s] and 
the y-axis is amplitude [µV] with all signals plotted in the same amplitude range.  
 
 The Friedman test showed that the segments did not exhibit significant 
differences (p>0.05) in amplitude (Design= 20×5, see section 2.4). The median 
amplitude between the segments ranged from 33.0 µV (TQ2) to 36.0 µV (TQ1).  
 AF amplitude temporal variability was quantified by the IQR of amplitude 
across the five AF segments in each subject to investigate if amplitude was 
more stable over time in subjects with larger amplitude. The linear regression 
analysis was performed between the median AF amplitude and its temporal 
variability as shown in Figure 122.    
126 
 
 
Figure 122. Linear relationship between the median and inter-quartile range of 
amplitude estimated from the body surface (20 subjects). Amplitude temporal 
variability in µV (left) and percentage of the actual amplitude (right).        
 
 The results showed a positive but weak linear relationship between the 
median and temporal variability of AF amplitude (p=0.014,   = 29.4 %) shown 
in Figure 122, left panel. However, there was no relationship between the 
median and temporal variation of the actual AF amplitude in percentage 
(p=0.789,   = 0.4 %) shown in Figure 122, right panel. The results suggested 
that subjects with large amplitude were unlikely to possess more stable 
amplitude over time. For example subject 3 with the largest median amplitude 
(86.5 µV) had 11.6% temporal variability, subject 19 with the median amplitude 
of 68.2 µV had 15.7% temporal variability, and subject 4 with the median 
amplitude of 28.7 µV had 2.8% temporal variability. Moreover, subjects with 
small amplitude temporal variability (e.g. in subjects 2, 4, and 18 where 
temporal variability was less than 2 µV) were not necessarily in organised AF. 
Consequently, temporal variability was unlikely to indicate stability of the AF 
rhythm.      
 The limitations of this analysis were: (1) the AF segments were collected 
at different times within the two minute recordings for each subject; (2) the 
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duration of the segments was different between subjects, so observations for 
the same study group could be different if other segments were to be studied.  
5.2. Dominant Frequency Temporal Variability 
I. Temporal Variability of Body Surface Dominant Frequency  
 To investigate whether AF DF changes over time, DF was estimated at 
each site for each subject in three ways: (1) over two minute BSPM recordings 
(T120); (2) for two consecutive, non-overlapping segments, each 60 seconds 
long (T1-60  and T2-60); (3) for four consecutive, non-overlapping segments, each 
30 seconds long (T1-30, T2-30, T3-30, and T4-30). Median DF across the body 
surface sites for each subject in each segment was calculated and is shown in 
Figure 123.  
 
Figure 123. The median DF for each segment. Each bar is constructed from 20 
values calculated as the median across the body surface sites for each subject.   
  
 The Friedman test showed that DF did not exhibit significant differences 
(p>0.05) between either 60 seconds (Design= 20×2) or 30 seconds (Design= 
20×4). Furthermore, paired comparison using the Wilcoxon signed-rank test 
between DF estimated from the two minutes and the other time segments 
showed no significant differences (p>0.05).   
128 
 
 The median DF calculated for the two segments ranged from 5.8 Hz (T1-
60) to 5.9 Hz (T2-60), and for the four segments ranged from 5.6 Hz (T2-30) to 5.9 
Hz (T1-30). Table 9 shows the median DF difference between each 60 second 
segment and each 30 second segment. 
BSPM Median DF [Hz] 
Source Difference 
T1-60  and T1-30   -0.1 
T1-60  and T2-30   0.1 
T1-60  and T3-30   0.1 
T1-60  and T4-30   -0.1 
T2-60  and T1-30   0.0 
T2-60  and T2-30   0.3 
T2-60  and T3-30   0.3 
T2-60  and T4-30   0.1 
Table 9. The BSPM median DF variability between each 60 second segment 
and each 30 second segment. 
 
 DF temporal variability was quantified by the IQR of DF across the 
segments in each subject to investigate if DF was more stable over time in 
subjects with smaller DF. The linear regression analysis between the median 
DF and its temporal variability showed no significant correlation (p>0.05 with 
  < 0.4 %). This suggested that the subjects with small median DF were 
unlikely to possess more stable DF over time.   
II. Temporal Variability of Inside the Heart Dominant Frequency  
DF temporal variability of intracardiac measurements was also 
investigated in the same manner as described for the BSPM recordings. The 
median DF across the five CS and five PVAC sites for each segment is shown 
in Figure 124.  
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Figure 124. The median DF for each segment. Each bar is constructed from 20 
values, calculated as the median DF across the five CS sites (left) and five 
PVAC sites (right) for each subject.  
 
 The Friedman test indicated that DF was not significantly different 
between the segments for both CS and PVAC (p>0.05). Moreover, paired 
comparison using the Wilcoxon signed-rank test between DF estimated from 
the two minute and other time segments indicated that there was no significant 
difference over time (p>0.05). The CS median DF calculated for the two 
segments ranged from 5.6 Hz (T1-60) to 5.7 Hz (T2-60), and for the four segments 
ranged from 5.4 Hz (T1-30 and T2-30) to 5.5 Hz (T3-30  and T4-30). The PVAC 
median DF calculated for the two segments ranged from 5.5 Hz (T1-60) to 5.6 Hz 
(T2-60), and for the four segments ranged from 5.4 Hz (T1-30) to 5.6 Hz (T4-30). 
Table 10 shows the median DF difference between each 60 second segment 
and each 30 second segment. Intracardiac DF temporal variability was also 
quantified by the IQR of DF across the segments in each subject. The linear 
regression analysis between the median DF and its temporal variability showed 
no significant correlation (p>0.05,   < 0.4 %). This agreed with the BSPM 
results which suggested that subjects with small median DF were unlikely to 
possess more stable DF over time. 
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Median DF [Hz] 
Source Difference 
CS PVAC 
T1-60  and T1-30   0.2 0.0 
T1-60  and T2-30   0.0 -0.1 
T1-60  and T3-30   0.1 -0.1 
T1-60  and T4-30   0.1 -0.1 
T2-60  and T1-30   0.3 0.2 
T2-60  and T2-30   0.1 0.1 
T2-60  and T3-30   0.2 0.1 
T2-60  and T4-30   0.1 0.1 
Table 10. The EGM median DF variability between each 60 second segment 
and each 30 second segment.  
 
III. Differences of the Dominant Frequency Variance over Different 
Time Periods 
 To investigate DF variance over time, DF difference (ΔDF) was 
calculated between the longer segments (T1-60  and T2-60 ), and shorter segments 
(T1-30, T2-30, T3-30, and T4-30). Then variance of the ΔDF were compared between 
the longer and shorter segments in each measurement source (BSPM and 
EGM), using the Levene's test (non-parametric F-test), as shown in Figure 125. 
 The ΔDF between the longer segments was calculated by subtracting the 
T2-60 DF from the T1-60 DF. The ΔDF between the shorter segments was 
calculated as follows:   
 Minimum and maximum DF were identified between the four segments, 
 The segments with the minimum and maximum DF were collected for 
each subject to calculate the ΔDF from them. It resulted a table (Design 
= 20×2) containing subjects at each raw, and the collected segments at 
each column with the maximum or minimum DF. Note: maximum or 
minimum DF may come from different segments (either T1-30, T2-30, T3-30, 
or T4-30) for different subjects, 
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 The second column's DF (either maximum or minimum) was subtracted 
from the first column 's DF. This way helped to avoid missing the sign of 
the ΔDF.   
 
Figure 125. Paired changes of DF between 60 second and between 30 second 
segments for BSPM, CS and PVAC recordings. Each bar is constructed from 20 
values calculated as the DF difference between the segments for each subject.     
The statistical p-value indicates a difference in variance using the Levene's test.    
 
There was a significant difference in the DF difference variances 
estimated from the 60 seconds and 30 seconds duration of the BSPM 
recordings (p=0.001). However, there was no significant difference in the DF 
difference variances estimated from the 60 seconds and 30 seconds duration of 
the EGM recordings (p>0.05).   
These results showed that the body surface DF estimated from the 
longer duration had smaller variance compared to the shorter duration. The 
variance of BSPM DF for the 60 seconds was 0.1    , and for the 30 seconds 
was 0.3    . The two minute recording is likely to have smaller variability 
compared to the 60 seconds recordings.   
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IV. Comparison of the Dominant Frequency Temporal Variability 
Estimated from Body Surface and Inside the Heart  
In this section differences between BSPM and EGM of the paired 
changes was investigated (see Figure 125). Paired comparison of the DF 
differences between segments was performed between BSPM and EGM using 
the Wilcoxon signed-rank test. There was no significant difference between DF 
differences estimated from the body surface and inside the heart (p>0.05). 
The relationship of the DF temporal variability estimated from the BSPM 
and EGM recordings was investigated using linear regression analysis between 
paired of the BSPM ΔDF (calculated as T1-60 - T2-60) and  EGM ΔDF (calculated 
as T1-60 - T2-60 for both CS and PVAC), and also between paired of the BSPM 
ΔDF (calculated as T3-30 - T1-30) and  EGM ΔDF (calculated as T1-30 - T2-30 for CS 
and T1-30 - T4-30 for PVAC). There was no correlation between the DF temporal 
changes estimated from the BSPM and EGM (p>0.05,   < 3.0%). This 
suggested that  the DF temporal variability estimated from the body surface 
may be affected by other factors or sources of AF, as it may capture several re-
entrant pathways (with possible variations in frequency) circulating round the 
atria, taking different paths or directional switches in time. It is important to bear 
in mind that these differences were not statistically significant.   
5.3. Spectral Concentration Temporal Variability  
I. Temporal Variability of Body Surface Spectral Concentration 
 To investigate whether AF SC changed over the two minute BSPM 
recordings, SC was estimated in the same approach as DF. Median SC across 
the body surface sites in each subject for each segment is shown in Figure 126.   
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Figure 126. The median SC for each segment. Each bar is constructed from 20 
values calculated as the median across the body surface sites for each subject.    
 
 The Friedman test showed that SC did not exhibit significant differences 
between either 60 second or 30 second (p>0.05). Paired comparison using the 
Wilcoxon signed-rank test between SC estimated from the two minutes and the 
other time segments showed no significant differences over time (p>0.05).  
 The median SC calculated for the two segments ranged from 30.5 % 
(T2-60) to 31.2 % (T1-60), and for the four segments ranged from 30.0 % (T2-30) to 
32.0 % (T4-30). The median SC variability between each 60 second segment and 
each 30 second segment are shown in Table 11.  
 SC temporal variability was quantified by the IQR of SC across the 
segments in each subject to investigate if SC was more stable over time in 
subjects with larger SC. The linear regression analysis between the median SC 
and its temporal variability showed no significant correlation (p>0.05,   < 0.9 
%). This suggested that subjects with large median SC were unlikely to possess 
more stable SC over time.      
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BSPM Median SC [%] 
Source Difference 
T1-60  and T1-30   -1.0 
T1-60  and T2-30   0.5 
T1-60  and T3-30   0.5 
T1-60  and T4-30   -1.5 
T2-60  and T1-30   -1.3 
T2-60  and T2-30   0.3 
T2-60  and T3-30   0.3 
T2-60  and T4-30   -1.8 
Table 11. The BSPM median SC variability between each 60 second segment 
and each 30 second segment. 
  
II. Temporal Variability of Inside the Heart Spectral Concentration  
 The SC temporal variability was also investigated from inside the heart in 
the same manner as described earlier. The median SC for each subject 
calculated across the five CS and five PVAC sites for each segment is shown in 
Figure 127. The Friedman test showed that SC did not exhibit significant 
differences (p>0.05) between either 60 second or 30 second. The median SC 
calculated for the two segments ranged from 44.6 % (T2-60) to 47.5 % (T1-60) for 
CS, and ranged from 48.9 % (T2-60) to 51.2 % (T1-60) for PVAC.  The median SC 
calculated for four segments ranged from 47.5 % (T1-30 and T3-30) to 51.0 % (T4-
30) for both CS and PVAC recordings. The median SC variability between each 
60 second segment and each 30 second segment are shown in Table 12.     
 
Figure 127. The median SC for each segment. Each bar is constructed from 20 
values, calculated as the median SC across the five CS sites (left) and five 
PVAC sites (right) for each subject.  
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Median SC [%] 
Source Difference 
CS PVAC 
T1-60  and T1-30   -3.4 3.2 
T1-60  and T2-30   -4.4 2.2 
T1-60  and T3-30   -3.4 3.2 
T1-60  and T4-30   -5.9 0.6 
T2-60  and T1-30   -3.4 0.9 
T2-60  and T2-30   -4.4 -0.1 
T2-60  and T3-30   -3.4 0.9 
T2-60  and T4-30   -5.9 -1.7 
Table 12. The EGM median SC variability between each 60 second segment 
and each 30 second segment. 
 
 Paired comparison using the Wilcoxon signed-rank test was performed 
between SC estimated from the two minute and the other time segments. The 
results showed that SC estimated from the EGM did not change significantly 
between the two minute with first and second minute, or between the two 
minute with each 30 second (p>0.05). Intracardiac SC temporal variability was 
quantified by the IQR across the segments in each subject. The linear 
regression analysis between the median SC and its temporal variability showed 
no significant correlation (p>0.05,   < 2.0 %). This agreed with the BSPM 
results which suggested that subjects with larger SC were unlikely to possess 
more stable SC over time. Moreover, stability over time was less likely to 
indicate the degree of AF organisation.  In other words, subjects with stable SC 
temporal variability over time were not necessarily in organised AF. It is 
important to bear in mind that these differences were not statistically significant.  
III. Differences of the Spectral Concentration Variance over Different 
Time Periods 
 To investigate SC variance between the two segments of 60 second and 
four segments of 30 second for BSPM and EGM, Figure 128 was constructed. 
SC differences were calculated in the same manner as DF.  
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Figure 128. Paired changes of SC between 60 second and between 30 second 
segments for BSPM, CS and PVAC recordings. Each bar is constructed from 20 
values calculated as the SC difference between the segments for each subject. 
The statistics indicates no significant difference in variance using Levene's test. 
 
Figure 128 shows the SC differences between the two segments of 60 
seconds duration, and SC differences between the four segments of 30 
seconds duration estimated from the BSPM, CS and PVAC recordings. The 
variances of the SC differences were compared between the two segments and 
four segments in each measurement source using the Levene's test. There was 
no significant difference of the SC difference variances estimated from the 60 
seconds and 30 seconds duration in both the BSPM and EGM recordings 
(p>0.05).   
These results showed that body surface and intracardiac SC estimated 
from the longer duration had smaller variance compared to the shorter duration; 
bear in mind that the variance was not statistically significant. Consequently, the 
two minute recording was reliable for the analysis of AF SC.    
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IV. Comparison of the Spectral Concentration Temporal Variability 
Estimated from Body Surface and Inside the Heart  
In this section differences between BSPM and EGM of the paired 
changes (see Figure 128) was investigated. Paired comparison of the SC 
differences between segments was performed between BSPM and EGM using 
the Wilcoxon signed-rank test. There was no significant difference between SC 
differences estimated from the body surface and inside the heart (p>0.05). 
The relationship of the SC temporal variability estimated from the BSPM 
and EGM was investigated using linear regression analysis between paired of 
the BSPM ΔSC (calculated as T1-60 - T2-60) and  EGM ΔSC (calculated as T1-60 - 
T2-60 for both CS and PVAC), and also between paired of the BSPM ΔSC 
(calculated as T2-30 - T4-30) and  EGM ΔSC (calculated as T1-30 - T4-30 for both CS 
and PVAC). There was no correlation between the BSPM and EGM SC 
temporal variability (p>0.05,   < 16.2%). This suggested that the BSPM SC 
temporal variability may be affected by other factors or sources of AF, as it may 
capture several re-entrant pathways circulating round the atria. It is important to 
bear in mind that these differences were not statistically significant.  
Chapter Summary 
 In this chapter the repeatability of AF amplitude estimated from the body 
surface recordings was assessed over the two minutes by studying the five 
longest AF segments. The repeatability of DF and SC estimated from the body 
surface and inside the heart were also assessed by dividing the two minute 
recordings into two segments of 60 seconds and four segments of 30 seconds 
duration.  The AF characteristics estimated from the body surface and inside 
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the heart were repeatable over the duration of the recordings. There was no 
evidence that subjects with large AF amplitude and high SC had more stable 
amplitude over the two minute recordings. There was no evidence that subjects 
with small DF had more stable DF over the two minute recordings.  Moreover, 
the temporal variation of DF was small (0.1 Hz) compared to between subject 
variability (3.4 Hz, see chapter 3), which suggested that the two minute 
recording variation was acceptable for AF analysis.  
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Chapter 6. Spatial Variability of Atrial Fibrillation 
Characteristics  
This chapter investigates spatial variability of the AF characteristics 
estimated from the body surface and inside the heart. The aim was to explore 
how AF characteristics were expressed across the body surface and along the 
catheters sites. This could potentially discover body surface sites which might 
be particularly sensitive to the left atrial activity, and it may spur the 
development of a greater understanding of the AF mechanism from the body 
surface. Moreover, the linear relationship between each body surface site and 
selected intracardiac sites were investigated across all subjects.              
6.1. Spatial Variability of Body Surface Amplitude  
 To investigate AF amplitude spatial variability, peak to peak amplitude 
was estimated from the longest AF segment within the two minute recordings 
for each body surface site in each subject. Figure 129 illustrates the amplitude 
range for each site across subjects.  
  
Figure 129. AF amplitude for each body surface site. Each bar is constructed 
from 20 values from each subject. Outliers from subject 3 (blue), subject 15 
(pink), and subject 19 (red) are also displayed. The largest AF amplitude could 
be seen on the anterior central right, close to site 22 (dash red marked).  
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 To visualise the differences in amplitude between the body surface sites, 
Figure 130 shows a colour map of the median amplitude across subjects. 
 
Figure 130. Spatial colour map of the median amplitude across subjects (values 
are from the horizontal lines in each bar in Figure 129).  
 
 The Friedman test showed that AF amplitude exhibited significant 
differences (p<0.001) between the sites (Design=20×64, see section 2.4).  
 The median amplitude measured across subjects ranged from 21.8 µV 
(site 60) to 77.4 µV (site 22), with median and IQR of 34.4 (29.2 – 44.9) µV 
across all the sites.   
 To investigate more precisely where on the body surface the amplitude 
differences occurred, the body surface sites were grouped according to their 
anatomical location into four groups: anterior and posterior, left and right, 
vertical lines and horizontal lines (see chapter 2 for definition of electrode 
groups).  
Spatial Variability of Amplitude at the Anterior and Posterior Sites: Paired 
comparison using the Wilcoxon signed-rank test showed that amplitude was 
significantly different between the anterior and posterior sites (p<0.001), 
Design= 20×2, see Figure 131.   
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Figure 131. AF amplitude of the anterior and posterior body surface sites. Each 
bar is constructed from 20 values calculated as the median across the anterior 
and posterior sites in each subject.   
 
Spatial Variability of Amplitude at the Left and Right Sites: (I) Paired 
comparison using the Wilcoxon signed-rank test showed that amplitude was 
significantly different between the left and right sites (p=0.001), Design= 20×2. 
(II) Paired comparison using the Wilcoxon signed-rank test showed significant 
differences in amplitude between the possible pairs except between the 
posterior left and posterior right (p=0.001), see Figure 132.      
      
Figure 132. AF amplitude for the left and right body surface sites. Each bar is 
constructed from 20 values calculated as the median across the left and right 
sites in each subject.   
 
Spatial Variability of Amplitude at the Vertical Electrode Lines: The 
Friedman test showed that amplitude exhibited significant differences between 
the vertical lines (p<0.001), Design= 20×8, see Figure 133. Paired comparison 
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using the Wilcoxon signed-rank showed significant differences between all 
possible pairs except ACL & ALR, PLL & PCL, and PCR & PLR (see Appendix 
D, Table 18).  
 
Figure 133. AF amplitude for the vertical lines on body surface sites. Each bar is 
constructed from 20 values calculated as the median across the vertical 
electrodes in each strip for each subject.  
 
Spatial Variability of Amplitude at the Horizontal Electrode Lines: The 
Friedman test showed that AF amplitude exhibited significant differences 
between the horizontal lines (p<0.001), Design= 20×16, see Figure 134. Paired 
comparison using the Wilcoxon signed-rank showed significant differences 
between the possible pairs except between some anterior lower body surface 
and some posterior lower body surface sites (see Appendix D, Table 19).  
  
Figure 134. AF amplitude for the horizontal lines on body surface sites. Each 
bar is constructed from 20 amplitude values calculated as the median across 
the horizontal electrodes in each line for each subject.  
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 According to the results, AF amplitude was significantly larger on the 
body surface sites close to the anterior upper central right. This may suggest 
that these sites represent AF better than other body surface sites (in terms of 
the amplitude). According to the literature in the 12-lead ECG, lead V1 is used 
for AF analysis due to its proximal location to the RA. The anterior upper central 
right sites are close to lead V1, therefore they may capture AA from the RA. To 
investigate whether these sites also capture AA from the LA, DF estimated from 
the anterior upper central right sites was compared with DF estimated from 
inside the heart (see section 6.2, part III).  
6.2. Spatial Variability of Dominant Frequency  
I. Spatial Variability of Dominant Frequency at the Body Surface  
 To investigate AF DF spatial variability, DF was estimated over the two 
minute BSPM recordings in each subject for each site. Figure 135  illustrates 
DF for each site across subjects, and Figure 136 shows a colour map of the 
median DF across subjects. The Friedman test showed that AF DF exhibited 
significant differences between the sites (p=0.025), Design=20×64.    
 
Figure 135. DF for each body surface site. Each bar is constructed from 20 
values from each subject. Outliers belong to subjects 11 and 18.  
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Figure 136. Spatial colour map of the median DF across subjects (values are 
from the horizontal lines in each bar in Figure 135).   
  
 The median DF, measured across subjects ranged from 5.5 Hz (site 45) 
to 6.1 Hz (site 22), with median and IQR of 5.6 (5.3 – 6.0) Hz across all the 
sites.  
 To investigate where on the body surface the DF differences occurred, 
DF changes was studied between the anterior and posterior, left and right, 
vertical lines and horizontal lines.  
Spatial Variability of DF at the Anterior and Posterior Sites: Paired 
comparison using the Wilcoxon signed-rank test showed that DF was not 
significantly different between the anterior and posterior sites (p>0.05), Design= 
20×2, see Figure 137.   
 
Figure 137. DF for the anterior and posterior body surface sites. Each bar is 
constructed from 20 values calculated as the median across the anterior and 
posterior sites in each subject.   
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Spatial Variability of DF at the Left and Right Sites: (I) Paired comparison 
using the Wilcoxon signed-rank test showed no significant differences between 
the left and right sites (p>0.05), Design= 20×2. (II) The factorial ANOVA test 
showed that DF was not significantly different between the left and right anterior 
and the left and right posterior sites (p>0.05), Design = (20×4) ×3, see Figure 
138.      
 
Figure 138. DF for the left and right body surface sites. Each bar is constructed 
from 20 DF values calculated as the median across the left and right sites in 
each subject. 
 
Spatial Variability of DF at the Vertical Electrode Lines: The Friedman test 
showed that AF DF did not exhibit significant differences between the vertical 
lines (p>0.05), Design = 20×8, see Figure 139.   
 
Figure 139. DF for the vertical lines on body surface. Each bar is constructed 
from 20 values calculated as the median across the vertical electrodes in each 
strip for each subject.   
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Spatial Variability of DF at the Horizontal Electrode Lines: The Friedman 
test showed that DF exhibited significant differences between the horizontal 
lines (p=0.020), Design= 20×16, see Figure 140. Paired comparison of all 
possible pairs using the Wilcoxon signed-rank test showed significant 
differences between the anterior central sites and anterior upper sites 
(p=0.035), and between the anterior upper sites and posterior central sites 
(p=0.032).   
 
Figure 140. DF for the horizontal lines on body surface sites. Each bar is 
constructed from 20 values calculated as the median across the horizontal 
electrodes in each line for each subject.    
  
  According to the results, DF changed significantly across the body 
surface sites, more precisely between the anterior upper sites with the anterior 
and posterior central sites with DF difference of 0.5 Hz. 
II.  Spatial Variability of Dominant Frequency at the Intracardiac Sites 
 To investigate changes in DF along catheter sites, DF was estimated 
with the same methodology as applied to the BSPM recordings for each EGM 
site in each subject. Figure 141 illustrates DF for each site across subjects. The 
factorial ANOVA showed that DF exhibited significant differences between ten 
EGM sites (p=0.040) including five CS and five PVAC, Design = (20×10)×3. 
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However, DF did not exhibit significant differences between either CS or PVAC 
(p>0.05), Design = (20×5) ×3.  
 The median DF (measured across subjects) between the CS sites 
ranged from 5.4 Hz (CS5) to 5.7 Hz (CS2), and between the PVAC sites ranged 
from 5.5 Hz (PVAC3) to 5.8 Hz (PVAC5).  
 
Figure 141. DF for the CS (light grey) and PVAC (dark grey) sites. Each bar is 
constructed from 20 values for each subject. The outliers belong to subjects 7 
and 11.    
 
 There was no significant difference in DF estimated from any of the 
electrodes of the same catheter, either CS or PVAC. However, there was a 
significant difference in DF between the CS and PVAC catheters. The DF 
difference (smallest CS DF vs. largest PVAC DF) was 0.4 Hz. The difference in 
DF between CS and PVAC catheters may suggest that the CS captured 
different frequencies from different far-field sources.  
III. Comparison of Body Surface and Intracardiac Dominant Frequency 
for Each Site 
 In this section, linear correlation analysis was performed between each 
body surface site and the selected intracardiac sites CS4 and PVAC4 (see 
section 2.2.4). The aim was to investigate whether BSPM DF spatial variability 
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could determine which body surface site represent the CS recordings, and 
which body surface represent the PVAC recordings. Figure 142 shows a colour 
map of the correlation coefficient between BSPM and EGM DF at each body 
surface site. 
 
Figure 142. Spatial colour maps of the correlation coefficient between BSPM 
and CS DF (left), and between BSPM and PVAC DF (right).  
  
   The results showed that DF at anterior and posterior upper right sites 
had the strongest linear relationship with CS DF. Also, DF at posterior upper left 
and lower right sites had the strongest linear relationship with PVAC DF. This 
analysis potentially suggested that the body surface sites close to the anterior 
upper central right were a good representation of CS DF, or more likely the RA 
DF. Moreover, the body surface sites close to the posterior upper left and lower 
right were a good representation of the LA DF.   
6.3. Spatial Variability of Spectral Concentration   
I. Spatial Variability of Spectral Concentration at the Body Surface 
 To investigate SC spatial variability, SC was estimated in each subject 
for each body surface site. Figure 143 illustrates SC for each site across 
subjects. Figure 144 shows a colour map of the median SC across subjects. 
The Friedman test showed that SC exhibited significant differences between the 
sites (p<0.001), Design = 20×64.    
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 The median SC measured across subjects ranged from 22.0 % (site 5) to 
44.5 % (site 23) with median and IQR of 31.0 (28.5 – 36.0) % across all sites.  
 
Figure 143. SC for each body surface site. Each bar is constructed from 20 
values from each subject. Outliers belong to subjects 3, 7, 8 and 14.     
 
 
Figure 144. Spatial colour map of the median SC (values are from the horizontal 
lines in each bar in Figure 143).  
  
 The body surface sites were grouped into anterior and posterior, left and 
right, vertical lines and horizontal lines, and SC changes were analysed 
between each group.   
Spatial Variability of SC at the Anterior and Posterior Sites: Paired 
comparison using the Wilcoxon signed-rank test showed that SC was not 
significantly different between the anterior and posterior sites (p>0.05), Design= 
20×2, see Figure 145.     
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Figure 145. SC for the anterior and posterior body surface sites. Each bar is 
constructed from 20 values calculated as the median across the anterior and 
posterior sites in each subject.   
 
Spatial Variability of SC at the Left and Right Sites: (I) Paired comparison 
using the Wilcoxon signed-rank test showed that SC was significantly different 
between the left and right sites (p=0.008), Design= 20×2. (II) Paired comparison 
using the Wilcoxon signed-rank test between all possible pairs showed that SC 
was significantly different between the anterior right with anterior left (p<0.001), 
posterior left (p<0.001) and posterior right (p=0.001) as shown in Figure 146 
(see Appendix D, Table 20).         
 
Figure 146. SC for the left and right body surface sites. Each bar is constructed 
from 20 values calculated as the median across the left and right sites in each 
subject.    
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Spatial Variability of SC at the Vertical Electrode Lines: The Friedman test 
showed that SC exhibited significant differences between the vertical lines 
(p<0.001), Design = 20×8, as shown in Figure 147 (see Appendix D, Table 21).  
 
Figure 147. SC for the vertical lines on body surface sites. Each bar is 
constructed from 20 values calculated as the median across the vertical 
electrodes in each strip for each subject.  
 
Spatial Variability of SC at the Horizontal Electrode Lines: The Freidman 
test showed that SC did not exhibit significant differences between the 
horizontal lines (p>0.05), Design= 20×16, see Figure 148. 
  
Figure 148. SC for the horizontal lines on body surface sites. Each bar is 
constructed from 20 values calculated as the median across the horizontal 
electrodes in each line for each subject. 
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 The results showed that SC changed significantly across the 64 body 
surface sites, between the left and right, and also between the vertical lines. 
This could suggest: (1) body surface sites captured AA from different AF 
sources with different frequencies. (2) Some of the body surface sites have low 
SC due to noise.  
II. Spatial Variability of Spectral Concentration at the Intracardiac Sites 
 To investigate changes in SC along the catheter sites, SC for each EGM 
site in each subject was estimated with the same method as used for the BSPM 
recordings. Figure 149 illustrates SC for each site across subjects. The factorial 
ANOVA showed that AF SC exhibited significant differences between ten EGM 
sites (p<0.001), Design = (20×10) ×3. However, it did not exhibit significant 
differences between either CS or PVAC sites (p>0.05), design = (20×5) ×3. 
 The median SC across subjects ranged from 47.0% (CS2) to 51.0% 
(CS4) for CS, and 60.5% (PVAC2) to 68.5 % (PVAC5) for PVAC. 
 
Figure 149. SC for each intracardiac site. Each bar is constructed from 20 
values for each subject. 
 
 SC consistency along the sites in each catheter, either CS or PVAC, may 
suggest that each catheter might capture more localised frequency. However, 
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SC significant differences between CS and PVAC catheters, with CS SC being 
smaller than PVAC SC, may suggest that there were far-field atrial activities 
from RA or other AF pathways on the CS recordings.   
III. Comparison of Body Surface and Intracardiac Spectral 
Concentration for Each Site 
 The linear correlation analysis was performed to investigate whether 
there were any body surface sites that corresponded to AF complexity 
estimated from CS or PVAC. Figure 150 shows a colour map of the linear 
relationship between BSPM and EGM SC at each body surface site.  
  
Figure 150. Spatial colour maps of the correlation coefficients between BSPM 
and CS SC (left), and between BSPM and PVAC SC (right). The BSPM sites 
with strongest linear relationship with EGM SC are marked with dashed circles. 
 
 The results showed that SC at anterior upper left sites had the strongest 
linear relationship with CS. Also, SC at anterior central lateral left had the 
strongest linear relationship with PVAC. This analysis potentially suggested that 
the body surface sites close to the anterior upper left might be a good 
representation of AF organisation estimated from the CS. 
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Chapter Summary 
 In this chapter the spatial variability of the AF characteristics between the 
body surface and intracardiac sites were investigated. AF characteristics 
(amplitude, DF, and SC) changed significantly across the body surface sites. 
However, DF and SC did not change significantly from any of the sites of the 
same catheter, either CS or PVAC.  
There was a consistent pattern of high AF characteristics on the anterior 
upper central right body surface sites in all subjects. These sites also had the 
largest correlation coefficients of DF compared between the body surface and 
CS. This may suggest that the body surface sites close to the anterior upper 
central right were the best representatives of DF estimated from the CS 
recordings. Furthermore, the body surface sites close to the posterior upper 
central left and the posterior lower right had the largest correlation coefficients 
of DF compared between the body surface and PVAC that may suggest that 
these sites were the best representatives of DF estimated from the PVAC 
recordings.    
 The body surface sites close to the anterior central lateral left gave the 
best representation of SC estimated from the PVAC recordings. Moreover, the 
body surface sites close to the anterior upper central left gave the best 
representation of SC estimated from the CS recordings. This may suggest that 
the anterior central lateral left sites were the best representatives of AF 
organisation estimated from the PVAC recordings, and the anterior upper 
central left sites were the best representatives of AF organisation estimated 
from the CS recordings.  Since the anterior upper central right body surface 
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sites had the highest AF characteristics and strongest relationship with CS DF, 
it suggested that these sites may be capturing AA from the RA.  
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Chapter 7. Relationship Between Frequencies Derived from 
Individual and Groups of Body Surface Sites and Those 
Derived from Intracardiac Sites   
 To investigate agreement of the body surface and intracardiac spectra, 
the body surface and intracardiac recordings were compared in the frequency 
domain using five different approaches. Intracardiac spectra from CS4 and 
PVAC4 were overlapped with body surface spectra at each site for each 
subject. The relationships between the spectral peaks were manually checked 
(see section 7.1). The same approach was performed automatically using the 
morphology correlation analysis of the body surface and intracardiac spectra 
(see section 7.2). Body surface DF agreement estimated from groups of sites 
(the anterior and posterior, and also the vertical electrode lines) were examined 
with the median DF across the CS and PVAC sites using Bland-Altman plot 
(see section 7.3). Paired comparison of DF was performed between each body 
surface site with each intracardiac site (see section 7.4). DF estimated from 
body surface with the largest SC was also compared with CS4 and PVAC4 (see 
section 7.5).    
7.1. Visual Comparison of Body Surface and Intracardiac Spectra 
 To visually investigate the relationship between BSPM and EGM spectra, 
the spectra from the CS4 and PVAC4 were plotted on top of each body surface 
site. Figure 151 and Figure 152 show the BSPM spectra from subject 3 overlaid 
with the CS4 and PVAC4 spectrum, respectively. Figure 153 and Figure 154 
show the BSPM spectra for subject 1 overlaid with the CS4 and PVAC4 
spectrum, respectively.  
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Figure 151. Spatial illustration of the spectra estimated from each body surface 
site (identified 1 to 64) in black, and CS4 in red for subject 3 with single peak 
spectra (highly organised AF). For each PSD, the x-axis is frequency 2 - 12 Hz 
and the y-axis denotes normalised power density to the maximum of each site.  
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Figure 152. Spatial illustration of the spectra estimated from each body surface 
site (identified 1 to 64) in black, and PVAC4 in green for subject 3 with single 
peak spectra (highly organised AF). For each PSD, the x-axis is frequency 2 - 
12 Hz and the y-axis denotes normalised power density to the maximum of 
each site.  
 
159 
 
 
Figure 153. Spatial illustration of the spectra estimated from each body surface 
site (identified 1 to 64) in black, and CS4 in red for subject 1 with multiple peaks 
(less organised AF). For each PSD, the x-axis is frequency 2 - 12 Hz and the y-
axis denotes normalised power density to the maximum of each site. 
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Figure 154. Spatial illustration of the spectra estimated from each body surface 
site (identified 1 to 64) in black, and PVAC4 in green for subject 1 with multiple 
peaks (less organised AF). For each PSD, the x-axis is frequency 2 - 12 Hz and 
the y-axis denotes normalised power density to the maximum of each site.  
     
 According to the results (Figure 151 and Figure 152), in some subjects 
where the spectra had a single peak, good agreement between EGM and 
BSPM was apparent in the entire spectra. The presence of a single frequency 
component with the same dominant peak in the BSPM and EGM was thought to 
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be the result of a simple organised AF rhythm with one frequency re-entry 
pathway, so all EGM and BSPM sites captured one frequency. 
 Conversely, according to the results of Figure 153 and Figure 154, in 
some subjects the BSPM spectra had multiple peaks, which these peaks may 
or may not be agree with the EGM dominant peak. The presence of additional 
frequency components suggests less organised AF with multiple re-entrant 
pathways circulating round the atria, taking different paths, with possible 
variations in frequency, or directional switches in time. Consequently, the BSPM 
sites may reflect all or some of the frequency components presented on the 
EGM spectra. 
The BSPM and EGM spectra were visually checked for all sites in all 
subjects. There was no BSPM site that showed only the EGM dominant peak 
consistently among 20 subjects. There was no BSPM site that did not have 
corresponding spectral peak to the EGM dominant peak consistently among 20 
subjects.           
 Overall the results showed agreement between the body surface and 
intracardiac spectral peaks, but may or may not be the dominant peaks. This 
results illustrated the limitation of using only DF as a measure for comparing the 
body surface and intracardiac recordings, since it failed to capture the full 
details of the underlying frequency spectrum in less organised AF cases. 
Moreover, in clinical practice, in well organised AF cases measurements of DF 
represents the electrical activity of the inside the heart. However, in complex AF 
cases it may not represent the inside the heart events.   
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7.2. Morphology Correlation of Body Surface and Intracardiac Spectra 
 To quantify similarities in the morphology between the BSPM and EGM 
spectra, linear correlation was computed between normalised PSDs of each 
BSPM site with EGM (CS4 and PVAC4) in AF band of 3 - 8.5 Hz. The median 
correlation coefficient, r, was calculated across subjects for each BSPM site 
(BSPM vs. CS4 and BSPM vs. PVAC4). A spatial colour map of the median r is 
shown in Figure 155.      
 
Figure 155. Spatial colour maps of the median correlation coefficients. The 
BSPM and CS (left), and BSPM and PVAC (right). Regions with largest 
correlation are shown with red dashed circles. Regions with lowest correlation 
are shown with blue dashed circles.  
 
  The results showed stronger correlation between the body surface and 
CS spectra rather than PVAC. The largest correlation was between the anterior 
body surface site 22 and the posterior body surface site 43 with the CS.  
Moreover, the largest correlation between the anterior body surface and PVAC 
was at site 20, and between the posterior body surface and PVAC was at site 
49. The smallest correlation between the anterior and posterior body surface for 
both CS and PVAC were at sites 5 and 36, respectively. The median and IQR of 
the DF difference between four body surface sites (sites 20, 22, 43 and 49) 
which had the largest correlation with intracardiac recordings are given in Table 
16 across all subjects.       
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 To investigate whether there was a significant difference between the 
anterior and posterior body surface sites with the largest and smallest 
correlation coefficient values, linear regression analysis was performed. The 
results showed that the anterior and posterior sites indicating the largest and 
smallest r were significantly different, see Figure 156. 
 
Figure 156. The correlation coefficients between the largest and smallest 
anterior body surface sites with CS and PVAC (top), and between the largest 
and smallest posterior body surface sites with CS and PVAC (bottom). 
 
 This analysis suggested that body surface sites close to the anterior 
upper central right and posterior lower central had the strongest morphology 
correlation with intracardiac recordings. 
7.3. Dominant Frequency Agreement Using Bland-Altman Plot 
 To investigate how well body surface and intracardiac DF measurements 
agreed, the Bland-Altman plot was constructed. The median DF was computed 
across the anterior and posterior sites, and across the CS and PVAC sites. 
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Then the CS and PVAC median DF were compared with the anterior and 
posterior median DF (see Figure 157). The Bland-Altman results are shown in 
Table 13.  
  
Figure 157. Bland-Altman plots of BSPM and EGM DF. Top left: anterior body 
surface and CS. Top right: anterior body surface and PVAC. Bottom left: 
posterior body surface and CS. Bottom right: posterior body surface and PVAC. 
Black squares indicate 20 subjects.      
 
Source 
DF [Hz] 
Bias  LOA  PTrend 
Anterior    vs. CS -0.1 1.1 0.8 
Posterior  vs. CS 0.0 1.2 0.1 
Anterior    vs. PVAC 0.1 1.0 0.6 
Posterior  vs. PVAC 0.1 1.0 0.4 
Table 13. Bland-Altman results of the anterior and posterior body surface sites 
and intracardiac DF for 20 subjects.  
 
 The results showed that the differences did not increase or decrease by  
increasing or decreasing the average (PTrend>0.05, the fitted line between the 
two measurements has zero slope). There was no bias if DF estimated from the 
body surface was used to predict EGM DF, indicating that the two methods 
were systematically producing the same results. Moreover, there was no 
increasing of the scatter around the bias line by increasing the average, which 
suggested the variability of the measurements were consistent.  However, the 
LOA was about 1.0 Hz, meaning that the difference between measurements 
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lied within 2.0 Hz (± LOA) approximately 95% of the time. Overall the results 
showed small bias, not narrow LOA, and no relation between the average and 
difference DF. These suggested that DF estimated from the anterior and 
posterior sites were not in perfect agreement with DF estimated from the CS 
and PVAC recordings. However, the average discrepancy between methods 
was very small (between -0.1 and 0.1). To investigate whether analysing 
precise regions of the body surface reduced the LOA, BSPM DF in eight vertical 
lines were studied with DF estimated from the CS and PVAC recordings. The 
median DF was computed across each vertical line and then compared with CS 
and PVAC at each of the lines (see Figure 158, Figure 159, and Table 14). The 
results were similar to the previous analysis. DF estimated from the body 
surface and inside the heart agreed with the small average discrepancy 
between the methods. The median and IQR of the DF difference between the 
body surface regions compared with EGM recordings (shown in Table 13 and 
Table 14) are given in Table 16 across all subjects. 
    
Figure 158. Bland-Altman plots of body surface vertical lines and CS DF. Black 
squares indicate 20 subjects.   
166 
 
   
Figure 159. Bland-Altman plots of body surface vertical lines and PVAC DF. 
Black squares indicate 20 subjects.   
 
Source 
DF [Hz] 
Bias  LOA  PTrend 
BSPM strip ALL   vs. CS -0.1 1.5 0.5 
BSPM strip ACL   vs. CS 0.0 1.3 0.4 
BSPM strip ACR   vs. CS 0.0 1.2 0.6 
BSPM strip ALR   vs. CS 0.0 1.3 0.7 
BSPM strip PLL   vs. CS 0.1 1.2 0.7 
BSPM strip PCL   vs. CS 0.0 1.1 0.6 
BSPM strip PCR   vs. CS 0.0 1.3 0.5 
BSPM strip PLR   vs. CS -0.1 1.3 0.4 
BSPM strip ALL   vs. PVAC 0.0 1.5 0.4 
BSPM strip ACL   vs. PVAC 0.1 1.2 0.3 
BSPM strip ACR   vs. PVAC 0.1 1.0 0.4 
BSPM strip ALR   vs. PVAC 0.1 0.9 0.4 
BSPM strip PLL   vs. PVAC 0.1 1.1 0.3 
BSPM strip PCL   vs. PVAC 0.1 0.8 0.3 
BSPM strip PCR   vs. PVAC 0.1 1.0 0.2 
BSPM strip PLR   vs. PVAC 0.0 1.0 0.1 
Table 14. Bland-Altman results of the vertical lines of body surface sites and 
intracardiac DF for 20 subjects.  
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7.4. Dominant Frequency Paired Comparison   
 DF estimated from the body surface and inside the heart were 
investigated using paired comparisons between each site of these sources. For 
example, DF from each BSPM site was paired with DF from each EGM site for 
all subjects. A Kolmogorov-Smirnov test was used to check the distribution for 
each pair. According to the result of the normality test, paired comparison using 
the Wilcoxon signed-rank test or the paired t-test was used to examine 
significant differences. The Bonferroni correction test was used to adjust the 
significant level. The results showed that there was no significant difference 
between any of the BSPM and EGM sites. To investigate if there were any body 
surface site that had the same DF as the intracardiac sites, the DF difference 
between the BSPM and EGM for each site were investigated by subtracting 
each EGM site from each BSPM site in each subject (e.g. ∆DF (BSPM 1 vs. CS1) = 
BSPM site 1 - CS1, ∆DF (BSPM 2 vs. CS1) = BSPM site 2 - CS1, ..., ∆DF (BSPM 64 vs. 
CS1) = BSPM site 64 - CS1, for subject 1). Two examples of the ∆DF are shown 
in Figure 160 (BSPM vs. CS4) and Figure 161 (BSPM vs. PVAC4) across 20 
subjects.  Figure 162 shows spatial colour maps of the median ∆DF for CS and 
PVAC.  
 
Figure 160. Illustration of the ∆DF for BSPM vs. CS4. Each bar is constructed 
from 20 values.  
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Figure 161. Illustration of the ∆DF for BSPM vs. PVAC4. Each bar is 
constructed from 20 values.  
 
 
 
Figure 162. Spatial colour maps of the median ∆DF. BSPM vs. CS4 (left), and 
BSPM vs. PVAC4 (right) across subjects. The dashed circles indicate the 
smallest median ∆DF, representing the BSPM sites in good agreement with 
EGM DF. 
 
 According to the normality test result, the one-sample Wilcoxon signed-
rank test or one-sample t-test was used to test for significant differences 
(Design = 64×1). The Bonferroni correction test was used to adjust the 
significant level.   
 The results showed that there was no significant difference in DF 
between the BSPM and EGM sites. The median ∆DF of BSPM vs. CS4 was 
zero in sites 16, 22, 23, 24, 31, 32, and 58 (see Figure 163). The median ∆DF 
of BSPM vs. PVAC4 was zero in sites 2, 7, 41, 42, 43, 45, 47, 49, 50, 53, 54, 
and 62. This showed that on these sites BSPM and EGM DF were the same.   
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Figure 163. Illustration of the body surface sites where their median DF were 
the same as CS4 (red) and PVAC4 (green). 
 
 Although it is common in the literature to use lead V1 of a 12-lead ECG 
to analyse the AF, these results suggested that the anterior upper central right 
sites (which are closest to lead V1) may overestimate PVAC DF. It is important 
to bear in mind that these differences were not statistically significant. The 
median and IQR of the DF difference between two body surface sites (sites 22 
and 49) which had zero DF difference with intracardiac recordings are given in 
Table 16 across all subjects.    
7.5. Dominant Frequency Comparison Based on Body Surface Site with 
the Largest Spectral Concentration    
 Body surface sites with the largest SC can have less influence of noise, 
and therefore these sites may give better estimation of DF compared to other 
body surface sites. This section investigated whether body surface sites with 
the largest SC were in good agreement with AF DF estimated from inside the 
heart. For this purpose, DF difference was calculated by subtracting EGM DF 
estimated from selected sites (CS4 and PVAC4) from the body surface site with 
the largest SC, see Table 15. 
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Subject 
 
BSPM site 
 
SC [%] 
ΔDF [Hz] 
BSPM vs. CS BSPM vs. PVAC 
1 23 48.2 -0.9 -1.3 
2 23 27.0 -1.1 -0.5 
3 22 83.4 0.0 0.0 
4 22 47.6 -0.1 -0.4 
5 22 39.4 1.3 0.4 
6 21 50.5 -1.2 -1.0 
7 21 74.7 0.9 0.5 
8 25 78.9 0.0 0.0 
9 27 55.3 -1.6 -0.5 
10 22 49.1 -1.1 -0.8 
11 29 43.5 -0.5 -0.5 
12 25 41.0 -1.0 0.6 
13 23 35.7 0.3 -0.4 
14 21 75.5 0.0 -1.0 
15 23 45.3 -0.3 1.3 
16 23 51.6 0.1 0.1 
17 23 37.2 -0.6 0.3 
18 24 50.9 -0.4 -0.8 
19 28 40.0 -1.1 -0.9 
20 22 57.5 -0.4 0.4 
Median (IQR) - 48.7(15.1) -0.4(-1.0) -0.4(-1.1) 
Table 15. The DF differences between the body surface (from the sites with the 
largest SC), and intracardiac recordings. 
 
 According to the results, DF in subjects 3, 8, and 14 were in good 
agreement between the BSPM and EGM recordings. However, subjects 3 and 8 
were well organised AF and DF in these subjects was the same in all sites 
(BSPM and EGM). These results suggested that DF estimated from the body 
surface sites with the largest SC were not in good agreement (zero difference) 
with DF estimated from inside the heart. Consequently, the body surface sites 
with the largest SC were not necessarily good representation of AF DF, and 
may have been related to a different intracardiac site. Table 16 shows the DF 
differences between the body surface sites in close agreement with the 
intracardiac recordings (according to the results of the this chapter) with CS4 
and PVAC4 sites.    
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                  Source 
ΔDF [Hz]  
Median (IQR) 
BSPM site 22 vs. CS 0.0 (1.2) 
BSPM site 43 vs. CS 0.0 (0.7) 
BSPM site 20 vs. PVAC 0.0 (0.6) 
BSPM site 49 vs. PVAC 0.0 (0.8) 
BSPM anterior  vs. CS 0.0 (0.1) 
BSPM posterior  vs. CS 0.0 (0.7) 
BSPM anterior  vs. PVAC 0.0 (0.9) 
BSPM posterior  vs. PVAC 0.0 (0.5) 
BSPM strip ALL   vs. CS 0.0 (0.6) 
BSPM strip ACL   vs. CS 0.0 (0.4) 
BSPM strip ACR   vs. CS 0.1 (0.8) 
BSPM strip ALR   vs. CS 0.1 (0.8) 
BSPM strip PLL   vs. CS 0.0 (0.4) 
BSPM strip PCL   vs. CS 0.0 (0.3) 
BSPM strip PCR   vs. CS 0.0 (0.4) 
BSPM strip PLR   vs. CS 0.0 (0.5) 
BSPM strip ALL   vs. PVAC -0.1 (1.1) 
BSPM strip ACL   vs. PVAC -0.1 (1.1) 
BSPM strip ACR   vs. PVAC 0.0 (0.8) 
BSPM strip ALR   vs. PVAC -0.1 (1.0) 
BSPM strip PLL   vs. PVAC 0.0 (0.9) 
BSPM strip PCL   vs. PVAC 0.0 (0.7) 
BSPM strip PCR   vs. PVAC 0.0 (0.7) 
BSPM strip PLR   vs. PVAC -0.1 (0.8)  
BSPM site with the largest SC vs. CS -0.4(-1.0) 
BSPM site with the largest SC vs. PVAC -0.4(-1.1) 
Table 16. The median and IQR of the DF differences between the selected 
body surface and intracardiac sites for 20 subjects. The body surface sites were 
selected according to the results of this chapter. 
 
This table suggested that the median DF across the anterior body 
surface sites had the smallest difference with the CS DF, and the median DF 
across the posterior body surface sites had the smallest difference with PVAC 
DF among 20 subjects.     
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Chapter Summary 
 In this chapter the body surface and intracardiac spectra were compared 
using different methods. The visual comparison showed an agreement between 
the BSPM and EGM spectral peaks at all BSPM sites, but these peaks may or 
may not be the dominant one. The morphology correlation analysis showed that 
body surface site 22 (close to anterior upper central right) and site 43 (close to 
posterior lower central left) had the largest morphology correlation between the 
BSPM and CS spectra. Also, body surface site 20 (close to anterior central 
right) and site 49 (close to posterior lower central right) had the largest 
morphology correlation between the BSPM and PVAC spectra. The Bland-
Altman plot showed that the DF estimated from the body surface and inside the 
heart agreed with the small (close to zero) average discrepancy and the large 
LOA (about 2 Hz) between the methods. The dominant frequency paired 
comparison showed that the median ∆DF (BSPM vs. CS4) was zero in sites 
close to anterior upper right and posterior lower lateral right. Also, the median 
∆DF (BSPM vs. PVAC4) was zero at sites located on the vertical electrode lines 
close to anterior lateral left, posterior central left, posterior central right, and 
posterior lateral right.  
Joining the results from the morphology correlation and DF paired 
comparison showed that body surface site 22 (close to anterior upper central 
right), and site 49 (close to posterior lower central right) had the largest 
morphology correlation and the smallest DF difference with CS4 and PVAC4, 
respectively. Overall these results suggested that the body surface site 22 was 
a good representative of the CS recordings, and site 49 was a good 
representative of the LA recordings.     
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Chapter 8. Innovative Methods for Examining the Relationship 
Between Body Surface and Intracardiac Signals 
 This chapter introduces two novel AF characteristics for comparing the 
body surface and intracardiac recordings in the frequency domain. These novel 
AF characteristics were called EGM power distribution (see section 8.1) and 
Type of the BSPM spectral peak (see section 8.2). The aim of introducing these 
methods was to examine the entire spectra in the frequency range of interest at 
each body surface site based on intracardiac DF.   
Also in this chapter, results of another new approach were described for 
the BSPM and EGM comparison in the time domain. The aim was to identify if 
there was a distinct F-wave on the AF segment corresponding to EGM atrial 
activity.  
8.1. Estimation of Intracardiac Dominant Frequency Power Distribution on 
the Body Surface Spectra   
 This section investigated which body surface site expresed EGM DF with 
the highest power, P, (see section 2.3.5), and if there was any pattern for the 
EGM power distribution across the body surface. To do this, EGM DF power 
distribution was measured for the CS4 and PVAC4 DF on each body surface 
site. An example is shown in Figure 164.      
 The Box and Whisker plots of     and        were constructed for each 
BSPM site as shown in Figure 165. Figure 166 shows the spatial colour map of 
the median     and       .   
 Spatial colour maps of       and       were also constructed for each 
subject, as shown in Figure 167 and Figure 168. 
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Figure 164. The BSPM PSD for each body surface (identified 1 to 64), subject 
19. The red line indicates CS DF, and the dashed green line indicates PVAC 
DF. The y-axis represents the normalised power to maximum of all BSPM sites. 
  
     
Figure 165. Top:     , and bottom:       across subjects for each body surface 
site. Each bar is constructed from 20 values. Outliers are associated with 
subjects 3, 8 and 12. 
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Figure 166. Spatial colour maps of the median      (left) and       (right) across 
subjects (horizontal lines in each bar from Figure 165). The dashed circles 
indicate the largest EGM DF power distribution on the body surface sites.  
    
    Figure 167. Spatial colour map of     for each subject (identified 1 to 20). 
 
Figure 168. Spatial colour map of       for each subject (identified 1 to 20).  
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 Visual inspection of EGM DF power distribution on BSPM spectra (see 
Figure 167 and Figure 168) suggested a natural grouping of subjects in terms of 
EGM power distribution;   
1. High     and       on all BSPM sites (subjects 3 and 8, the continuous red 
maps), indicated good agreement between BSPM, CS and PVAC DF. 
These subjects have homogeneous power distribution across body surface 
sites while the majority of subjects exhibit spatial variation in power 
distribution. 
2. Power distribution was the same for CS and PVAC, e.g.  subjects 4, 6, 7, 
10, 11, and 18.   
3. Low     indicated poor agreement between BSPM and CS DF, e.g. subjects 
5, 6, 7, 9, 11 12 and 17.  
4. Low       indicated the observed poor agreement between BSPM and 
PVAC DF, e.g. subjects 7, 11, 15, and 20.        
 In group 1, the distribution in P was the same across all BSPM and EGM 
sites, suggesting  that this group may indicate well organised AF. In group 2, 
the P distribution was the same for both CS and PVAC across all body surface 
sites although EGM DF did not necessarily agree with BSPM DF. This group 
may indicate cases where the AF was less organised possibly as a result of 
multiple re-entrant AF pathways. It was also observed that EGM DF agreed with 
some of the BSPM sites in DF but not with others. This suggested that the EGM 
sites were not able to capture some re-entrant pathways since they were not 
located in parts of the LA and CS which placed on the re-entrant pathways that 
some BSPM sites could capture.  An alternative explanation was that the re-
entrant pathways cancel each other out from the view of some of the BSPM 
sites. In groups 3 and 4, EGM DF did not agree with BSPM DF. This group 
indicated very disorganised AF cases suggesting BSPM sites were not able to 
capture some CS or PVAC re-entrant pathways.    
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 The results showed that in most of the subjects      was larger on the 
anterior upper right body surface sites. This may suggest that these sites were 
more likely to express CS DF in comparison to other surface sites. The results 
also showed that        was larger on the lower posterior body surface sites. 
This may suggest that these sites were more likely to express PVAC DF in 
comparison to other surface sites.  
 The paired t-test was used to test if there was a significant difference 
between the upper and lower sites in     and       , also between the     and 
      for all possible pairs. The results showed a significant difference 
(p<0.001) between the upper and lower sites for     and       , and also 
between the lower body surface sites for     and       (see Figure 169).   
 
Figure 169. EGM power distribution of the upper and lower body surface sites. 
Each bar is constructed from 8 values. 
 
 Overall these results suggested that AF had an individual behaviour. In 
some subjects there were some BSPM sites that completely expressed EGM 
DF with high value of the power, and other BSPM sites did not. In an attempt to 
explain these differences, subjects were grouped according to the AF type, BMI 
and the number of previous ablations. However, none of the attempted 
groupings showed any consistent distribution, and so the underlying cause of 
these differences in BSPM remains unknown.   
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8.2. Classifying Body Surface Frequency Components According to 
Intracardiac Dominant Frequency 
 This analysis is motivated by some important questions: Are there any 
body surface sites where spectral peak is classified as Type I (dominant peak 
which correspond to EGM DF) ? (see section 2.3.6). If so, are these sites 
consistent across subjects? If not, are these body surface sites have any 
spectral peaks are classified as Type II (non- dominant peak which correspond 
to EGM DF) ? To answer these questions this section investigated whether 
there were any distinct frequency peaks on the BSPM spectra which 
corresponded to EGM DF. The type of BSPM peaks for each site were  
identified for selected EGM sites (CS4 and PVAC4). An example of the peak 
types of the BSPM spectra (according to EGM DF) is shown in Figure 170.  
 
Figure 170. Spatial illustration of a typical BSPM spectra and its corresponding 
peaks to EGM DF. The body surface sites were identified 1 to 64, for subject 5. 
EGM DF were plotted as dots (bottom CS4 and top PVAC4) and coloured in red 
if they were Type I BSPM spectra, coloured in green if they were Type II, and 
coloured in black if there was no associated peak in BSPM spectra to them.  
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 Bar plot of peaks Type I and  II according to CS DF was constructed 
across subjects for each body surface site as shown in Figure 171. This 
illustrated which body surface site had peak Type I in the majority of subjects 
(as shown by the highest red bar), and which body surface site had peak Type 
II in the majority of subjects (highest green bar). 
               
Figure 171. BSPM peak type according to CS DF. At each body surface site, 
number of subjects with Type I peak shown in the red bar and Type II peak 
shown in the green bar. On BSPM sites 21, 23, 46 and 48 (blue circles) more 
subjects capture CS DF (Type I, red bar). On BSPM site 54, fewer subjects 
capture CS DF.   
 
 
The results showed that sites 21, 23, 46 and 48 captured CS DF in the 
dominant peak of the BSPM spectra in fifty percent of subjects. Moreover, sites 
8, 16, 32, 35, and 54 captured CS DF in the non-dominant peak of the BSPM 
spectra in sixty percent of subjects. This may suggest that these sites were a 
good representation of DF estimated from the atria. The reason is, the CS has a 
four chambers view of the heart, and far-field VA had been cancelled on the CS 
recordings, so the results of the CS measurements are more likely to represent 
the atria.  
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Bar plot of the peaks type I and  II was constructed across subjects for 
each body surface site according to PVAC DF, as shown in Figure 172. This 
illustrated which body surface site had peak Type I or II in the majority of 
subjects.  
 
Figure 172. BSPM peak type according to PVAC DF. At each body surface site, 
number of subjects with Type I peak shown in the red bar and Type II peak 
shown in the green bar. On BSPM sites 16 and 59 (blue circles) more subjects 
capture PVAC DF (Type I, red bar). On BSPM site 31, fewer subjects capture 
PVAC DF.   
 
The results showed that sites 16 and 59 captured PVAC DF in the 
dominant peak of the BSPM spectra in forty-five percent of subjects (nine 
subjects). Moreover, sites 34 and 43 captured PVAC DF in the non-dominant 
peak of the BSPM spectra in seventy-five percent of subjects (fifteen subjects). 
Summing up the number of subjects with dominant and non-dominant 
peak at each body surface site (red and green bars in Figure 171 and Figure 
172), showed that CS and PVAC DF was apparent on all of the BSPM sites in  
at least sixty-five percent of subjects as shown in Figure 173.      
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Figure 173. Body surface sites with Type I and Type II peaks according to CS 
DF (left) and PVAC DF (right). The grey dashed circle shows that in the 
posterior lower body surface sites all 20 subjects captured PVAC DF as a 
dominant peak on the body surface spectra. 
 
The significant differences across the BSPM sites between Type I peak 
from CS and PVAC, between Type II peak from CS and PVAC, between CS 
Type I and II peaks, and finally between PVAC Type I and II peaks was 
investigated by paired comparison using the Wilcoxon signed-rank test. The 
results (see Table 17) showed that the BSPM sites that indicated peak type I 
were significantly different to the sites that indicated peak type II for both CS 
and PVAC. Moreover, the BSPM sites that represented CS DF were 
significantly different when compared to the BSPM sites that represented PVAC 
DF.  
 
Table 17. The Wilcoxon signed-rank test results for type of body surface 
spectral peak according to either CS or PVAC DF. 
 
 The results suggested that all body surface sites detected EGM DF, such 
that in some sites it agreed with BSPM dominant peak and in some sites it 
agreed with BSPM non-dominant peak. No BSPM site was found that did not 
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have a corresponding (dominant or non-dominant) peak to EGM DF across all 
subjects. Sixty-five percent of subjects captured a corresponding peak to EGM 
DF on the entire BSPM site. For CS a dominant peak was more observed than 
a non-dominant peak.  Conversely, for PVAC a non-dominant peak was more 
observed than a dominant peak.  There were no consistent BSPM sites that 
EGM DF captured differentially. AF EGM DF was likely to be seen as a 
dominant or non-dominant frequency peak on any of the body surface sites.    
8.3. Time Domain Analysis to Identify Intracardiac Activations on the Body 
Surface   
 This section investigated if there were any relationships, evident in the 
time series, between the AA from the body surface and activations from the 
intracardiac recordings. In other words, can electrical activity from intracardiac 
recordings be seen as distinct F-waves on AF segments of the body surface 
recordings? For this purpose, the CS and PVAC activations were detected and 
marked onto each body surface recordings (see section 2.3.4). Figure 174 
shows examples of the CS and PVAC activation time points on the anterior and 
posterior BSPM sites in one subject.     
 To investigate the consistency of EGM activations on the body surface 
sites, EGM activation time points were marked on the AF segment and a 
window around these EGM activations on the BSPM AA was defined. The AA 
within these windows were averaged and marked on the EGM activations of the 
average waveform. Figure 175 shows an example of the generated activations 
across the body surface based on the CS and PVAC activation time points.  
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Figure 174. Spatial illustration of EGM activations time points on anterior (top) 
posterior (bottom) BSPM sites, subject 1. The CS4 and PVAC4 activations were 
mapped on BSPM signals, displayed as the red and green lines, respectively, 
on each site.  
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Figure 175. Spatial illustration of the average BSPM AA according to CS (A) 
and PVAC (B) activations for each site, subject 1. In each site the x-axis 
represents time with duration of 0.12 s, and the y-axis denotes normalised 
amplitude to the maximum of each site. 
 
 Visual inspection of all 20 subjects showed that in six subjects (1, 6, 7, 
10, 19, and 20) the CS activations corresponded closer to the peak of AA on the 
lower body surface sites. However, the PVAC activations corresponded more 
with the trough of AA on these sites. In contrast, the CS activations 
corresponded closer to the trough and the PVAC activations corresponded 
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more with the peak of AA on the upper BSPM sites. On the body surface 
anterior central right sites the CS and PVAC activation time points moved 
between the peak and trough on a positive and negative gradient, respectively. 
Moreover, the generated BSPM average beat based on the EGM activations 
showed morphology of the AA on the majority of sites. This may suggest that 
the EGM activations were consistent on each body surface site. If this was not 
the case, the average would be flat or not have any clear morphology. 
Conversely, in three subjects (3, 8 and 9) the CS and PVAC activations were 
almost aligned with each other as well as with the peak of the AA on the body 
surface. In eleven subjects the EGM activations were more varied between the 
peak and trough in different body surface sites. Moving the location of the EGM 
time points on the body surface activations from lower to upper sites was more 
likely due to propagation of the AA which was a result of the temporal changes 
in the voltage distribution throughout the F-wave cycle or mechanism of the AF. 
 To quantify the results, correlation analysis between the body surface 
and intracardiac MCL were attempted as follows: the BSPM, CS and PVAC 
activations were detected separately from the longest AF segment. The mean 
of the time differences between the activations were calculated for each source. 
The idea was to identify if the MCL of any of the body surface sites had a large 
correlation with the CS and PVAC MCL. However, this study could not be 
completed as detection of the atrial activations on some of the body surface 
sites were impossible due to low amplitude and noise. Unfortunately this could 
not be tracked with the available study group. A greater number of subjects with 
the same AF history would be needed to draw firm conclusions.  
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Chapter Summary 
 The body surface sites close to the anterior upper right sites had larger    
   , and the body surface sites close to the posterior lower right sites had larger    
     . This suggested that at these sites EGM DF was closer to the BSPM DF 
which resulted higher power of EGM DF on the BSPM spectra. Moreover, all 
body surface sites detected EGM DF, such that in some sites it agreed with 
BSPM dominant peak and in some sites it agreed with BSPM non-dominant 
peak. There was no body surface site that did not have a corresponding 
(dominant or non-dominant) peak to EGM DF across all subjects. Moreover, 
there was no body surface site that did not have a corresponding (dominant or 
non-dominant) peak to either CS or PVACDF. 
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Chapter 9. Conclusion  
9.1. Main Findings 
 In this thesis, the objectives that were outlined at each chapter have all 
been accomplished. This chapter summarises the main scientific contributions 
of these analysis.  
Objective: Quantifying the AF characteristics in each subject allowing between 
subject comparisons. 
Response: In this study, AF amplitude estimated from the body surface in 20 
subjects ranged from 19.0 to 90.0 µV. AF DF estimated from the body surface 
ranged from 3.5 to 8 Hz between subjects which agreed with the DF estimated 
from inside the heart. AF SC between subjects ranged from 19.0% to 60.5% 
estimated from the body surface, and ranged from 21.0% to 90.0% estimated 
from inside the heart. It can be concluded that DF estimated from the body 
surface recordings represent main AF rate. However, SC estimated from the 
body surface recordings is unlikely to estimate AF degree of organisation. 
Subjects in organised AF had larger AF amplitude, lower DF and greater SC 
compared to subjects in complex AF. There was a consistent pattern of high AF 
characteristics on the anterior upper right body surface sites in all subjects. It 
can be concluded that these sites were best representative of AF characteristics 
on the body surface. Moreover, BMI explained approximately 20.0% of 
amplitude and DF variability estimated from the body surface compared to 
measurements from inside the heart.  
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Objective: Study of temporal and spatial variability of the AF characteristics. 
Response: The AF characteristics estimated from the body surface and inside 
the heart were consistent over the two minute recordings. 
 The AF characteristic differences across the body surface in less 
organised AF suggested that body surface sites may capture atrial activations 
from different AF re-entrant pathways.  
Objective: Comparing the AF characteristics estimated from the body surface 
and inside the heart. 
Response:  There was evidence of more accurate estimation of the AF 
characteristics using additional electrodes to lead V1 in the 12-lead ECG. The 
AF characteristics were apparent on all 64 body surface sites. However, the 
anterior upper central body surface sites were more likely to express AF from 
the CS recordings, and the posterior lower central body surface sites were more 
likely to express AF from the PVAC recordings. Overall the results suggested 
that the body surface site 22 was the best representative of the RA, and site 49 
was the best representative of the LA.        
9.2. Guide for Future Work 
 The following should be considered in future studies: subjects to be 
studied with the same AF histories and similar range of physiological factors, 
have more recording sites in the left atrium, include recording sites in the right 
atrium, and stay consistent in anatomical location across subjects. These would 
help to compare intracardiac signals with body surface recordings more 
accurately.  
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9.3. Clinical Application  
 Covering the anterior and posterior sides of the torso and calculating the 
median across them would provide more precise estimation of the AF 
characteristics.  This may not be practical due to additional cost, the extra time 
taken and the need for additional training of the cardiac technicians. Some 
additional electrodes to the 12-lead ECG on the posterior lower body surface 
may facilitate estimation of the AF characteristics from the left atrium.   
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Appendix A 
Illustration of More Sophisticated Intracardiac Recording Systems 
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 Catheter, amplifier, and display have been explained in Chapter 2. 
Generator, electrode pads, and pressure transducer are explained below. 
Generator: The GENius™ multi-channel RF generator, generates RF energy 
that is delivered to the heart by the PVAC catheter with the following 
specifications: A thermocouple (for temperature measurement), maximum 
temperature limit 100°C, RF output frequency 450-550 kHz, impedance range 
40-250 ohm, and power 100 watt. Typically values for the energy vary between 
15 and 40 watt. In temperature control, basically a target temperature is set, 
when the temperature reaches this target and then become consistent power is 
subsequently varied to maintain the temperature. For ablation purposes, energy 
is delivered from one electrode to another (two poles). The number of times 
energy is pulsed between the electrodes is also set. In fact the number of 
pulses in relation to the selected electrodes (energy delivery between two 
poles) gives the ablation. There are different ratios available from 1:1 to 4:1. 
The choice of ratio is dependent on the thickness of tissue and the depth of the 
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required lesion. 1:1 is typically used for a 7 mm burn, whereas 4:1 is 3 mm burn 
in depth. A small footprint allows placement in nearly any location. 
Electrode Pads: Electrode pads, dispersive electrode, patient plate, grounding 
pad or return electrode has a large and wide surface area, promotes low current 
density, which in turn can be safely directed out of the patient's body during the 
EP procedure to prevent burn. It prevents patient burns if the surgical 
instruments become accidentally energized during the procedure. The electrode 
pad also is designed to offset the noise. 
Pressure Transducer: A pressure transducer is used for direct blood pressure 
measuring. It converts the mechanical pressure to an electrical signal that is 
displayed on a monitor. It includes a domed portion which is connected to a line 
interposed in a patient's blood supply system (e.g. vein). A sterile solution 
serves to interface the patient's blood system and the pressuring measuring 
apparatus. The Wheatstone bridge is a measuring instrument and is used to 
measure an unknown electrical resistance by balancing two legs of a bridge 
circuit, one leg of which includes the unknown component.  
  
Its operation is similar to the original potentiometer. A tube attached at the end 
of the catheter is connected to the pressure transducer hose, which is joined to 
pressure bag. The pressure bag is placed with saline and inflates to 200-300 
mmHg to ensure adequate pressure exists above the patient’s systolic 
measurement. Pressure in the heart pushes down the fluid on the tube and it 
goes all the way down to the end of the tube and deflects the black dome, and 
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that goes upon on screen. This setup allows 1–3 ml per hour of flush solution to 
be delivered through the catheter to maintain patency, minimize clot formation, 
and prevent backflow of blood from the catheter as it sits in the pulmonary 
artery. The low-compliance tubing from the flush system is in turn connected to 
a pressure transducer a device that translates one form of energy into another. 
As the catheter moves through the heart chambers, pulsating waves created by 
changes in the systolic and diastolic pressures within the heart are transmitted 
from the catheter tip through the low-compliance tubing to the diaphragm of this 
transducer. These pulsations induce motion on the diaphragm and are 
converted to low-voltage electric signals that are transmitted via the cables to 
the bedside monitor. A time-temperature curve is plotted which represents the 
time it takes for the blood to change from a warmer baseline temperature to a 
cooler temperature after the injection and then back to the baseline temperature 
as the blood circulates.  
 
 At the monitor, these signals are amplified, filtered, and displayed as 
pressure waveforms and numerical pressure readings. These waveforms 
change as the catheter progresses through the heart during insertion, letting 
clinicians know exactly where in the heart the catheter is. It's important to 
continuously monitor these waveforms to ensure that the catheter does not slip 
into other chambers, example below. A chest radiograph is always used to 
verify the placement.  
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Appendix B 
Participant Information Sheet 
Relationship Between Intracardiac and Body Surface Potentials 
November 2010  
 
An invitation to take part in a pilot research study 
You are being invited to take part in a pilot research study.  Before you decide it is 
important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with others if 
you wish.  Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The electrocardiogram (12-lead ECG) is a simple measurement for detecting heart 
abnormal heart rhythms from body surface.  We believe there is important information 
contained in the ECG which is currently not used.  In order to test this we need to 
record electrocardiograms with more than 12 leads in patients with abnormal heart 
rhythms. 
 
Why have I been chosen? 
Patients with abnormal heart rhythms will be asked to take part in this study. So you 
may have been asked to take part because you have an abnormal heart rhythm. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form.   If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason.  Your decision to withdraw at any time or not to take part, will not affect the 
standard of care that you receive. 
 
What will happen to me if I take part? 
You will be having your routine electrophysiological (EP) study to manage your 
irregular heart rhythm. 
 
Prior to entering the theatre you will have 32 electrodes attached to your chest and 32 
electrodes attached to your back as shown in the picture. Attaching the electrodes will 
take less than 10 minutes. Once you are on the theatre table and ready for the EP 
study, a 5 minute ECG recording will be taken. 
 
The clinician will then perform their standard procedure of the EP study, and ECG 
recording will be taken at several intervals throughout the EP study. This does not 
interrupt or effect EP study. 
 
At the end of the procedure a final 5 minute ECG recording will be taken before you go 
to the recovery area where the electrodes will then be removed.  
Another 5 minute ECG recording will be taken before you discharge from hospital and it 
can be done at any time which is convenient for you. 
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Is there any risk in taking part? 
There is no risk from ECG electrodes although there might be slight discomfort from 
having electrodes attached on the body. If you request we can remove the electrodes 
at any time.  
 
Will my taking part in this study be kept confidential? 
Your participation will be kept confidential and your ECG data will be anonymised and 
allocated a study number.  Your personal details will not be seen by anyone.  
 
What will happen to the results of the research study? 
We hope to publish the results of this research in science, medical and medical 
engineering journals, at conferences, and through press releases. No personal data is 
published. 
 
Who is organising and funding the research? 
This is a PhD research study undertaken by Marjan Bojarnejad. It is being organised by 
the lead researcher Dr Philip Langley, the director of Medical Physics Department 
Professor Allan Murray, and Dr John Bourke Cardiologist at Freeman Hospital. It is 
funded party by the Engineering and Physical Sciences Research Council (EPSRC) 
and partly by Medical Faculty of Newcastle University. 
 
Contact for further information, 
If you have any questions or would like further information please contact: 
 
Miss Marjan Bojarnejad  
Medical Physics Department 
Freeman Hospital 
Newcastle upon Tyne 
NE7 7DN 
Tel. 0191 2336161 ext 26727  
Marjan.bojarnejad@nuth.nhs.uk 
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Appendix C 
Effect of BMI on the Atrial Fibrillation Characteristics Figures 
 
Figure C-1: Linear relationship between BMI and AF amplitude estimated from 
site 49.   
 
 
 
Figure C-2: Linear relationship between BMI and the median AF amplitude 
estimated across the body surface sites.   
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Figure C-3: Linear relationship between BMI and AF DF estimated from site 22.   
 
 
 
Figure C-4: Linear relationship between BMI and AF DF estimated from site 49.   
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Figure C-5: Linear relationship between BMI and AF SC estimated from site 22.   
 
 
Figure C-6: Linear relationship between BMI and AF SC estimated from site 49.   
 
 
Figure C-7: Linear relationship between BMI and the median SC estimated 
across the body surface sites.  
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Appendix D 
Spatial Variability of the Atrial Fibrillation Characteristics Tables 
AF Amplitude [µV] 
Sources p-value Sources p-value 
A_LL and A_CL 0.004 A_CR and P_LL <0.001 
A_LL and A_CR <0.001 A_CR and P_CL <0.001 
A_LL and A_LR 0.044 A_CR and P_CR <0.001 
A_LL and P_LL <0.001 A_CR and P_LR <0.001 
A_LL and P_CL 0.001 A_LR and P_LL <0.001 
A_LL and P_CR 0.019 A_LR and P_CL <0.001 
A_LL and P_LR 0.017 A_LR and P_CR <0.001 
A_CL and A_CR 0.001 A_LR and P_LR <0.001 
A_CL and A_LR 0.881 P_LL and P_CL 0.117 
A_CL and P_LL <0.001 P_LL and P_CR 0.017 
A_CL and P_CL <0.001 P_LL and P_LR 0.023 
A_CL and P_CR <0.001 P_CL and P_CR 0.015 
A_CL and P_LR <0.001 P_CL and P_LR 0.052 
A_CR and A_LR <0.001 P_CR and P_LR 0.881 
Table 18. AF amplitude paired comparison between the vertical lines.  
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AF Amplitude [µV] 
Sources p-value Sources p-value Sources p-value 
1 and 2 <0.001 3 and 15 0.001 7 and 13 0.427 
1 and 3 <0.001   3 and 16 <0.001 7 and 14 <0.001 
1 and 4 0.001 4 and 5 0.244 7 and 15 0.002 
1 and 5 0.002 4 and 6 0.001 7 and 16 0.438 
1 and 6 0.642 4 and 7 <0.001 8 and 9 0.187 
1 and 7 0.044 4 and 8 <0.001 8 and 10 0.163 
1 and 8 0.698 4 and 9 0.001 8 and 11  0.365 
1 and 9 0.234  4 and 10 <0.001 8 and 12 0.001 
1 and 10 0.301 4 and 11  <0.001 8 and 13 0.079 
1 and 11  0.796 4 and 12 0.079 8 and 14 0.179 
1 and 12 0.002 4 and 13 0.001 8 and 15 0.088 
1 and 13 0.023 4 and 14 <0.001 8 and 16 0.039 
1 and 14 0.163 4 and 15 <0.001 9 and 10 0.959 
1 and 15 0.301  4 and 16 0.003 9 and 11  0.088 
1 And 16 0.002 5 and 6 0.005 9 and 12 0.003 
2 and 3 <0.001 5 and 7 0.001 9 and 13 0.277 
2 and 4 0.017 5 and 8 0.001 9 and 14 0.001 
2 and 5 0.013 5 and 9 0.004 9 and 15 0.063 
2 and 6 <0.001  5 and 10 0.003   9 and 16 0.014 
2 and 7 <0.001 5 and 11  0.001 10 and 11  0.438 
2 and 8 <0.001 5 and 12 0.211 10 and 12 0.017 
2 and 9 0.001 5 and 13 0.007 10 and 13 0.66 
2 and 10 <0.001 5 and 14 <0.001 10 and 14 0.013 
2 and 11  <0.001 5 and 15 <0.001 10 and 15 0.023 
2 and 12 0.002   5 and 16 0.109 10 and 16 0.121 
2 and 13 <0.001 6 and 7 0.717 11 and 12 0.001 
2 and 14 <0.001 6 and 8 0.365 11 and 13 0.088 
2 and 15 <0.001 6 and 9 0.535 11 and 14 0.056 
  2 and 16 <0.001 6 and 10 0.698 11 and 15 0.134 
3 and 4 <0.001 6 and 11  0.535 11 and 16 0.039 
3 and 5 <0.001 6 and 12 0.004 12 and 13 0.01 
3 and 6 <0.001 6 and 13 0.605 12 and 14 <0.001 
3 and 7 <0.001 6 and 14 0.179 12 and 15 0.001 
3 and 8 <0.001 6 and 15 0.056   12 and 16 0.163 
3 and 9 <0.001   6 and 16 0.196 13 and 14 0.011 
3 and 10 <0.001 7 and 8 0.002 13 and 15 0.026 
3 and 11  0.001 7 and 9 0.329 13 and 16 0.352 
3 and 12 <0.001 7 and 10 0.301 14 and 15 0.301 
3 and 13 <0.001 7 and 11  0.021  14 and 16 0.002 
3 and 14 0.001 7 and 12 0.004 15 and 16 0.015 
Table 19. AF amplitude paired comparison between the horizontal lines.  
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AF SC [%] 
Source p-value 
Left_Anterior   and Right_Anterior   0.001 
Right_Anterior    and Left_Posterior 0.972 
Right_Anterior    and Right_Posterior 0.942 
Left_Anterior    and Left_Posterior 0.002 
Left_Anterior    and Right_Posterior 0.009 
Left_Posterior   and Right_Posterior 0.739 
Table 20. AF SC paired comparison between the left and right sites.  
 
 
AF SC [%] 
Sources p-value Sources p-value 
A_LL and A_CL 0.003 A_CR and A_LR 0.655 
A_LL and A_CR <0.001 A_CR and P_CL 0.008 
A_LL and A_LR <0.001 A_CR and P_CR 0.017 
A_LL and P_LL 0.258 A_CR and P_LR 0.004 
A_LL and P_CL 0.008 A_LR and P_LL 0.001 
A_LL and P_CR 0.013 A_LR and P_CL 0.006 
A_LL and P_LR 0.020 A_LR and P_LR 0.005 
A_CL and A_CR <0.001 P_LL and P_CR 0.028 
A_CL and A_LR <0.001 P_LL and P_CL 0.033 
A_CL and P_LL  0.057 P_LL and P_LR 0.058 
A_CL and P_CL 1.000 P_LR and P_CR 0.020 
A_CL and P_CR 0.763 P_LR and P_LR 0.564 
A_CL and P_LR 0.492 P_CL and P_LR 0.617 
A_CR and P_LL 0.001  P_CR and P_LR 0.157 
Table 21. AF SC paired comparison between the vertical lines.  
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